

Chair: R. Jalali, IN; M. Hegi, CH; M. Preusser, AT

17-11-2017

10:30 - 12:30 Type: Opening session Hall 406
 Title: Opening and Keynotes
 Chair: F. Ciardiello, IT

10:30 - 10:35 Opening

10:35 - 10:45 Welcome address by the ESMO President
F. Ciardiello, IT

10:45 - 10:55 Welcome address by the Minister for Health

10:55 - 11:00 Welcome address by the President of the Singapore Society of Oncology
R. Kanesvaran, SG

11:00 - 11:25 Presentation of Token of Appreciation to the endorsing National Oncology Societies
F. Ciardiello, IT

11:25 - 11:40 Scientific address
E. Voest¹, K.C. Park²; ¹NL, ²KR

11:40 - 12:05 Keynote address: Overcoming inequalities and maximising research opportunities in Asia
J. Chia, SG

12:05 - 12:30 Keynote address: Mechanisms of acquired resistance to immunotherapy
A. Ribas, CA/US

12:45 - 14:15 Type: Industry Satellite Symposium Hall 404
 Title: Industry Satellite Symposium

12:45 - 13:05 Presentation

12:45 - 14:15 Type: Industry Satellite Symposium Hall 405
Title: Industry Satellite Symposium

12:45 - 13:05 Presentation
R.A. Stahel, CH

13:05 - 13:25 Presentation 2

12:45 - 14:15 Type: Industry Satellite Symposium Room 309
Title: Industry Satellite Symposium

12:45 - 13:05 Presentation

12:45 - 14:15 Type: Industry Satellite Symposium Room 310
Title: Industry Satellite Symposium

12:45 - 13:05 Presentation

12:45 - 14:15 Type: Industry Satellite Symposium Room 324
Title: Industry Satellite Symposium

12:45 - 13:05 Presentation

13:05 - 13:25 Presentation 2

12:45 - 14:15 Type: Industry Satellite Symposium Room 325
Title: Industry Satellite Symposium

12:45 - 14:15 Presentation

14:30 - 16:00	Type: Multidisciplinary patient cases Title: Multi-modality treatment approach in HCC Chair: J.M. Kim, KR; M. Kudo, JP; T. Okusaka, JP	Hall 404
14:30 - 14:45	Surgery/RFA <u>J.M. Kim</u> , KR	
14:45 - 14:55	Discussion	
14:55 - 15:10	Locally advanced, non-resectable disease <u>M. Kudo</u> , JP	
15:10 - 15:20	Discussion	
15:20 - 15:35	Metastatic disease / relapse <u>T. Okusaka</u> , JP	
15:35 - 15:45	Discussion	
15:45 - 16:00	General discussion	

14:30 - 16:00	Type: Special Symposium Title: Immunotherapy in GU malignancies Chair: P. Parikh, IN; L. Albiges, FR	Hall 405
14:30 - 14:35	Introduction <u>P. Parikh</u> , Dadar (W)/IN	
14:35 - 14:55	Immunotherapy in GU cancers <u>L. Pickering</u> , GB	
14:55 - 15:15	Predictive immunotherapy biomarkers in GU malignancies <u>L. Albiges</u> , FR	
15:15 - 15:35	Intravesicle therapy in early bladder cancer: immunotherapy to the fore again <u>T.A. Ong</u> , MY	
15:35 - 15:55	Radiation and checkpoint inhibitor treatment: mechanisms of synergy <u>V. Grünwald</u> , DE	
15:55 - 16:00	Conclusions and clinical perspectives <u>L. Albiges</u> , FR	
14:30 - 15:15	Type: Mini Oral session Title: Melanoma Chair: R. Dummer, CH	Hall 407
14:30 - 14:35	379O - Phase Ic trial of intralesional OrienX010 oncolytic viral therapy into liver metastases among melanoma patients <u>C. Cui</u> , B. Lian, Z. Chi, L. Si, X. Sheng, T. Bixia, L. Mao, X. Wang, X. Yan, S. Li, L. Zhou, X. Bai, J. Guo; CN	
14:35 - 14:40	381O - Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: A single-institutional retrospective study <u>K. Namikawa</u> , A. Takahashi, A. Tsutsumida, T. Mori, N. Motoi, S. Jinnai, Y. Kage, Y. Muto, E. Nakano, N. Yamazaki; JP	
14:40 - 14:45	382O - Final results of phase I trial of HF10, oncolytic virus immunotherapy, in Japanese patients with refractory superficial cancers <u>N. Yamazaki</u> ¹ , A. Takahashi ¹ , A. Tsutsumida ¹ , M. Tanaka ² , K. Namikawa ¹ ; ¹ JP, ² Shiga/JP	
14:45 - 14:50	383O - Chronic arsenic poisoning leading to skin malignancy in a community <u>V. Goel</u> , IN	
14:50 - 15:15	Discussion <u>R. Dummer</u> , CH	

14:30 - 16:00	Type: Multidisciplinary patient cases Title: Challenging cases: Primary and secondary brain tumours Chair: J.H. Chang, KR; Y. Nakasu, JP; D. Hargrave, GB	Room 309
14:30 - 14:45	First-line therapy of IDH-mutated diffuse low grade glioma in an adult patient <u>J.H. Chang</u> , KR	
14:45 - 14:55	Discussion	
14:55 - 15:10	BRAF mutated glioma in childhood <u>D. Hargrave</u> , GB	
15:10 - 15:20	Discussion	
15:20 - 15:35	Leptomeningeal carcinomatosis of solid cancer <u>Y. Nakasu</u> , Shizuoka/JP	
15:35 - 15:45	Discussion	
15:45 - 16:00	General discussion	
14:30 - 16:00	Type: Educational session Title: The role of microenvironment and drug resistance Chair: E. Medico, IT; R. Beijersbergen, NL	Room 310
14:30 - 15:10	The impact of stroma on cancer subtype <u>E. Medico</u> , IT	
15:10 - 15:50	Functional genomics for the translational cancer research <u>R. Beijersbergen</u> , NL	
15:50 - 16:00	Discussion	

14:30 - 16:00 Type: Multidisciplinary patient cases Room 324
Title: Management of head and neck in the elderly population
Chair: M.-J. Ahn, KR; S.-P. Hao, TW; J. Bourhis, CH

14:30 - 14:45 The Surgeon point of view
S.-P. Hao, TW

14:45 - 14:55 Discussion

14:55 - 15:10 The Medical Oncologist point of view
M.-J. Ahn, KR

15:10 - 15:20 Discussion

15:20 - 15:35 The Radiation Oncologist point of view
J. Bourhis, CH

15:35 - 15:45 Discussion

15:45 - 16:00 General discussion

14:30 - 16:00 Type: Educational session Room 325
Title: Optimal management of ER+ and HER-2 negative patients
Chair: N. Harbeck, DE; J.W.-H. Tsang, HK

14:30 - 15:00 The role of MTOR/P3K inhibitors
J.H. Kim, Gyeonggi-do/KR

15:00 - 15:30 The role of CDK4/6 inhibitors
S. Saji, Fukushima/JP

15:30 - 16:00 Is there room for endocrine therapy alone? Which one and which sequence?
N. Harbeck, DE

15:30 - 16:15	Type: Mini Oral session Title: Thoracic malignancies 1 Chair: E. Smit, NL; H. Loong, HK	Hall 407
15:30 - 15:35	414O - Gene mutational profiling of Chinese EGFR-T790M mutation NSCLC patients required resistance to osimertinib by next generation sequencing <u>C. Xu</u> , W. Wang, W. Zhuang, Z. Song, G. Lin, X. Chen, Y. Zhu, M. Fang, H. Zhang, H. Wang, J. Zhang, Z. Yu, R. Chen, Y. Guan, X. Yi, Y. Chen, G. Chen, T. Lv, Y. Song; CN	
15:35 - 15:40	415O - Prevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer <u>A. Nakamura</u> ¹ , H. UDAGAWA ² , S. Matsumoto ² , S. Sugawara ³ , M. Shingyoji ² , A. Horiike ² , I. Okamoto ² , T. Hida ⁴ , S. Saeki ² , Y. Ohe ² , D. Ogawara ² , Y. Kataoka ² , Y. Miyata ⁵ , H. Mitsufuji ² , S. Kuyama ² , R. Kanemaru ² , T. Kato ² , A. Hirata ² , K. Yoh ² , K. Goto ⁶ ; ¹ JM, ² JP, ³ Miyagi/JP, ⁴ Aichi/JP, ⁵ Hiroshima/JP, ⁶ Chiba/JP	
15:40 - 15:45	536O - Comprehensive genomic profiling (CGP) of thymic gland carcinomas <u>J. Creeden</u> ¹ , J. Ross ² , P. Vanden Borre ³ , N. Almog ² , A. Schrock ² , J. Chung ² , J.-A. Vergilio ² , J. Suh ³ , S. Ramkissoon ² , S. Ali ² , V. Miller ² , P. Stephens ³ , J. Elvin ² , L. Gay ² ; ¹ CN, ² MA/US, ³ US	
15:45 - 15:50	395O - The clinical impact of PD-L1 protein expression in non-small cell lung carcinoma <u>N. Yanagawa</u> , S. Shiono, S.-Y. Ogata; JP	
15:50 - 15:55	416O - Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis <u>H. Wang</u> , M. Zhang, G. Zhang, J. Ma, Z. Ma; CN	
15:55 - 16:15	Discussion <u>H. Loong</u> ¹ , <u>E. Smit</u> ² ; ¹ HK, ² NL	
16:00 - 16:30	Type: Young Oncologist session Title: Meet your mentor Chair: K. Park, KR; A. Cervantes, ES	Exhibition area

16:30 - 18:00	Type: Educational session Title: Diagnosis and management of early-stage NSCLC Chair: E. Smit, NL; J. Ho, HK	Hall 404
16:30 - 17:00	CT screening: Are we ready to translate findings of clinical trials to practice? <u>E. Smit</u> , NL	
17:00 - 17:30	Are Western guidelines appropriate for managing solitary lung nodules in Asia? <u>W.-Z. Zhong</u> , CN	
17:30 - 18:00	Diagnosis and management Co-existing TB and in early-stage lung cancer <u>J. Ho</u> , HK	
16:30 - 18:00	Type: Educational session Title: Contemporaneous and future approach of localised gastro-oesophageal cancer treatment Chair: S. Law, HK; F. Lordick, DE	Hall 405
16:30 - 17:00	Chemo- and radiotherapy in squamous cell carcinoma of the oesophagus <u>S. Law</u> , HK	
17:00 - 17:30	Should oesophageal adenocarcinoma be treated differently from squamous cell carcinoma? <u>C. Jackson</u> , NZ	
17:30 - 18:00	Integration of biology-targeted drugs in the peri-operative setting of oesophago-gastric cancer <u>F. Lordick</u> , DE	

16:30 - 17:15	Type: Mini Oral session Title: Basic science Chair: T.S.K. Mok, HK; C. Dive, GB	Hall 407
16:30 - 16:35	20 - Expanding the use of approved drugs: The CPCT's Drug Rediscovery Protocol (DRUP) D. van der Velden, L. Hoes, H. Bloemendal, K. Grunberg, A.D.R. Huitema, E. Lugtenburg, F. De Vos, C. van Herpen, D.J.A. de Groot, P. Hamberg, E. Smit, E. Cuppen, N. Steeghs, S. Sleijfer, H. Verheul, H. Gelderblom, <u>E. Voest</u> , H. van der Wijngaart; NL	
16:35 - 16:40	230 - Clonal diversity of MYC amplification evaluated by FISH and digital droplet polymerase chain reaction (ddPCR) in oesophagogastric (OG) cancer <u>M. Davidson</u> ¹ , H. Bryant ¹ , L. Aronson ¹ , J. Howard-Reeves ¹ , D. Cunningham ¹ , N. Starling ¹ , D. Watkins ² , S. Rao ¹ , R. Cutts ¹ , M. Llorca-Cardenosa ¹ , R. Begum ¹ , I. Rana ¹ , A. Wotherspoon ¹ , J. Swansbury ¹ , I. Chau ³ , I. Chong ¹ ; ¹ GB, ² IR, ³ Surrey/GB	
16:40 - 16:45	240 - Comprehensive circular RNA profile and bioinformatics analyses reveal that circLMTK2 is upregulated and as a proliferative factor and prognostic marker in gastric cancer <u>J. Chen</u> , Y. Wang; CN	
16:45 - 16:50	5430 - Predictive value of the improvement in tumor microenvironment for progression in breast cancer patients treated with neoadjuvant chemotherapy <u>W. Goto</u> ¹ , S. Kashiwagi ² , Y. Asano ² , K. Takada ¹ , K. Takahashi ¹ , S. Noda ² , T. Takashima ² , N. Onoda ¹ , S. Tomita ¹ , K. Hirakawa ¹ , M. Ohira ¹ ; ¹ JP, ² Osaka/JP	
16:50 - 16:55	5500 - Systematic identification of (personalized) tumor-specific neoantigens through whole genome & whole transcriptomic analyses of 158 Asian colorectal cancers <u>S.-L. Koo</u> ¹ , C. Chua ¹ , A. Nguyen ² , S. Benz ² , W.S. Tan ¹ , C.L. Tang ¹ , M.H. Chew ¹ , B. Goh ¹ , C.Y. Chan ¹ , A. Gan ¹ , W.L. Tan ¹ , X.Q. Koh ¹ , A. Lezhava ¹ , S. Yan ¹ , S. Rabizadeh ³ , A. Skanderup ¹ , I.B. Tan ¹ ; ¹ SG, ² US, ³ CA/US	
16:55 - 17:15	Discussion <u>T.S.K. Mok</u> ¹ , <u>C. Dive</u> ² ; ¹ HK, ² GB	

16:30 - 18:00	Type: Special Symposium Title: Cultural issues in cancer treatment and care Chair: S. Subongkot, TH; M. Tsuchiya, JP	Room 309
16:30 - 16:35	Introduction <u>S. Subongkot</u> , TH	
16:35 - 16:55	Cultural Considerations in Planning Survivorship Care in Asia: Lessons learnt from the STEP Study <u>R. Chan</u> , AU	
16:55 - 17:15	Body image and sexuality issues among cancer survivors: A focus in Asian adolescent and young adult cancer patients <u>M. Tsuchiya</u> , JP	
17:15 - 17:35	Cultural adaptation and preferences in cancer survivorship: The Asian Model <u>T. Ng</u> , SG	
17:35 - 17:55	Priorities and preferences in advanced cancer: Quality of life matters <u>S. Subongkot</u> , TH	
17:55 - 18:00	Conclusions and clinical perspectives <u>M. Tsuchiya</u> , JP	
16:30 - 18:00	Type: Special Symposium Title: Molecular alterations in clinical perspective: From discovery to everyday application in patient management Chair: M. Hegi, CH; V. Santosh, IN	Room 310
16:30 - 16:35	Introduction <u>V. Santosh</u> , IN	
16:35 - 16:55	MGMT <u>M. Hegi</u> , CH	
16:55 - 17:15	IDH and 1p19q <u>A. IDBAIH</u> , FR	
17:15 - 17:35	Molecular subtyping in medulloblastoma <u>V. Santosh</u> , IN	
17:35 - 17:55	Clonal evolution of GBM under therapy: Impact on choice of therapy <u>D.-H. Nam</u> , KR	
17:55 - 18:00	Conclusions and clinical perspectives <u>M. Hegi</u> , CH	

16:30 - 18:00	Type: Special Symposium Title: Cancer in pregnancy and management challenges Chair: B.-G. Kim, KR; M. Halaska, CZ	Room 324
16:30 - 16:35	Introduction <u>M. Halaska</u> , CZ	
16:35 - 16:55	International registry on cancer in pregnancy: Interim analysis on more than 1000 cases <u>J. de Haan</u> , BE	
16:55 - 17:15	The long term effects of chemotherapy during pregnancy on the offspring <u>T. Van den Broucke</u> , BE	
17:15 - 17:35	Fertility preservation and special issues in BRCA carriers <u>M. Lambertini</u> , BE	
17:35 - 17:55	Gynaecological cancers during pregnancy <u>M. Halaska</u> , CZ	
17:55 - 18:00	Conclusions and clinical perspectives <u>B.-G. Kim</u> , KR	
16:30 - 18:00	Type: Educational session Title: Immuno-oncology in clinical practice in 2017 Chair: C. Rossig, DE; R. Soo, SG	Room 325
16:30 - 17:00	Immune-targeting of cancer: Principles and Strategies <u>C. Rossig</u> , DE	
17:00 - 17:30	Recent trial results <u>R. Soo</u> , SG	
17:30 - 18:00	Toxicity management and IO drugs in non-trial populations <u>A. Menzies</u> , AU	

17:30 - 18:25	Type: Young Oncologist session Title: Young oncologist session: case presentations Chair: M. Preusser, AT; G. Pentheroudakis, GR; S. Banerjee, GB	Hall 407
17:30 - 17:35	Introduction <u>M. Preusser</u> , AT	
17:35 - 17:40	YO8 - Focal leptomeningeal metastasis from carcinoma anorectum: A Case Report <u>M. Kumar</u> , S. K, S. Srivastava, S. Kumar; IN	
17:40 - 17:50	Q&A and discussion led by Chairs	
17:50 - 17:55	YO21 - Adenoid Cystic Carcinoma of the Trachea: A Case Report <u>M.M. Mopon</u> , A.J. Uson; PH	
17:55 - 18:05	Q&A and discussion led by Chairs	
18:05 - 18:10	YO33 - Trimodality Therapy for Recurrent Intimal Sarcoma of the Left Atrium with Multiple Distant Metastases: A Case Report <u>K. Fujimura</u> , T. Harada, T. Nakamura, M. Ono, T. Okuda, T. Tsubokura, S. Kin, A. Nagata, T. Komaki, K. Kagawa; JP	
18:10 - 18:20	Q&A and discussion led by Chairs	
18:20 - 18:25	Conclusions <u>G. Pentheroudakis</u> , GR	

18-11-2017

08:30 - 10:30	Type: Proffered Paper session Title: Proffered paper session 1 Chair: T.S.K. Mok, HK; R.A. Stahel, CH	Hall 405
08:30 - 08:42	4100_PR - Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study <u>T.S.K. Mok</u> ¹ , S. Peters ² , D.R. Camidge ³ , S.-H.I. Ou ⁴ , J.S. Ahn ⁵ , E.H. Tan ⁶ , Z. Li ⁷ , J.-S. Lee ⁵ , B.C. Cho ⁵ , S. Geater ⁸ , V. Sriuranpong ⁸ , J. Ho ¹ , O.S.-H. Chan ¹ , A. Zeaiter ² , B. Balas ² , E. Nueesch ² , E. Mitry ² , P. Morcos ⁹ , D.-W. Kim ⁵ ; ¹ HK, ² CH, ³ US, ⁴ CA/US, ⁵ KR, ⁶ SG, ⁷ CN, ⁸ TH, ⁹ NY/US	
08:42 - 08:54	Invited Discussant 4100 <u>D. Tan</u> , SG	

- 08:54 - 09:06 411O - Humanized recombinant endostatin combined with vinorelbine plus cisplatin followed by maintenance therapy with humanized recombinant endostatin in advanced non-small cell lung cancer: A multicentre, double-blind, randomised phase 3 trial
Y.-K. Shi, L. Zhang, S. Zhang, M. Shi, S. Qin, C. Wu, Z. Zhuang, G. Mao, D. Hua, X. Zhou, Y. Qu, Y. Wang, X. Shi, C. Hu, W. Li, M. Ouyang, L. Chen, Y. Sun, G. Wu, Y. Sun, Y. Wang, Y. Wang, Y. Wang; CN
- 09:06 - 09:18 412O - A global phase II study of olmutinib (HM61713) in patients with T790M-positive NSCLC after failure of first-line EGFR-TKI
K. Park¹, P. Jänne², C.-J. Yu³, L. Bazhenova⁴, L. Paz-Ares⁵, E. Baek¹, O. Han¹, K.Y. Hong¹, H. Kwon¹, Y. Kim¹, S.R. Kim¹; ¹KR, ²MA/US, ³TW, ⁴CA/US, ⁵ES
- 09:18 - 09:33 Invited Discussant 411O and 412O
Z. Qing, Guangdong/CN
- 09:33 - 09:45 403O - PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
S. Murakami¹, M. Özgüroğlu², A. Villegas³, D. Daniel⁴, D. Baz⁵, R. Hui⁶, T. Yokoi¹, A. Chiappori³, K.H. Lee⁷, M. de Wit⁸, B.C. Cho⁷, M. Bourhaba⁹, X. Quantin¹⁰, T. Tokito¹, T. Mekhail³, D. Planchard¹⁰, H. Jiang¹¹, Y. Huang¹¹, P. Dennis¹¹, S. Antonia³; ¹JP, ²TR, ³FL/US, ⁴TN/US, ⁵ES, ⁶NSW/AU, ⁷KR, ⁸DE, ⁹BE, ¹⁰FR, ¹¹MD/US
- 09:45 - 09:57 413O - Osimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA
Y. Ohe¹, S. Ramalingam², T. Reungwetwattana³, B. Chewaskulyong³, A. Dechaphunkul³, K.H. Lee⁴, F. Imamura¹, N. Nogami¹, Y. Cheng⁵, B.C. Cho⁴, E.K. Cho⁴, J. Vansteenkiste⁶, P.J. Voon⁷, C. Zhou⁵, J. Gray⁸, R. Hodge⁹, Y. Rukazenkov¹⁰, J.-C. Soria¹¹; ¹JP, ²GA/US, ³TH, ⁴KR, ⁵CN, ⁶BE, ⁷MY, ⁸FL/US, ⁹GB, ¹⁰Cheshire/GB, ¹¹CEDEX/FR
- 09:57 - 10:09 LBA5 - CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study
J. Vansteenkiste¹, T. Reungwetwattana², K. Nakagawa³, B.C. Cho⁴, M. Cobo Dols⁵, E.K. Cho⁴, A. Bertolini⁶, S. Bohnet⁷, C. Zhou⁸, K.H. Lee⁴, N. Nogami³, I. Okamoto³, N. Leigh⁹, R. Hodge¹⁰, A. McKeown¹⁰, A.P. Brown¹⁰, Y. Rukazaencov¹⁰, S. Ramalingam¹¹; ¹BE, ²TH, ³JP, ⁴KR, ⁵ES, ⁶IT, ⁷DE, ⁸CN, ⁹Ontario/CA, ¹⁰GB, ¹¹GA/US
- 10:09 - 10:24 Invited Discussant 403O, 413O and One LBA TBC
S. Peters, CH

09:00 - 10:30	Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines 1 Chair: G. Pentheroudakis, GR; F. Cardoso, PT	Hall 404
09:00 - 09:15	Introduction to ESMO Guidelines <u>G. Pentheroudakis</u> , GR	
09:15 - 09:45	Advanced HER2-negative breast cancer (ABC4) <u>F. Cardoso</u> ¹ , <u>J.W.-H. Tsang</u> ² ; ¹ PT, ² Pokfulam/HK	
09:45 - 10:15	Toxicities from immunotherapy <u>J. Haanen</u> ¹ , <u>R. Soo</u> ² ; ¹ NL, ² SG	
10:15 - 10:30	Q&A	
09:00 - 09:45	Type: Mini Oral session Title: Developmental therapeutics Chair: K. Shitara, JP; H. Wasan, GB	Hall 407
09:00 - 09:05	133O - An open-label, randomized cross-over bioavailability study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours <u>C. Jackson</u> ¹ , <u>S. Deva</u> ¹ , <u>K. Bayston</u> ¹ , <u>P. Barlow</u> ¹ , <u>K. Eden</u> ¹ , <u>N. Hung</u> ¹ , <u>G. Fetterly</u> ² , <u>D. Cutler</u> ² , <u>R. Kwan</u> ² , <u>D. Kramer</u> ² , <u>W.-K. Chan</u> ² , <u>T. Hung</u> ¹ ; ¹ NZ, ² NJ/US	
09:05 - 09:10	134O - Pharmacological PFKFB3 inhibition influences tumor angiogenesis <u>K. Khodova</u> , <u>T. Eremeeva</u> , <u>D. Shishov</u> , <u>P. Fedichev</u> ; RU	
09:10 - 09:15	135O - Antiangiogenic activity of Annona muricata (soursop) leaf extract <u>C.C. Cauilan</u> , <u>M.T. Amil</u> , <u>C.A. Condalor</u> , <u>K.M. Orodio</u> , <u>V.E. Santos</u> , <u>A. Teves</u> , <u>M.O. Igot</u> ; PH	
09:15 - 09:20	LBA2 - NOX66 plus carboplatin - a phase 1 signalling study <u>I. Minns</u> , <u>G. Kelly</u> , <u>M. Messina</u> ; AU	
09:20 - 09:25	136O - A phase I pharmacokinetic study of metronomic vinorelbine and sorafenib using two schedules in Asian non-small cell lung cancer (NSCLC) patients <u>S. Chen</u> , <u>N. Sutiman</u> , <u>V. Shih</u> , <u>D. Tan</u> , <u>M.K. Ang</u> , <u>C.K. Toh</u> , <u>D. Lim</u> , <u>Q.S. Ng</u> , <u>E.H. Tan</u> , <u>B. Chowbay</u> ; SG	
09:25 - 09:45	Discussion <u>H. Wasan</u> ¹ , <u>K. Shitara</u> ² ; ¹ GB, ² Chiba/JP	

09:00 - 10:30 Type: Special Symposium Room 309
Title: Extranodal NK/T-cell lymphoma
Chair: L. Specht, DK; Y.-L. Kwong, HK

09:00 - 09:05 Introduction
Y.-L. Kwong, HK

09:05 - 09:25 Advances in the treatment and clinical aspects during the last decade
W.S. Kim, KR

09:25 - 09:45 Understanding genomic alterations in ENKL
W. Zhao, CN

09:45 - 10:05 Molecular epidemiology and molecular prognostic models in ENKL
S.T. Lim, SG

10:05 - 10:25 The role of circulating EBV DNA monitoring: Consensus from the Asia Lymphoma Study Group
Y.-L. Kwong, HK

10:25 - 10:30 Conclusions and clinical perspectives
L. Specht, DK

09:00 - 10:30 Type: Special Symposium Room 310
Title: New strategies in personalised medicine
Chair: M. Quintela-Fandino, ES; P. Tan, SG

09:00 - 09:05 Introduction
M. Quintela-Fandino, ES

09:05 - 09:25 Liquid biopsies
S.-J. Dawson, VIC/AU

09:25 - 09:45 Single cell analysis
C. Dive, GB

09:45 - 10:05 Phosphoproteomics
M. Quintela-Fandino, ES

10:05 - 10:25 Tumour microenvironment: Safe havens and drug resistance
E. Hirata, JP

10:25 - 10:30 Conclusions and clinical perspectives
P. Tan, SG

09:00 - 10:30	Type: Multidisciplinary patient cases Title: Challenging rare gynaecological cancers Chair: A. van der Zee, NL; M. Friedlander, AU; B.-G. Kim, KR	Room 324
09:00 - 09:15	Vulvar carcinoma <u>A. van der Zee</u> , NL	
09:15 - 09:20	Discussion	
09:20 - 09:35	Granulosa tumour <u>M. Friedlander</u> , NSW/AU	
09:35 - 09:40	Discussion	
09:40 - 09:55	Small cell cervical cancer <u>D.S. Tan</u> , SG	
09:55 - 10:00	Discussion	
10:00 - 10:15	Uterine sarcomas <u>B.-G. Kim</u> , KR	
10:15 - 10:30	General discussion	
09:00 - 10:30	Type: Educational session Title: Novel therapeutics for advanced prostate cancer Chair: L. Pickering, GB; R. Kanesvaran, SG	Room 325
09:00 - 09:30	PSMA-targeted radionuclide therapy in mCRPC <u>S.P. Thang</u> , SG	
09:30 - 10:00	Novel therapies: New AR and non-AR approaches <u>A. Azad</u> , British Columbia/AU	
10:00 - 10:30	Liquid biopsies: The future of minimally invasive diagnostics in advanced prostate cancer <u>M.-H. Tan</u> , SG	

10:00 - 10:45	Type: Mini Oral session Title: Head and neck Chair: J. Bourhis, CH; A. D'Cruz, IN	Hall 407
10:00 - 10:05	337O - Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of Cabazitaxel versus docetaxel in recurrent Head and Neck Cancer <u>V. TALREJA</u> , V. Patil, A. Joshi, V. Noronha, A. Chandrasekharan, S. Dhumal, N. Pande, S. Turkar, S. Shrirangwar, A. Mahajan, S. Juvrekar, A. Bhattacharjee, K. Prabhash; IN	
10:05 - 10:10	338O - Oncological outcome following intensification of treatment by transoral robotic surgery (TORS) for HPV negative stage IV oropharyngeal cancer: A prospective trial <u>K. Gupta</u> , S. Dabas; IN	
10:10 - 10:15	339O - Can ultrasound accurately assess tumor thickness in carcinoma tongue to predict lymph node metastasis: A validation study <u>T. Chauhan</u> , R. Tankshali; IN	
10:15 - 10:20	340O - Risk of second primary tumors in patients with nasopharyngeal carcinoma following definitive intensity-modulated radiotherapy <u>C.H.J. Chow</u> , K. Au, O. Mang, K. Cheung, R. Ngan; HK	
10:20 - 10:25	341O - Comparing survival outcomes in operable treatment naïve T4b and T4a oral cavity cancers <u>M. Mair</u> , S. Nair, P. Chaturvedi; IN	
10:25 - 10:45	Discussion <u>J. Bourhis</u> , CH	
10:30 - 11:00	Type: Young Oncologist session Title: Meet your mentor Chair: R. Jalali, IN; F. Cardoso, PT	Exhibition area

10:45 - 12:30	Type: Proffered Paper session Title: Proffered paper session 2 Chair: L. Licitra, IT; A. Menzies, AU	Hall 405
10:45 - 10:57	336O - Biomarker analysis of randomized controlled trial (RCT) of adjuvant chemotherapy (CT) using plasma EBV DNA to identify patients (pts) at higher risk of relapse after radiotherapy (RT) or chemoradiation (CRT) in nasopharyngeal cancer (NPC) <u>E. Hui</u> , A. Chan, R. Ngan, S. Tung, A. Cheng, W. Ng, V. Lee, B. Ma, H. Cheng, F. Wong, H. Loong, M. Tong, D. Poon, A. Ahuja, A. King, K. Wang, F. Mo, B. Zee, K.C. Chan, Y.M. Lo; HK	
10:57 - 11:09	Invited Discussant 336O <u>L. Licitra</u> , IT	
11:09 - 11:21	LBA4_PR - Mainstreaming genetic counselling for genetic testing of BRCA1 and BRCA2 in ovarian cancer patients in Malaysia (MaGiC study) <u>S.Y. Yoon</u> ¹ , N.S. Ahmad Bashah ¹ , S.W. Wong ¹ , S. Mariapun ¹ , T. Hassan ¹ , H. Padmanabhan ¹ , J. Lim ¹ , S.Y. Lau ¹ , N. Rahman ² , M.K. Thong ¹ , G.S. Ch'Ng ¹ , S.H. Teo ¹ , E. Bleiker ³ , Y.L. Woo ¹ ; ¹ MY, ² GB, ³ NL	
11:21 - 11:33	Invited Discussant One LBA TBC <u>M. Friedlander</u> , NSW/AU	
11:33 - 11:45	287O - Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT) <u>S. Gupta</u> , P. Parab, R. Kerkar, U. Mahantshetty, A. Maheshwari, S. Sastri, R. Engineer, R. Hawaldar, J. Ghosh, S. Gulia, S. Godbole, N. Kumar, J. Malliga, R. Dalvi, Y. Kembhavi, M. Gaikar, R. Ranade, H. Tongaonkar, R. Badwe, S. Shrivastava; IN	
11:45 - 11:57	Invited Discussant 287O <u>J. Bourhis</u> , CH	
11:57 - 12:09	378O - Subgroup analysis of a phase II multicenter trial of HF10, oncolytic virus immunotherapy, and ipilimumab combination treatment in unresectable or metastatic melanoma patients <u>R. Andtbacka</u> ¹ , M. Ross ² , S. Agarwala ³ , M. Taylor ⁴ , J. Vetto ² , R. Neves ³ , A. Daud ² , H. Khong ² , R. Ungerleider ² , M. Tanaka ⁵ , K. Grossmann ¹ ; ¹ UT/US, ² US, ³ PA/US, ⁴ OR/US, ⁵ JP	
12:09 - 12:21	Invited Discussant 378O <u>A. Menzies</u> , AU	

11:00 - 12:30	Type: Special Symposium Title: What is new in the management of triple negative breast cancer Chair: R. Dent, SG	Hall 404
11:00 - 11:05	Introduction	
11:05 - 11:25	Standard management of early triple negative breast cancer <u>S. Kim</u> , KR	
11:25 - 11:45	Where are we with PARP inhibition? <u>R. Dent</u> , SG	
11:45 - 12:05	The role of immunotherapy <u>G. Curigliano</u> , IT	
12:05 - 12:25	Future management of triple negative breast cancer <u>J. Cortes Castan</u> , ES	
12:25 - 12:30	Conclusions and clinical perspectives <u>R. Dent</u> , SG	

11:00 - 11:45	Type: Mini Oral session Title: Sarcoma Chair: R. Quek, SG; P.G. Casali, IT	Hall 407
11:00 - 11:05	484O - Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors (GIST) treated with imatinib <u>P. Rutkowski</u> , P. Teterycz, A. Klimczak, E. Bylina, K. Szamotulska, I. Lugowska; PL	
11:05 - 11:10	485O - A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma <u>P. Huang</u> , A. Lee, F. McCarthy, K. Thway, J. Morden, C. Messiou, F. Daley, R. Buus, C. Fisher, M. Cheang, I. Judson, R. Jones; GB	
11:10 - 11:15	486O - Phase 2 clinical study of metronomic oral cyclophosphamide (MOC) in advanced sarcomas <u>R. Quek</u> , S.L. Lim, W.Y. Chay, L.T. Soh, S.H. Tan, W.L. Goh, M. Leong, R. Khoo, S. Selvarajan, K. Sittampalam, M. Tao, T. Tang, S.T. Lim, M. Farid; SG	
11:15 - 11:20	487O - Tumour histology and primary site but not MDM2 amplification levels are prognostic for clinical outcomes in well differentiated and dedifferentiated liposarcoma <u>W. Chew</u> ¹ , J. Chan ² , W.L. Goh ² , J. Lim ² , S.H. Tan ² , N. Somasundaram ² , E. Poon ² , A. Lim ² , M.H. Tan ² , K.C. Soo ² , M. Teo ² , T. Tay ² , S. Selvarajan ² , K. Sittampalam ² , R. Quek ² ; ¹ GB, ² SG	
11:20 - 11:25	488O - Serum miRNA discriminates treatment-naive localized synovial sarcoma patients from those in follow-up after radical combined therapy <u>H. Kosela Paterczyk</u> , M. Mikula, A. Paziewska, M. Kulecka, J. Kaczmarek, M. Dabrowska, A. Kluska, A. Balabas, M. Piatkowska, P. Rutkowski, J. Ostrowski; PL	
11:25 - 11:45	Discussion <u>P.G. Casali</u> , IT	

11:00 - 12:30	Type: Multidisciplinary patient cases Title: Biomarkers for precision oncology or When does translational genomics meet oncologist? Chair: J.-H. Cheong, KR; D.H. Lee, KR; M. Garassino, IT	Room 309
11:00 - 11:15	Patient-derived models to select treatment <u>J.-H. Cheong</u> , KR	
11:15 - 11:25	Discussion	
11:25 - 11:40	Marker assisted targeted therapies in solid cancers <u>D.H. Lee</u> , KR	
11:40 - 11:50	Discussion	
11:50 - 12:05	Immunotherapy versus targeted therapy in non-small-cell-lung cancer <u>M. Garassino</u> , IT	
12:05 - 12:15	Discussion	
12:15 - 12:30	General discussion	

11:00 - 12:30	Type: Educational session Title: Standards of diagnosis and treatment of brain tumours Chair: M. Preusser, AT; R. Jalali, IN	Room 310
11:00 - 11:30	The 2016 WHO classification in clinical practice <u>T. Komori</u> , JP	
11:30 - 12:00	Impact of modern conformal radiotherapy in the outcomes of CNS tumours <u>R. Jalali</u> , IN	
12:00 - 12:15	Immunotherapy for primary brain tumours <u>M. Preusser</u> , AT	
12:15 - 12:20	1190 - Mismatch repair deficiency (MMRD) and PD-L1 expression in high grade glioma (HGG) patients from Siloam Hospital Jakarta Indonesia <u>D. Patricia</u> ¹ , J. July ¹ , E. Wahjoepramono ¹ , G. Prayogi ¹ , Z. Wuisan ² , D. Budhiarko ¹ , T. Putra ¹ , N. Masykura ¹ , A.R. Utomo ¹ ; ¹ ID, ² DE	
12:20 - 12:30	Discussion	
11:00 - 12:30	Type: Special Symposium Title: Population enrichment: Is it reliable? Chair: J. Zucman-Rossi, FR; A. Ohtsu, JP	Room 324
11:00 - 11:05	Population enrichment: Challenges facing us <u>A. Ohtsu</u> , Chiba/JP	
11:05 - 11:25	The challenge of tumour heterogeneity <u>J. Zucman-Rossi</u> , FR	
11:25 - 11:45	Enrichment for immunotherapy across tumour types <u>K. Shitara</u> , Chiba/JP	
11:45 - 12:05	Enrichment as per non-molecular profiling <u>A. Vogel</u> , DE	
12:05 - 12:25	New drugs on the horizon <u>A. Ohtsu</u> , Chiba/JP	
12:25 - 12:30	Conclusions and clinical perspectives <u>J. Zucman-Rossi</u> , FR	

11:00 - 12:30	Type: Multidisciplinary patient cases Title: Managing oligometastatic lung cancer in the era of effective systemic therapies Chair: B. Solomon, AU; S. Peters, CH; S. Senan, NL	Room 325
11:00 - 11:15	Patient with lung metastases <u>B. Solomon</u> , VIC/AU	
11:15 - 11:25	Discussion	
11:25 - 11:40	Limited volume liver metastases presenting 6 months following after resection of a T2 lung adenocarcinoma (no driver mutations) <u>S. Peters</u> , CH	
11:40 - 11:50	Discussion	
11:50 - 12:05	Left adrenal metastasis (5 cm) detected 6 months after resection of T2N0 squamous cell carcinoma <u>S. Senan</u> , NL	
12:05 - 12:15	Discussion	
12:15 - 12:30	General discussion	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 404
12:45 - 13:05	Presentation	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 405
12:45 - 13:05	Presentation	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 406
12:45 - 13:05	Presentation	

12:45 - 14:15	Type: ESMO Colloquium Title: ESMO Colloquium - Selection criteria for the treatment of castration-resistant prostate cancer (crpc) Chair: M. Saad, MY; V. Kataja, FI	Room 325
12:45 - 12:50	Introduction <u>M. Saad</u> , MY	
12:50 - 13:10	Outcome with Cytotoxic agents <u>V. Kataja</u> , FI	
13:10 - 13:30	Results of next generation androgen receptor axis inhibitors <u>A. Azad</u> , British Columbia/AU	
13:30 - 13:50	Bone targeting agents: Bisphosphonates and Rank ligands & Radionucleides <u>M. Saad</u> , MY	
13:50 - 14:10	Criteria for treatment choice decision <u>V. Kataja</u> , FI	
14:10 - 14:15	Conclusion <u>M. Saad</u> , MY	
13:00 - 14:00	Type: Poster Display session Title: Poster lunch	Exhibition area
13:00 - 13:00	3P - Prevalence and genotyping of HPV infection in Jiangsu, a high-risk region for esophageal cancer in China <u>Y. Miao</u> , R. Liu, Y. Pu, L. Yin; CN	
13:00 - 13:00	4P - Ganoderma Lucidum has immunostimulatory and antiinflammatory effect in breast cancer patients <u>R. Othman</u> , H. Saeed, N. Abdulkader; IQ	
13:00 - 13:00	5P - PARK2 deficiency promotes cervical tumorigenesis by deregulation in cyclin activity via P53 dependent pathway <u>Z. Hafeez</u> , K. Fakhri, Z. Iqbal, M. Rizvi; IN	
13:00 - 13:00	6P - Design, synthesis and evaluation of hybrid of quinazoline–triazine derivatives as FAK inhibitor with antitumor activity <u>A. Verma</u> ¹ , V. Kumar ² , P. Pathak ² , P. Shukla ² , A. Kumar ² , U. Singh ² , A. Singh ² ; ¹ Uttar Pradesh/IN, ² IN	
13:00 - 13:00	7P - Anti-breast cancer activity of folate-chitosan nanoparticles loaded with irinotecan <u>A. Singh</u> ¹ , A. Singh ² ; ¹ Telangana/IN, ² IN	

- 13:00 - 13:00 8P - Discovery of novel 1,3,5-triazine-thiozolidine (DDDL-251) based dual PI3K/mTOR inhibitor against breast cancer
U. Singh¹, A. Verma², H.R. Bhat¹; ¹IN, ²Uttar Pradesh/IN
- 13:00 - 13:00 9P - Anti-metastatic effect of riluzole on Mat-LyLu rat prostate cancer cell line
S. UZUN, S. Altun, İ. Bugan; TR
- 13:00 - 13:00 10P - Oleic acid induced SKOV3 ovarian carcinoma cell metastasis via uPA/uPAR signaling pathway
W.T. Kuan, M.S. Tan, Y.G. Goan, C.C. Tsai; TW
- 13:00 - 13:00 11P - hTERT mediated c-MET expression is p53 dependent in cancer cells
R. Prasad, D. Mishra, M. Kumar, A. Sharma, P. Yadava; IN
- 13:00 - 13:00 12P - BET inhibitors induce apoptosis through ATAD2 suppression in AR positive triple negative breast cancer cells
H. YANG, S.H. Shim, K.S. Lee, I.H. Park; KR
- 13:00 - 13:00 13P - Investigate the efficacy of Photodynamic Therapy on nasopharyngeal carcinoma multicellular tumor spheroids
R. Wu¹, E. Chu¹, J. Yuen¹, Z. Huang²; ¹HK, ²CN
- 13:00 - 13:00 14P - Evaluating anti-oxidant potential of Callistemon viminalis leaves extracts and their compounds in STAT 3 pathway in liver cancer
K. Ahmad, IN
- 13:00 - 13:00 15P - The n-hexane fraction of Myrmecodia pendans suppresses survival and proliferation in colon cancer cells
Y.A. Ruswandi¹, S. Hidayat¹, F. Huda¹, T. Putri¹, N. Qomarilla¹, D. Kurnia¹, M. Satari¹, M. Bashari²; ¹ID, ²Jawa Barat/ID
- 13:00 - 13:00 16P - Is there a link between BRCA1 and BRCA2 mutations and obesity, high blood pressure and diabetes mellitus in Romanian high-risk breast cancer cases?
N. Antone¹, L. Pop¹, E. Dronca¹, A. Stoian¹, R. Matei¹, M. Ligtenberg², H. Ouchene², A. Onisim¹, O. Rotaru¹, R. Eniu³, A. Eniu¹; ¹RO, ²NL, ³GB
- 13:00 - 13:00 17P - Endocrine disrupting chemicals, bisphenol A alters cardiomyocytes beating rate and cell morphology
S.H. Sheikh Abdul Kadir, Z. Rasidi, N.I. Hanafi, R. Kamaludin, S. Ab. Rahim, R. Siran, M.H.D. Othman; MY
- 13:00 - 13:00 18P - Surface engineered nanocapsules of crocetin as a novel inhibitor of VEGFR2 on cancer induced chick embryo
V. Kumar¹, M. Rahman²; ¹Uttar Pradesh/IN, ²IN
- 13:00 - 13:00 19P - Effectiveness of Liposomal Doxorubicin on MDR-1-Related Drug Resistance in Dedifferentiated Chondrosarcoma In vitro 2D and 3D Culture
E. Cakiroglu, T. Uysal, Y. Baskin, H. Ellidokuz, I. Oztog; TR

- 13:00 - 13:00 20P - Discovery of novel 2beta-hydroxybetulinic acid 3beta-oliate via NF- κ B pathway in diethylnitrosamine induced hepatocellular carcinoma in rats
D. Ahmed, M. Sharma; IN
- 13:00 - 13:00 21P - Liposomal nanoparticles for photomagnetic controlled drug release with radical pair mechanism
H. Nakagawa, M. Ohuchi; JP
- 13:00 - 13:00 22P - Non-coding MIR491 is associated with less EGFR expression and greater radiosensitivity in human head and neck cancer cell lines
J. Bonner, E. Yang, H. Trummell, S. Nozell, C. Willey, M. Bredel; AL/US
- 13:00 - 13:00 25P - Utility of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) predictive and prognostic biomarkers in patients with hepatocellular carcinoma, prostate carcinoma, stomach carcinoma, aplastic anemia
V.S. Srikanth, M.G. Pillai, T. Tushar, J. Ashwin, K. Cinzia; IN
- 13:00 - 13:00 26P - Essential roles of microRNA-222 containing exosomes in breast cancer with chemotherapeutic resistance
J. Tang, S. Yang; CN
- 13:00 - 13:00 27P - High-throughput proteome identifies ANHAK as a novel biomarker for bladder urothelial carcinoma diagnosis in liquid-based cytology
H. Lee, H. Ryu, D. Han; KR
- 13:00 - 13:00 28P - Next generation proteomic profiling to predict the response to neoadjuvant chemotherapy in breast cancer
H. Ryu, D. Han; KR
- 13:00 - 13:00 29P - Clinical significance of the wild-type p53-induced phosphatase 1(Wip1) expression in invasive breast cancer
Y. Inoue¹, N. Yamashita¹, E. Tokunaga¹, H. Saeki¹, E. Oki², H. Kitao¹, Y. Maehara¹; ¹JP, ²Fukuoka/JF
- 13:00 - 13:00 30P - A liquid biopsy gene panel for pancreatic cancer detection
K. Kato, K. Ohkawa, R. Takada, H. Uehara, Y. Kukita, K. Katayama; JP
- 13:00 - 13:00 31P - Cell-free circulating tumor DNA (CFTDNA) – in cervical carcinoma: A diagnostic and screening marker
H.B. Govardhan¹, I. Khaleel², N. Sarkar², S. Supriya², M.N. Suma²; ¹Karnatka/IN, ²IN
- 13:00 - 13:00 32P - SPARCL1, a novel prognostic predictive factor for GI malignancies: A meta-analysis
W. Cai, H. Hu, W. Ge; CN
- 13:00 - 13:00 33P - Prognostic significance of serum Beta 2 Microglobulin in Non-Hodgkin Lymphoma
G. Gupta, V. Ghalaut, V. Lokanathan, P. Sharma; IN
- 13:00 - 13:00 34P - AFR as a prognostic biomarker to predict clinical outcome of NSCLC individuals
S.-Q. Li, Y.-H. Jiang, X.-Z. Wang, H.-Q. Ying; CN

- 13:00 - 13:00 35P_PR - Analysis of EGFR mutation status in blood and CSF in lung adenocarcinoma patients with EGFR mutation and CNS metastasis by ddPCR
Y. Sen, Q. Wang; CN
- 13:00 - 13:00 36P - Prognostic significance of circulating microRNA-155 expression in breast cancer patients
P. Yadav, M. Mirza, K. Nandi, S. Jain, R. Kaza, N. Khurana, A. Saxena; IN
- 13:00 - 13:00 37P - Association of mammographic density and fibroglandular tissue volume with the subtype of breast cancer
W.-C. Shia, D.-R. Chen; TW
- 13:00 - 13:00 38P - A novel ADS prognostic score containing prospective AFR, Alb and dNLR predicted overall survival in esophageal cancer patients
Q.-F. Gao, X.-H. Huang, J.-C. Qiu, H.-Q. Ying, X.-Z. Wang; CN
- 13:00 - 13:00 39P - Brain metastases-related microRNAs in the advanced breast cancer patients
J. Sato, A. Shimomura, J. Kawauchi, J. Matsuzaki, S. Takizawa, H. Sakamoto, M. Ohno, Y. Narita, K. Tamura, T. Ochiya; JP
- 13:00 - 13:00 40P - Cell-free microRNA‐200c expression as a prognostic/predictive biomarker in breast cancer patients
M. Masroor, IN
- 13:00 - 13:00 41P - Biomarker analysis of TPD regimen (trastuzumab, ertuzumab and docetaxel) for advanced HER2-positive breast cancer by HER family expression
K. Takada¹, S. Kashiwagi², W. Goto¹, Y. Asano², T. Takashima², T. Morisaki¹, S. Noda², N. Onoda¹, K. Hirakawa¹, M. Ohira¹; ¹JP, ²Osaka/JP
- 13:00 - 13:00 42P - New candidate biomarkers discerning benign liver tumors from hepatocellular carcinoma
A. Budko, M. Chesnokov, P. Skovorodnikova, D. Shavochkina, I. Kustova, N. Kudashkin, Y. Patyutko, N. Lazarevich; RU
- 13:00 - 13:00 43P - Loss of CDKL2 expression correlates with differentiation, stage, and poor prognosis of gastric cancer
K.-Y. Lin, Y.-H. Uen; TW
- 13:00 - 13:00 44P - Genomic analysis, biomarker and PDL1 expression in NUT midline carcinoma
S. Chouial¹, A. Mustafa², J. Xiu³, S. Rashad¹, H. Aboud⁴, A. Bulbul¹; ¹NM/US, ²IN, ³AZ/US, ⁴MI/US
- 13:00 - 13:00 45P - Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types
T. Ishiba¹, K. Danenberg², J. Usher³, T. Nakagawa¹, G. Oda¹, H. Uetake¹, N. Hoshino¹, Y. Nishioka¹, T. Kawano¹; ¹JP, ²CA/US, ³US
- 13:00 - 13:00 46P - The frequency of somatic AKT1 mutation among Japanese breast and endometrial cancer patients

T. Seo¹, T. Shimoi², A. Hamada², A. Shimomura², K. Sudo², E. Noguchi², K. Yonemori², C. Shimizu², Y. Fujiwara², K. Tamura²; ¹Hiroshima/JP, ²JP

- 13:00 - 13:00 47P - Study of tumor immune contexture in patients with squamous carcinomas of head and neck in the Indian population – A pilot study
M. Venkata, B. Saha; IN
- 13:00 - 13:00 48P - Genetic association of matrix metalloproteinase MMP- 1, MMP-3 and MMP-9 genes with HCV-related hepatocellular carcinoma in Egyptian patients
A. Alhanafy, B. Montaser, W. Fathy, N. Elabd, S. Tayel; EG
- 13:00 - 13:00 49P - Circulating cell-free DNAs as a biomarker in the serum of colorectal cancer patients
A. Alhanafy, M. El Shafei, M. Safan, E. Elnour, M. Habib, T. Rageh, A. Salah El-Din; EG
- 13:00 - 13:00 50P - TLE3 expression and the survival rates of patients with advanced serous ovarian cancer
H. Anishchanka, S. Shelkovich; BY
- 13:00 - 13:00 51P - Prognostic merit of glucose transporter GLUT1 expression status in gastric cancer
J. Wang, X. Ying, L. Wang; CN
- 13:00 - 13:00 52P - FPR as a prognostic biomarker in stage II and III gastric cancer
J. Zhang, X.-Z. Wang, H.-Q. Ying; CN
- 13:00 - 13:00 53P - Predictive factors for detectability of genomic alterations from circulating cell-free DNA in patients with advanced non-small cell lung cancer
H. Kimura¹, H. Koba², K. Kasahara¹; ¹JP, ²Ishikawa/JP
- 13:00 - 13:00 54P - Cripto-1 expression and its correlation with outcomes in oropharyngeal carcinoma treated by chemoradiation
M. Kumar, S. Ghoshal, A. Pal; IN
- 13:00 - 13:00 55P - Screening the serum differential protein to predict chemoradiotherapy Efficacy of Xinjiang Uygur Patients with locally advanced Esophageal cancer
M. Yang, CN
- 13:00 - 13:00 56P - Association between HER2 oncoprotein and hormonal receptors (estrogen receptor and progesterone receptor) on breast cancer
F. Fulkiadli¹, D. Khambri², W. Harahap¹; ¹ID, ²West Sumatra/ID
- 13:00 - 13:00 58P - Evaluation of awareness, cosmetic and psychological satisfaction following breast oncoplasty among breast cancer patients
S. Gupta, V. Seenu; IN
- 13:00 - 13:00 59P - Development and validation of a nomogram for predicting survival in patients with operable triple negative breast cancer
J. Liu, Y. Yang, H. Deng, C. Tan, W. Wei, E. Zhou, Q. Liu; CN

- 13:00 - 13:00 60P - Incidence of hypothyroidism in patients treated for carcinoma breast with incidental radiation dose to thyroid gland treated with different fractionation and correlation of these doses with thyroid function test
N. Sarkar¹, H.B. Govardhan²; ¹IN, ²Karnatka/IN
- 13:00 - 13:00 61P - No change in mean age of diagnosis of breast cancer during 30 years from 1981 to 2011 in the north east of Iran, report of six thousand patients
M. Salehi, S. Shahidsales, M. Seilaniantousi, G. Noferesti; IR
- 13:00 - 13:00 62P - The pattern of recurrence in initial pure ductal carcinoma-in-situ of the breast: 19 years experience of King Chulalongkorn Memorial Hospital, Thailand
P. Wanchaijiraboon, T. Atikankul, N. Parinyanitikul; TH
- 13:00 - 13:00 63P - Early drop of LV ejection fraction can predict trastuzumab-related cardiotoxicity in patients with breast cancer
J. Cho, E.K. Kim, K.H. Yoo, H. Lee, H.K. Kim, M.H. Heo, J. Park, J.S. Ahn, Y.-H. Im, Y.H. Park; KR
- 13:00 - 13:00 64P - Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes within fibrotic foci of tumor stroma (FF-TILs)
S. Kashiwagi¹, Y. Asano¹, W. Goto², K. Takada², T. Takashima¹, T. Morisaki², S. Noda¹, N. Onoda², K. Hirakawa², M. Ohira²; ¹Osaka/JP, ²JP
- 13:00 - 13:00 65P - The possibility of omitting axillary clearance by using indocyanine green fluorescence method in detection of sentinel lymph nodes in early-stage breast cancer
Y. Maeshima, A. Oobayashi, R. Katsuragi, Y. Yoshimoto, S. Takahara, A. Yamauchi; JP
- 13:00 - 13:00 66P - Prognostic and clinical values for prediction of breast cancer recurrence in HER2 positive early breast cancer after surgery in King Chulalongkorn Memorial Hospital 2005-2016
S. Prapatsornvichit, N. Parinyanitikul, T. Atikankul, S. Virote, N. Poovorawan; TH
- 13:00 - 13:00 67P - Prediction model of low risk recurrence distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer: A validation study
Y. Tsuchida, N. Hayashi, F. Omata, S. Ohde, Y. Kanada, S. Tazawa, M. Takimoto, K. Suzuki, S. Nakamura, H. Yamauchi; JP
- 13:00 - 13:00 68P - Breast cancer epidemiology: Worldwide data
P. Bagri¹, S. Narayan², P. Pareek²; ¹Rajasthan/IN, ²IN
- 13:00 - 13:00 69P - Prognostic significance of biomarker discordance in breast cancer patients with neoadjuvant chemotherapy
A. Matsumoto, M. Yoshikawa, H. Jinno; JP
- 13:00 - 13:00 70P - Outcomes of sentinel lymph node biopsy after neoadjuvant chemotherapy
A. Bulbul¹, S. Rashad¹, E.A. Mino¹, A. Bautista¹, A. Mustafa², S. Chouial¹, M. Khorsand¹; ¹NM/US, ²IN
- 13:00 - 13:00 71P - Is sentinel lymph node biopsy necessary in breast cancer patients who were diagnosed as initially clinically node-negative before neoadjuvant chemotherapy?
T. Fujita¹, M. Sakuragi², C. Miyazaki², S. Siba², Y. Tanaka², R. Koike², M. Shiozawa²; ¹Tochigi/JP, ²JP

- 13:00 - 13:00 72P - Prognostic significance of tumor-infiltrating lymphocytes (TILs) in patients with early-stage triple-negative breast cancer (TNBC) treated with curative resection alone
J.H. Park¹, H.J. Lee², J.-H. Ahn², J.E. Kim², K.H. Jung², G. Gong², S.-B. Kim²; ¹Songpa-gu/KR, ²KR
- 13:00 - 13:00 73P - Role of post mastectomy radiotherapy in T1, T2 lesions with 1-3 positive axillary lymph nodes-study of 101 cases
N. Garg, IN
- 13:00 - 13:00 74P - Febrile neutropenia and primary prophylactics in docetaxel plus cyclophosphamide chemotherapy for breast cancer: A Japanese institution experience
Y. Kimura¹, S. Sasada², N. Goda¹, A. Emi¹, K. Kajitani¹, N. Masumoto¹, R. Haruta¹, T. Kadoya¹, T. Kataoka¹, M. Okada¹; ¹JP, ²Hiroshima/JP
- 13:00 - 13:00 75P - Can sentinel lymph node biopsy be omitted in patients with clinical node negative before neoadjuvant chemotherapy
T. Yoshida, A. Yoshida, N. Hayashi, H. Yamauchi; JP
- 13:00 - 13:00 76P - Computed tomography liver spleen ratio as predictive marker of liver injury in early breast cancer receiving neoadjuvant therapy from 2010-2016
A.T. Gerona, PH
- 13:00 - 13:00 77P - Impact of apparent diffusion coefficient for the prediction of responses in patients with breast cancer treated with neoadjuvant chemotherapy
Y. Mizuno, K. Nakamura, M. Shizuku, T. Mori; JP
- 13:00 - 13:00 78P - In vivo activation of mitochondrial pathway and cell cycle arrest through silymarin loaded iron nanoparticles as proficient nanocomplex system for triple negative breast cancer therapy
M. Paulpandi, IN
- 13:00 - 13:00 79P - Evaluation of tissue computed tomography number changes and dosimetric shifts after conventionally fractionated irradiation in patients undergoing breast conserving surgery
D.S. Lee, Y.K. Lee, J.S. Kim, J. Lee, Y.S. Kim; KR
- 13:00 - 13:00 80P - Incidence of permanent chemotherapy-induced alopecia among breast cancer patients: A five-year prospective cohort study
D. Kang¹, I.-R. Kim¹, D.-Y. Lee¹, J.S. Ahn¹, J.-H. Park¹, E. Guallar², J. Cho¹; ¹KR, ²AL/US
- 13:00 - 13:00 81P - Quantitation of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentration (sTK1)
B. Tribukait, K. Jagarlamudi, J. Bergh, T. Hatschek; SE
- 13:00 - 13:00 82P - Indian triple-negative breast cancer – immune, molecular and clinical landscape
A. Korlimarla¹, C. Ragulan², J. Prabhu¹, H. Shankaranarayana¹, M. Cheang², T.S. Sridhar¹, A. Sadanandam²; ¹IN, ²GB
- 13:00 - 13:00 83P - Circulating tumor DNA detection in primary breast cancer patients by targeted sequencing: Consistency with tumor DNA and factors influencing detection

Z. Yidong¹, W. Changjun¹, Z. Yanyan¹, G. Yuhua¹, G. Yanfang¹, P. Li¹, Y. Ling¹, Y. Xin¹, X. Xuefeng², S. Qiang¹; ¹CN, ²AS

- 13:00 - 13:00 84P - Effective strength training for breast cancer patients: literature review
R. Ceseiko, LV
- 13:00 - 13:00 85P - Polymorphism of genes of DNA repair enzymes in patients with breast cancer
G. Allayarovna, UZ
- 13:00 - 13:00 86P - Usefulness of neoadjuvant chemotherapy in patients with luminal HER2(-) locally advanced breast cancer
H.S. Kim, KR
- 13:00 - 13:00 87P - 70-gene signature, an encouraging prognostic tool to guide adjuvant therapy in early breast cancer
A. Cunquero Tomas, C. Avila Andrade, A.B. Fernandez Diaz, M. Meri Abad, I. Shaheen, L. Condori Farfan, A. Rodriguez Huaman, V. Sforza, F.D.A. Aparisi Aparisi, M.J. Safont Aguilera, A. Blasco Cordellat, M. Gil Raga, C. Caballero Diaz, A. Berrocal, M.C. Godes Sanz de Bremond, A. Pérez, V. Iranzo Gonzalez-Cruz, C. Camps Herrero; ES
- 13:00 - 13:00 88P - Role of HSP27 in trastuzumab resistance in HER2-overexpressing breast cancer
S.-Y. Hwang, S.-K. Choi, Y. Na, Y.-S. Lee, Y. Kwon; KR
- 13:00 - 13:00 89TiP - KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
J. Cortes Castan¹, Z. Guo², V. Karantza², G. Aktan³; ¹ES, ²NJ/US, ³PA/US
- 13:00 - 13:00 90TiP - A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/- endocrine therapy), or non-small-cell lung cancer (NSCLC)
D. Yee¹, A. Prat², M. Sablin³, H. Iwata⁴, E. Johnston⁵, T. Bogenrieder⁶, J. Serra², H. Hua⁷, P. Lo Russo⁸; ¹MN/US, ²ES, ³FR, ⁴JP, ⁵IN/US, ⁶AT, ⁷CN, ⁸CT/US
- 13:00 - 13:00 97P - Phase II trial of eribulin and S-1 combination therapy for advanced or recurrent breast cancer
T. Iwasa¹, J. Tsurutani¹, Y. Mizuno¹, Y. Kojima¹, T. Takashima², N. Matsunami¹, T. Morimoto¹, J. Yamamura¹, S. Ohtani¹, Y. Tanabe¹, S. Watanabe¹, R. Kato¹, H. Tanino¹, S. Tokunaga¹, H. Abe¹, S.T. Tsuyuki¹, F. Hara³, T. Takano¹, Y. Komoike¹, K. Nakagawa¹; ¹JP, ²Osaka/JP, ³BS
- 13:00 - 13:00 98P - Effect of postmastectomy radiotherapy on breast cancer with isolated tumor cells or micrometastases in regional lymph nodes: A propensity score matched analysis using the SEER database
Q. Zheng, W. Xia, Q. Lu, S. Wang; CN
- 13:00 - 13:00 99P - Frequency of pathogenic mutation in patients at high risk for hereditary breast cancer
H.C. Shin, T.-K. Yoo, H.-B. Lee, H.-G. Moon, D.-Y. Noh, W. Han; KR
- 13:00 - 13:00 100P - Impact of perioperative fluoropyrimidines on the efficacy of capecitabine in patients with advanced breast cancer: A retrospective study

S. Iizumi, A. Shimomura, T. Shimoi, K. Sudo, E. Noguchi, K. Yonemori, C. Shimizu, Y. Fujiwara, K. Tamura; JP

- 13:00 - 13:00 101P - The efficacy of eribulin mesylate with trastuzumab for locally advanced or metastatic HER2-positive breast cancer treated with prior pertuzumab and/or T-DM1: Results from a phase II, single arm, multicenter study (N-SOG 10 study)
M. Fujii¹, N. Tsunoda¹, M. Hattori², T. Murata¹, K. Akahane¹, K. Kamei¹, Y. Goto¹, T. Amemiya¹, K. Nishimae¹, T. Kubota¹, Y. Ito¹, Y. Kurumiya¹, M. Yoshihara¹, K. Nakanishi¹, T. Kikumori¹, M. Ando¹, M. Nagino¹; ¹JP, ²Aichi/JP
- 13:00 - 13:00 102P - Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy
S.C. Lee¹, S.-C. Chen², M.-S. Dai², G.E. Lee¹, C.-L. Liu², A. Chan³, H.-K. Chang², L.-M. Tseng², W.Y. Chay¹, L.W.C. Chow⁴, J.L. Peneyra⁵, K.-M. Rau², H.-C. Wang², A.A. Guancia⁵, M. Head⁶, J.W.Y. Chiu⁴, B. Robinson⁶, B. Lindmark¹, N. McIntyre⁷, C.-Y. Hsieh²; ¹SG, ²TW, ³AU, ⁴HK, ⁵PH, ⁶NZ, ⁷GB
- 13:00 - 13:00 103P - Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
K. Matsui, A. Yoshikawa, K. Oyama, Z. Nozaki, Y. Tanada, M. Earashi, K. Kiyohara, T. Nagata, W. Fukushima, T. Shimizu, K. Maeda; JP
- 13:00 - 13:00 104P - Clinical and pathological profile of patients with breast cancer in northwest Pakistani population
A. Ali, PK
- 13:00 - 13:00 105P - Cost-effectiveness analysis of exemestane versus chemotherapy in post-menopausal hormonal responsive advanced breast cancer patients
I. Chitapanarux, R. Sruamsiri, P. Klunklin, P. Sripan; TH
- 13:00 - 13:00 106P - Eribulin mesylate for HER2- metastatic breast cancer; analyses of pattern of disease progression and outcomes from the real world
J. Watanabe, Shizuoka/JP
- 13:00 - 13:00 107P - The utility of risk factors proposed in a prospective clinical trial in the management of ER-positive, HER2-negative metastatic breast cancer patients: Feedback from the real world
K. Yoshitsugu¹, J. Watanabe²; ¹JP, ²Shizuoka/JP
- 13:00 - 13:00 108P - Does non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?
H.K. Kim, Y. Kim, S.E. Park, H.S. Lee, S. Lim, J.-Y. Kim, M.H. Heo, Y.H. Park; KR
- 13:00 - 13:00 109P - Literature review of visceral and non-visceral metastatic breast cancer
T. Mehmood, N. Begum; PK
- 13:00 - 13:00 110P - Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer
M. Earashi, K. Matsui, K. Maeda, W. Fukushima, K. Shimada, T. Shimizu, Z. Nozaki, Y. Tanada, K. Oyama, T. Nagata, A. Tsuneda, A. Yoshikawa, T. Yoshida, K. Kiyohara, K. Iwata, T. Ii; JP

- 13:00 - 13:00 111P - Changes in urinary NTX in early phase of denosumab therapy might be a predictive indicator in breast cancer patients with bone metastases
M. Shizuku, Y. Mizuno; JP
- 13:00 - 13:00 112P - Phase II trial of metronomic combination chemotherapy with oral regimen in heavily pretreated metastatic breast cancer
R. Prasanna¹, E. Prasad²; ¹Tamil Nadu/IN, ²IN
- 13:00 - 13:00 113P - Importance of immunohistochemistry for quick selection of breast cancer patients having BRCA1/2 mutations for their better treatment strategy: Pilot study in eastern India
J. Basak¹, A. Chakraborty², A. Mukhopadhyay¹; ¹IN, ²AL/US
- 13:00 - 13:00 114P - Conquering cardiotoxicity of trastuzumab: A 99Tc radiolabelled bio-distribution study
A. Thakur, V. Dhote; IN
- 13:00 - 13:00 115P - Triple negative breast cancer: Survival and age at time of diagnosis among the Lebanese population
C. Kassab, F. Nasr; LB
- 13:00 - 13:00 116P - Real world data on use of palbociclib in hormone-receptor (ER) positive HER2 negative metastatic breast cancer (MBC) among Asian patients
J. Chiu, R. Leung, H. Sze, P. Teo, P. Choi, T.-C. Lam, T. Yau, P. Cheng, F.-Y. Cheung, P. Cheung; HK
- 13:00 - 13:00 117P - The role of ELF3 in metastasis of triple negative breast cancer
S. Park, Y. Kwon; KR
- 13:00 - 13:00 120P - Glioblastoma multiforme overcomes ultrasmall superparamagnetic iron oxide nanoparticle induced cytotoxicity through heat shock protein protective mechanisms
T.W.R. Pang¹, G. Fatseas², M.E. Koina³, S. Adamson², S. Wilkinson², T. Chan-Ling²; ¹AU, ²NSW/AU, ³ACT/AU
- 13:00 - 13:00 121P - SIRT1 inhibition exhibits decreased pluripotency in cancer stem cells of glioma
M. bhagat, IN
- 13:00 - 13:00 122P - Stereotactic radiosurgery in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma
H. Long, CN
- 13:00 - 13:00 123P - Curcumin downregulates FAT1 expression via NFkB in glioblastoma
C. Srivastava, Y. Gupta, K. Irshad, P. Chattopadhaya, C. Sarkar, A. Suri, S. Sinha, K. Chosdol; IN
- 13:00 - 13:00 124P - FAT1 on Salvador-Warts-Hippo (SWH) pathway in human Glioblastoma
Y. Gupta, S. Shivajirao, K. Irshad, B. Dikshit, T. Srivastav, P. Chattopadhyay, S. Sinha, K. Chosdol; IN
- 13:00 - 13:00 125P - Impact of the time to initiation of chemoradiation on outcome of glioblastoma
A. Al Alhumiqani, A.K.A. Altwaairgi, B. Basulaiman, A. Balbaid; SA

- 13:00 - 13:00 126P - Gamma knife radiosurgery for treatment of cavernous sinus meningioma patients in Tangerang, Indonesia: A preliminary study
A.D. Vatvani, P. Wibisono, S. Evangelina, A. Widjaja, E. Soediatmoko, I. Hasbiullah, L. Hendriansyah; ID
- 13:00 - 13:00 127P - Apatinib combined with irinotecan in treatment of recurrent high-grade gliomas
X. Jiang, L. Wang, T. Yang, Y. Xia, Y. Qiao; CN
- 13:00 - 13:00 128P - Is fotemustine a good option after irinotecan-bevacizumab in high-grade glioma?
P. Ramirez Daffós, M.J. Martinez Bautista, G. Blanco Sanchez, S. Estalella, J.M. Baena Cañada; ES
- 13:00 - 13:00 129P - Outcomes and prognostic factors in re-irradiation of intracranial gliomas: Single institution experience
S. Paul¹, N. Sesikeran¹, V. Reddy¹, K. Bhattacharyya¹, S.T. Ahmed¹, R. Patlola², P. Upadhyay¹, V.K. Reddy¹, K. Mohanti¹, S. Reddy¹; ¹IN, ²NJ/US
- 13:00 - 13:00 130P - Biomarker prevalence in high grade glioma patients from Siloam Hospital Karawaci Indonesia
G. Prayogi¹, Z. Wuisan², D. Budiharko¹, T. Putra¹, N. Masykura¹, P. Prasetyo¹, J. July¹, E. Wahjoepramono¹, A. Utomo¹; ¹ID, ²DE
- 13:00 - 13:00 131P - Role of chromosomal 1p/19q co-deletion on the prognosis of oligodendrogliomas in Pakistan
Z. Ahmed¹, M. Tariq², T. Moatter²; ¹Sindh/PK, ²PK
- 13:00 - 13:00 132P - Formalin fixed and paraffin embedded tissue samples: Potential valuable resource for molecular analysis in medical research
R. Narayanappa, M. Aithal, P. Rout, A. Chand; IN
- 13:00 - 13:00 137P - Prognostic factors of patients received immuncheckpoint inhibitors in oncology phase 1 trials
T. Ebata¹, T. Shimizu², S. Iizumi², T. Koyama², A. Shimomura², S. Iwasa², S. Kondo², S. Kitano³, K. Yonemori², Y. Fujiwara², N. Yamamoto²; ¹Chiba/JP, ²JP, ³NY/US
- 13:00 - 13:00 138P - Clinical outcome and prognostic factors for patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS)
C.E. Chee, R. Soo, B.-C. Goh, W.P. Yong, S.C. Lee, D.S. Tan, A. Wong, W.J. Chng, V. Heong, B.C. Tai; SG
- 13:00 - 13:00 139P - Repurposing non-cancer drugs in oncology: Aspirin and metformin are only the tip of the iceberg
B. Gyawali¹, P. Pantziarka², L. Meheus², G. Bouche²; ¹Aichi/JP, ²BE
- 13:00 - 13:00 140P - Effects of sinomenine, cepharanthine, and tetrandrine on 2D and 3D cultured triple negative breast cancer cells
A. Kiyomi, R. Miyakawa, N. Uematsu, H. Ono, Y. Nakajima, T. Hirano, M. Sugiura; JP
- 13:00 - 13:00 141P - Erbitux conjugated zinc oxide nanoparticles to enhance antitumor efficiency via targeted drug delivery system for breast cancer therapy
K. Vimala¹, K. Soundarapandian²; ¹Tamilnadu/IN, ²IN

- 13:00 - 13:00 146P - Overall survival in the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line SIRT in patients with mCRC
H. Wasan¹, G. van Hazel², V. Heinemann³, N. Sharma⁴, J. Taieb⁵, J. Ricke³, M. Peeters⁶, M. Findlay⁷, P. Virdee¹, S. Love¹, J. Moschandreass¹, P. Dutton¹, V. GebSKI⁸, A. Gray¹, R. Sharma¹, P. Gibbs⁹; ¹GB, ²ACT/AU, ³DE, ⁴PA/US, ⁵FR, ⁶BE, ⁷NZ, ⁸NSW/AU, ⁹VIC/AU
- 13:00 - 13:00 147P - S-1/oxaliplatin (SOX) plus bevacizumab (Bev) as first line followed by S-1/irinotecan (IRIS) plus cetuximab (Cmab) as second line therapy in metastatic colorectal cancer (mCRC) (SOBIC trial)
Y. Nakamoto, R. Mikami, M. Umeki, Y. Tokunaga, T. Okumoto, T. Kawamura, H. Fujiwara, S. Doi, M. Noda, N. Tomita; JP
- 13:00 - 13:00 148P - Update analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
T. Yamada¹, Y. Kito¹, H. Satake¹, H. Taniguchi², Y. Horie¹, T. Esaki¹, T. Denda³, K. Mori¹, K. Yamazaki¹; ¹JP, ²Aichi/JP, ³Chiba/JP
- 13:00 - 13:00 149P - Efficacy and safety of CapeIRI plus bevacizumab therapy as a second-line treatment for patients with metastatic colorectal cancer
Y. Sunagawa¹, G. Nakayama², N. Hattori¹, K. Ezaka¹, H. Uda¹, S. Umeda¹, B. Sato¹, S. Yamada¹, H. Sugimoto¹, M. Koike¹, Y. Koderu¹; ¹JP, ²Aichi/JP
- 13:00 - 13:00 150P - Safety and antitumor activity of arsenic trioxide (ATO) plus infusional 5-FU, leucovorin and irinotecan (FOLFIRI) as second-line treatment for refractory metastatic colorectal cancer: Preliminary results from a pilot study
T. Chaudhuri, K.C. Lakshmaiah, K.G. Babu, L. Dasappa, L. Jacob, M.C.S. Babu, A.H. Rudresha, K.N. Lokesh, L.K. Rajeev; IN
- 13:00 - 13:00 151P - The therapy of apatinib in the third line of colorectal cancer
D. Ma, D. Yang, X. Lai, F. Xu; CN
- 13:00 - 13:00 152P - Palliative treatment of refractory metastatic colorectal cancer using regorafenib: Macau experience
X. Peng, Y. Lin, Y. Wang, C. Hui, C. Lam; MO
- 13:00 - 13:00 153P - Retrospective analysis of TAS-102 for metastatic colorectal cancer
M. Aoki, F. Shimamoto, T. Ikegami, T. Yamaguchi, T. Terazawa, T. Kii, M. Goto, K. Higuchi; JP
- 13:00 - 13:00 154P - Analysis of tumor location: A retrospective trial for evaluating the safety and efficacy of regorafenib for patients with metastatic colorectal cancer: HGCSG1401
T. Miyagishima¹, S. Yuki², T. Muranaka², Y. Tsuji², Y. Ota¹, K. Hatanaka², H. Okuda², T. Sasaki², M. Dazai², J. Konno¹, M. Nakamura¹, T. Ohta¹, T. Honda¹, A. Ishiguro¹, O. Muto¹, S. Kato¹, A. Sato¹, M. Abe¹, Y. Sakata³, Y. Komatsu²; ¹JP, ²Hokkaido/JP, ³Aomori/JP
- 13:00 - 13:00 155P - First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503

H. Yoshita¹, S. Yuki², M. Yagisawa¹, Y. Tsuji², Y. Kobayashi², K. Hatanaka², H. Okuda², M. Dazai², K. Furukawa¹, K. Ogawa¹, S. Minami¹, A. Ishiguro¹, T. Honda¹, T. Ohta¹, K. Eto¹, T. Kato¹, J. Nakajima¹, T. Sasaki², Y. Sakata³, Y. Komatsu²; ¹JP, ²Hokkaido/JP, ³Aomori/JP

- 13:00 - 13:00 156P - Impact of nursing care management program on cetuximab in metastatic colorectal cancer
J.-T. Liang, J.-C. Lee, P.-C. Lin, B.-W. Lin, S.-C. Lin, Y.-T. Chen; TW
- 13:00 - 13:00 157P - Impact on survival of pulmonary metastasectomy in colorectal cancer
M. Meri Abad, C. Avila Andrade, A.J. Cunquero Tomas, A. Rodriguez Human, A.B. Fernandez Diaz, L. Condori Farfan, I. Shaheen, M.J. Safont Aguilera, C. Caballero Diaz, V. Iranzo Gonzalez-Cruz, A. Blasco Cordellat, M.C. Godes Sanz de Bremond, A. Berrocal, V. Sforza, M. Gil Raga, C. Camps Herrero; ES
- 13:00 - 13:00 158P - Comparative pharmacokinetics of a proposed biosimilar bevacizumab Bmab-100 and reference product bevacizumab in a multicentre double blind randomized clinical trial in metastatic colorectal carcinoma (mCRC) patients
S. Beniwal¹, M. Kothekar¹, S. Loganathan¹, A. Vishweswaramurthy¹, A. Marwah¹, E. Pennella², N. Sengupta¹; ¹IN, ²PA/US
- 13:00 - 13:00 159P - Efficacy of combined chemotherapy and surgical resection on survival of patients with colorectal liver metastases and concurrent extrahepatic disease
I. Uthman, A. Meshref, M. Faisal, M. Hassan, A. Amin, M. Hafez; EG
- 13:00 - 13:00 160P - Improved survival benefit of radiation therapy after surgery in patients with stage IV rectal cancer: A retrospective population-based and propensity score-matched study
Q. Liu, CN
- 13:00 - 13:00 161P - The impact of the type of progression on survival in patients with metastatic colorectal cancer
M. Shibutani¹, K. Maeda¹, H. Nagahara¹, T. Fukuoka¹, S. Nakao¹, S. Matsutani¹, S. Kashiwagi², K. Hirakawa¹, M. Ohira¹; ¹JP, ²Osaka/JP
- 13:00 - 13:00 162P - Real world use of palliative systemic therapy (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) within a UK specialist cancer centre
S. Khakoo¹, A. Georgiou², D. Hughes², A. Lanese², C. Baratelli², M. Coakley², S. Shepherd², V. Calamai², K. Kouvelakis², R. Kalaitzaki², A. Ring², I. Chau², D. Watkins², S. Rao², D. Cunningham², N. Starling²; ¹Surrey/GB, ²GB
- 13:00 - 13:00 163P - Modernization of radiological diagnostic methods of cancer of anal canal
K. Matyusupov, A. Ososkov, S. Abdujapparov, M. Ismailova; UZ
- 13:00 - 13:00 164P - Relationship between primary tumor location and mortality in stage II colon cancer
S. Pinto-Torres¹, M. Malheiro², J. Rato², T. André², A. Gradil², A. João², S. Braga², A. Xavier², A. Martins², T. Fiúza²; ¹Lisboa/PT, ²PT
- 13:00 - 13:00 165P - Survival contradiction between stage IIA and stage IIIA rectal cancer
S. Mo, B. Huang, W. Dai, Q. Li, G. Cai; CN

- 13:00 - 13:00 166P - Neoadjuvant modified FOLFOXIRI followed by laparoscopic surgery for locally advanced rectal cancer: A retrospective study
H. KODAMA, T. Terazawa, K. Higuchi, M. Goto, T. Kii, S. Kuwakado, H. Nishitani, F. Shimamoto, K. Asaishi, T. Yamaguchi, M. Aoki; JP
- 13:00 - 13:00 167P - Preoperative chemoradiotherapy in non metastatic locally advanced rectal cancer: A tertiary cancer center experience from India
A. Kapoor¹, A. Ramaswamy², R. Engineer², S. Lewis², S. Chopra², A. Desouza², A. Saklani², V. Ostwal²; ¹Uttar Pradesh/IN, ²IN
- 13:00 - 13:00 168P - Robotic versus laparoscopic intersphincteric resection for low rectal cancer: Systemic review and meta-analysis
S.W. Lim, J.I. Ju; KR
- 13:00 - 13:00 169P - Laparoscopic versus open right hemicolectomy: Results from a country with limited resources
I. Nasir, M. Ashraf, A. Malik, S. Khattak, A. Syed; PK
- 13:00 - 13:00 170P - Clinical impact of postoperative surgical complications on the colorectal cancer survival and recurrence: Analyses of pooled individual patients' data from three large phase III randomized trials
T. Aoyama¹, K. Oba¹, M. Honda¹, S. Sadahiro², C. Hamada¹, S. Mayanagi¹, M. Kanda¹, H. Maeda¹, J. Sakamoto³, S. Saji¹, T. Yoshikawa¹; ¹JP, ²Kanagawa/JP, ³Gifu/JP
- 13:00 - 13:00 171P - Colorectal obstruction is a potential prognostic factor for stage II/III colorectal cancer
T. Shimura, Y. Okuda, T. Yamada, Y. Hirata, T. Joh; JP
- 13:00 - 13:00 172P - Clinicopathological and outcome differences between right and left colon cancer: An institutional experience from South India
R. Kandula¹, S. Gundeti², K. Rajesh², A. Ravishankar², B. Stalin¹, A. Kumar²; ¹Andhra Pradesh/IN, ²IN
- 13:00 - 13:00 173P - Increasing disparities in age-related cause specific survival (CSS) among US patients with colorectal cancer: SEER analysis
Y. Feng, S. Cai; CN
- 13:00 - 13:00 174P - Prevalence, presentation and outcome of colorectal cancer patient with age less than screening recommendation
S. Chompoonuch, P. Chittinandana, O. Sukreeyapongse, C. Upachar; TH
- 13:00 - 13:00 175P - Situation analysis of colorectal cancer status in Uzbekistan and implementing measures to increase early detection and survival rate
Y. Ten, S. Abdujapparov, H. Islamov, D. Egamberdiev, Y. Ziyaev, S. Matniyazova, H. Bobokulov, B. Korahojayev, S. Djanklich, A. Abdujapparov; UZ
- 13:00 - 13:00 176P - Incidence and survival outcomes in mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinoma: A SEER analysis
Y. Li, Y. Feng, W. Dai, S. Mo, Q. Li, S. Cai; CN

- 13:00 - 13:00 177P - Comparative analysis of the clinicopathologic profile of colorectal cancer between younger and older patients in Saint Louis University Hospital of the Sacred Heart, Baguio City Philippines: A cross-sectional, analytical study
J.M. Cacanindin, PH
- 13:00 - 13:00 178P - A robust gene signature for the detection of early relapse in stage I-III colon cancer
W. Dai, Y. Li, Q. Li, G. Cai; CN
- 13:00 - 13:00 179P - PDGFR- β gene expression relates to recurrence in colorectal cancer
N. Miyoshi¹, S. Fujino¹, M. Ohue¹, Y. Takahashi¹, M. Yasui¹, H. Takahashi¹, N. Haraguchi¹, J. Nishimura¹, T. Hata¹, C. Matsuda¹, T. Mizushima², Y. Doki¹, M. Mori¹; ¹JP, ²Osaka/JP
- 13:00 - 13:00 180P - A novel prognostic score based on inflammation and nutrition in colorectal cancer patients
S. Fujino¹, N. Miyoshi¹, Y. Takahashi¹, M. Yasui¹, M. Ohue¹, K. Saso¹, T. Hata¹, C. Matsuda¹, T. Mizushima², Y. Doki¹, M. Mori¹; ¹JP, ²Osaka/JP
- 13:00 - 13:00 181P - Identifying prognostic subgroups for outcomes in wild-type RAS metastatic colorectal cancer (mCRC) treated with anti-EGFR drugs
O. Kit, L. Vladimirova, N. Abramova, A. Storozhakova, I. Popova, N. Tikhanovskaya, M. Ezhova; RU
- 13:00 - 13:00 182P - Clinical implementation of the universal tumor screening with the mismatch repair (MMR) proteins on decision impact of adjuvant chemotherapy in patients with resected stage II/III colorectal cancer (CRC)
Y. Yamamoto¹, Y. Tsukada¹, H. Bando¹, T. Sasaki¹, Y. Nishizawa¹, M. Kojima¹, T. Kuwata¹, M. Ito¹, T. Yoshino²; ¹JP, ²Chiba/JP
- 13:00 - 13:00 183P - The efficacy of Hydralazine to attenuate colorectal carcinoma (CRC) associated with CIN and/or MMR-deficient molecular aetiology
D. Dam, R. Bhattacharya, K. Chaudhuri, C. Prophan, A. Mukhopadhyay; IN
- 13:00 - 13:00 184P - Prevalence and association of microsatellite instability with PD-L1 expressions in colorectal cancer patients treated in an Indonesian private hospital
A. Sudoyo, A. Kurniawan, A. Budiayati, G. Kusumo, T. Putra, A. Utama, F. Rexana, A.R. Utomo; ID
- 13:00 - 13:00 185P - The change in the psoas muscle index in neoadjuvant therapy is a predictive prognostic marker in locally advanced rectal cancer
T. FUKUOKA¹, K. Maeda¹, H. Nagahara¹, M. Shibusaki¹, S. Nakao¹, S. Matsutani¹, S. Kashiwagi², K. Hirakawa¹, M. Ohira¹; ¹JP, ²Osaka/JP
- 13:00 - 13:00 186P - EMT status of circulating tumor cells can predict responses to chemo-radiotherapy and tumor metastasis in rectal cancer patients
W. Sun, J. Wan, L. Yang, Z. Zhang; CN
- 13:00 - 13:00 187P - Impact of KRAS mutational status and primary tumor location on the efficacy of aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer: An exploratory analysis in a phase II study

K. Yamazaki¹, T. Satoh², Y. Komatsu³, T. Taguchi¹, Y. Sunaga¹, T. Yoshino⁴; ¹JP, ²Osaka/Jp, ³Hokkaido/Jp, ⁴Chiba/Jp

- 13:00 - 13:00 188P - A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer
W. Okamoto¹, K. Muro², H. Taniguchi², K. Akagi¹, H. Hara¹, T. Nishina¹, T. Kajiwara¹, T. Denda³, S. Hironaka³, T. Kudo⁴, T. Satoh⁴, T. Yoshino³; ¹JP, ²Aichi/Jp, ³Chiba/Jp, ⁴Osaka/Jp
- 13:00 - 13:00 189P - FCyRIIa and FCyRIIIa single nucleotide polymorphisms (SNPs) and cetuximab benefit in the EXCITE trial
F. Scalfani¹, S. Gollins¹, D. Cunningham¹, S. Hulkki Wilson¹, K. Kouvelakis¹, A. Lopes¹, N. West¹, P. Quirke¹, R. Begum¹, N. Valeri¹, S. Beare¹, L. Hughes¹, D. Gonzalez De Castro¹, I. Chau²; ¹GB, ²Surrey/GB
- 13:00 - 13:00 190P - CXCR4 mRNA expression in patients with colorectal cancer
N. Yoshuantari, S. Hutajulu, A. Ghozali, D.S. Heriyanto, J. Kurnianda; ID
- 13:00 - 13:00 191P - Expression and mutational analysis of Exon 17 of TCF4 transcription factor in sporadic colorectal cancer
M. Anwar, R. Kochhar, A. Bhatia, R. Singh, S. Mahmood; IN
- 13:00 - 13:00 192TiP - S-1 and CPT-11 plus ramucirumab (IRIS+Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)
K. Kobayashi, M. Morita, S. Ito, Y. Inoue, I. Yamaguchi, T. Kosaka, S. Kuba, C. Sakimura, A. Soyama, T. Adachi, S. Ohno, S. Kobayashi, T. Hara, M. Hidaka, N. Hayashida, K. Yamanouchi, K. Kanetaka, M. Takatsuki, S. Eguchi; JP
- 13:00 - 13:00 197P - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: A prospective randomized controlled clinical study
Z. wang, G. Dai, Y. Zhou, H. Hui, P. Zhang, M. Gou; CN
- 13:00 - 13:00 198P - Cross-sectional location of gastric cancer affects the long-term survival of patients as tumor invasion deepens
Y.J. Jung, H.H. Lee; KR
- 13:00 - 13:00 199P - Cisplatin substitution with carboplatin during radical chemoradiation (CRT) for localised gastroesophageal carcinoma (GEC): Outcomes from a tertiary referral centre
A. Athauda¹, D. Watkins², K. Mohammed¹, A. Ramessur¹, I. Chau³, N. Starling¹, S. Rao¹, D. Tait¹, K. Aitken¹, N. van As¹, D. Cunningham¹; ¹GB, ²IR, ³Surrey/GB
- 13:00 - 13:00 200P - S-1 combined with oxaliplatin or cisplatin in neoadjuvant chemotherapy for stage IIb/III gastric adenocarcinoma - efficacy and safety results of a randomized clinical trial
J. Peng¹, J. Zhang², J. Ye², X. Zhang², H. Wu², J. Xu², Y. He²; ¹Guangdong/CN, ²CN
- 13:00 - 13:00 201P - Prognostic impact of metastasis to splenic hilar lymph nodes in proximal gastric carcinoma
O. Jeong, Y.K. Park, S.Y. Ryu; KR

- 13:00 - 13:00 202P - High circulating lymphocyte ratio has a positive relationship with pathological complete response and overall survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
Y. Li¹, Q. He², X. Ji², X. Wang², C. Fan², G. Li²; ¹Jiangsu Province/CN, ²CN
- 13:00 - 13:00 203P - Pathological complete response and outcome of FLEEOX vs. SEEEX as neoadjuvant chemotherapy in advanced gastric cancer
Y. Li¹, Q. He², X. Wang², C. Fan², G. Li²; ¹Jiangsu Province/CN, ²CN
- 13:00 - 13:00 204P - Rash, neutrophil-lymphocyte ratio (NLR) and survival in the REAL3 trial
E. Smyth¹, K. Kouvelakis¹, C. Peckitt¹, T. Waddell¹, D. Watkins², S. Rao¹, N. Starling¹, C. Saffery¹, A. Okines¹, I. Chau³, D. Cunningham¹; ¹GB, ²IR, ³Surrey/GB
- 13:00 - 13:00 205P - Real-world productivity, healthcare resource utilization (HRU), and quality of life (QOL) in patients with advanced gastric cancer (GC) in Korea and Japan
K. Muro¹, E. Calvo², G. Maglinte³, A. Rider⁴, M. Contente⁵, C. Middleton⁴, B. Clarke⁴, S.Y. Rha⁶; ¹Aichi/JP, ²ES, ³US, ⁴GB, ⁵BE, ⁶KR
- 13:00 - 13:00 206P - Outcomes and predictive markers of trastuzumab-containing 1st-line chemotherapy in patients with HER2-positive advanced gastric cancer
J. Cheon¹, M.-H. Ryu¹, S.R. Park¹, B.-Y. Ryoo², J. Jeong¹, J.H. Park², B. Kim², Y. Park¹, Y.-K. Kang²; ¹KR, ²Songpa-gu/KR
- 13:00 - 13:00 207P - Examination of utility in patients of unresectable or recurrent gastric cancer treated with paclitaxel or nab-paclitaxel or paclitaxel+ ramucirumab in our hospital
T. Kii¹, M. Gotoh², T. Terazawa², T. Yamaguchi¹, K. Asaishi¹, M. Aoki¹, T. Ikegami¹, K. Higuchi¹; ¹JP, ²Osaka/JP
- 13:00 - 13:00 208P - Real-world advanced gastric cancer treatment patterns in Western and Asian countries
S.Y. Rha¹, E. Calvo², M. Contente³, A. Rider⁴, G. Maglinte⁵, B. Clarke⁴, K. Muro⁶; ¹KR, ²ES, ³BE, ⁴GB, ⁵US, ⁶Aichi/JP
- 13:00 - 13:00 209P - Efficacy, safety and health-related quality of life with epirubicin, cisplatin plus 5-FU (ECF) and docetaxel, cisplatin plus 5-FU (DCF) regimens as first-line systemic chemotherapy in metastatic gastric cancer: Final results of a phase II study
T. Chaudhuri, K.G. Babu, K.C. Lakshmaiah, L. Dasappa, L. Jacob, M.C.S. Babu, A.H. Rudresha, K.N. Lokesh, L.K. Rajeev; IN
- 13:00 - 13:00 210P - MAGEA family gene expression influences survival in intestinal gastric cancer
S. Pattison¹, T. Leong², R. Busuttill², A. Boussioutas²; ¹NZ, ²VIC/AU
- 13:00 - 13:00 211P - Impact of preoperative sarcopenia on overall survival in gastric cancer surgery
T. Sato, T. Aoyama, Y. Maezawa, K. Kano, T. Hayashi, T. Yamada, T. Oshima, Y. Rino, T. Ogata, H. Cho, T. Yoshikawa, M. Masuda; JP

- 13:00 - 13:00 212P - The impact of the difference in total diameter of metastatic tumor as a prognostic factor for advanced gastric cancer treated with systemic chemotherapy
Y. Sasaki, J. Hirota, J. Konno; JP
- 13:00 - 13:00 213P - HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
Y. Kawamoto¹, S. Yuki¹, T. Meguro², K. Hatanaka¹, M. Uebayashi², I. Iwanaga³, M. Nakamura², K. Eto², H. Okuda¹, M. Abe², A. Aonuma², N. Abe², A. Sato², H. Nakatsumi², T. Muranaka¹, M. Yagisawa², K. Oba², Y. Sakata⁴, N. Sakamoto², Y. Komatsu¹; ¹Hokkaido/JP, ²JP, ³Hokkaido Prefecture/JP, ⁴Aomori/JP
- 13:00 - 13:00 214P - Priority of lymphadenectomy for each station in elderly patients with middle to distal advanced gastric cancer
M. Nakazono, T. Hayashi, T. Yamada, H. Osakabe, K. Hara, S. Nagasawa, Y. Kumazu, Y. Rino, M. Masuda, T. Ogata, T. Yoshikawa; JP
- 13:00 - 13:00 215P - Optimal cutoff of histological response by neoadjuvant chemotherapy for gastric cancer
K. Hara, T. Hayashi, H. Osakabe, M. Nakazono, S. Nagasawa, Y. Kumazu, T. Yamada, Y. Rino, M. Masuda, T. Ogata, T. Yoshikawa; JP
- 13:00 - 13:00 216P - Upfront surgery and pathological stage based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma
P.-K. Hsu, TW
- 13:00 - 13:00 217P - Nomogram to predict the overall survival for patients underwent preoperative radiation therapy with chemotherapy
M. Ma, X.-S. Gao; CN
- 13:00 - 13:00 218P - Profile of gastric adenocarcinoma in patients younger than 40 years- a single center experience from India
P. Patil, J.S. Dhingra, S. Mehta; IN
- 13:00 - 13:00 219P - Treatment of gastric cancer with brain metastasis or leptomeningeal carcinomatosis
M. Kano¹, J. Hihara², N. Hirabayashi¹; ¹JP, ²Hiroshima/JP
- 13:00 - 13:00 220P - Retrospective analysis of paclitaxel and ramucirumab for unresectable gastric cancer. Hypertension during 1st cycle has possibility of predictive factor
T. Matsumoto, JP
- 13:00 - 13:00 221P - The risk factors of recurrence of complete adjuvant chemotherapy following curative gastrectomy in patients with advanced gastric cancer
Y.J. Kim, W.C. Chung; KR
- 13:00 - 13:00 222P - Effectiveness and tolerability of nimotuzumab in locally advanced or recurrent/metastatic esophageal cancer: An Indian tertiary care hospital based study
S. Subramanian¹, N. Sridharan², V. Balasundaram², S. Chaudhari², D. Pawar²; ¹Tamil Nadu/IN, ²IN

- 13:00 - 13:00 223P - The number of negative lymph node within the thoracic cavity is a strong predictor for the extent of lymphadenectomy in patients with esophageal squamous cell carcinoma
J. Zhang, X. Heng; CN
- 13:00 - 13:00 224P - Evaluation of the safety and efficacy of combined the CART and chemotherapy for gastrointestinal cancers with massive ascites
Y. Nagata, K. Kato, T. Miyamoto, H. Shoji, S. Iwasa, Y. Honma, A. Takashima, T. Hamaguchi, M. Saruta, N. Boku; JP
- 13:00 - 13:00 225P - Feasibility study of preoperative chemotherapy for esophageal cancer with naso-gastric ED tube for patients with difficulty of oral ingestion
T. Ogata, H. Osakabe, S. Nagasawa, K. Hara, M. Nakazono, Y. Kumazu, T. Hayashi, T. Yamada, T. Yoshikawa; JP
- 13:00 - 13:00 226P - A molecular staging system in esophageal squamous cell carcinoma based on the status of EGFR and P53
J. Zhang, L. Li; CN
- 13:00 - 13:00 227P - CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
L.-T. Chen¹, A. Wang-Gillam², Y.-S. Shan¹, T. Macarulla Mercade³, J.F. Blanc⁴, R. Hubner⁵, C.-F. Chiu¹, G. Schwartzmann⁶, J. Siveke⁷, B. Belanger⁸, F. de Jong⁹, K. Mamlouk⁸, D. von Hoff¹⁰; ¹TW, ²MO/US, ³ES, ⁴FR, ⁵GB, ⁶RS/BR, ⁷DE, ⁸MA/US, ⁹CH, ¹⁰AZ/US
- 13:00 - 13:00 228P - Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
J.F. Blanc¹, R. Hubner², C.-P. Li³, A. Wang-Gillam⁴, G. Bodoky⁵, A. Dean⁶, Y.-S. Shan³, G. Jameson⁷, T. Macarulla Mercade⁸, K.-H. Lee⁹, D. Cunningham², C.-F. Chiu³, G. Schwartzmann¹⁰, F. Braiteh¹¹, D. von Hoff⁷, L.-T. Chen³, K. Mamlouk¹², F. de Jong¹³, J. Siveke¹⁴; ¹FR, ²GB, ³TW, ⁴MO/US, ⁵HU, ⁶WA/AU, ⁷AZ/US, ⁸ES, ⁹KR, ¹⁰RS/BR, ¹¹US, ¹²MA/US, ¹³CH, ¹⁴DE
- 13:00 - 13:00 229P - Gemcitabine + Nab-Paclitaxel for advanced pancreatic cancer: A retrospective audit of dose intensity, toxicity and efficacy
A. Mant¹, R. Wong², J. McKendrik², M. Lee²; ¹VIC/AU, ²AU
- 13:00 - 13:00 230P - Dose intensity and initial treatment effect of FOLFIRINOX supported with pegfilgrastim for patients with pancreatic ductal adenocarcinoma
H. Kido¹, T. Terashima², T. Yamashita², H. Takatori¹, K. Kitamura¹, S. Kaneko²; ¹JP, ²Ishikawa/JP
- 13:00 - 13:00 231P - Patterns of treatment outcomes in older patients with metastatic pancreatic cancer
J.Y. Jung, H.A. Jung, B. Han, H.Y. Kim, D.Y. Zang; KR
- 13:00 - 13:00 232P - Dacomitinib, a pan-ErbB inhibitor, inhibits proliferation and invasion of pancreatic ductal adenocarcinoma cells

F. Esmaeili¹, M. Momeny², H. Yousefi¹, H. Eyvani¹, Z. Sabourinejad¹, F. Barghi¹, S. Vaezijoze¹, Z. Alishahi¹, G. Zarrinrad¹, A. Poursheikhani¹, E. Aboutorabi¹, G. Sankanian¹, F. Moghaddaskho¹, S. Shamsaiegahkani¹, J. Tavakkoly-Bazzaz¹, K. Alimoghaddam¹, A. Ghavamzadeh¹, S. Ghaffari¹; ¹IR, ²FI

- 13:00 - 13:00 233P - Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
O. MAEDA, Y. Yokoyama, J. Yamaguchi, A. Ota, A. Matsuoka, S. Morita, M. Inoue, T. Mizutani, T. Shimokata, H. Urakawa, A. Mitsuma, M. Nagino, Y. Ando; JP
- 13:00 - 13:00 234P - Efficacy of chemotherapy for locally advanced and metastatic pancreatic cancer: A single institution experience from a third world country
S. Yasmeen, U. Ahmad; PK
- 13:00 - 13:00 235P - Clinical utility of PET/CT and diagnostic laparoscopy in pancreatic cancer staging
A. Bulbul¹, A. Mustafa², S. Chouial¹, S. Rashad¹, S. Gholam³, E.A. Mino¹, H. Aboud⁴, M. Khorsand¹; ¹NM/US, ²IN, ³CA/US, ⁴MI/US
- 13:00 - 13:00 236P - C4orf47 contributes to the induction of malignant phenotypes in pancreatic cancer
M. Kawamoto¹, H. Onishi², A. Yamasaki¹, M. Nakamura¹; ¹JP, ²Fukuoka/JF
- 13:00 - 13:00 237P - Personalized peptide vaccine induced adoptive immunocyte transfer combined chemotherapy and radiation improved the survival of advanced pancreatic cancer
Q. Liu, Z. Zou, W. Kong, F. Chen, F. Meng, B. Liu; CN
- 13:00 - 13:00 238P - Three-dimensional remnant pancreatic volumetry predicts the short-term outcomes of pancreatic cancer patients after pancreatoduodenectomy
R. Miyamoto, N. Sano, S. Tadano, S. Inagawa; JP
- 13:00 - 13:00 239P - Baseline sum of longest diameter in target lesions by response evaluation criteria in solid tumor as a prognostic factor in patients with advanced hepatocellular carcinoma receiving sorafenib treatment
E. Suzuki, T. Maeda, T. Chiba, S. Ogasawara, Y. Ooka, N. Kato; JP
- 13:00 - 13:00 240P - Hepatic reserve and the other conditions for regorafenib as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib in Japanese practical setting
T. Terashima, T. Yamashita, K. Arai, S. Kaneko; Ishikawa/JF
- 13:00 - 13:00 241P - Interferon-stimulated gene 20 induction by thyroid hormone promotes angiogenesis in hepatocellular carcinoma
K.-H. Lin, S.-L. Lin; TW
- 13:00 - 13:00 242P - Clinicopathological data and treatment outcomes in patients with hepatocellular carcinoma (10 years single institution experience 2003-2012)
H. Fahmy, EG
- 13:00 - 13:00 243P - Sorafenib's survival benefit and comparison with other treatment modalities in advanced hepatocellular carcinoma
P. Khatri, Rajasthan/IN

- 13:00 - 13:00 244P - Hepatocellular carcinoma may be closely associated with in-hospital mortality and failure to control to variceal bleeding
S.E. Kim, J.W. Park, D.M. Jung, C.K. Park; KR
- 13:00 - 13:00 245P - Gemcitabine and cisplatin based combination chemotherapy in patients of locally advanced and metastatic gall bladder cancer: An observational study
D. Panda, M. Aggarwal, V. Yadav, N. Agrawal, A. Arora, S. Baghmar, G. Kumar; IN
- 13:00 - 13:00 246P - Clinical profile and outcomes of carcinoma anal canal: A single institution experience
D. KOPPAKA, K.C. Lakshmaiah, K.G. Babu, L. Dasappa, L. Jacob, M.C.S. Babu, K.N. Lokesh, A.H. Rudresha, L.K. Rajeev, S. Saldanha; IN
- 13:00 - 13:00 247P - Survival trend of advanced gastrointestinal stromal tumors treated by tyrosine kinase inhibitors: A 14-year single center experience
J.H. Kim, M.-H. Ryu, C. Yoo, H. Chae, H. Na, M. Beck, K.-H. Kim, C.W. Kim, Y.-K. Kang; KR
- 13:00 - 13:00 248P - A Study Evaluating Diagnostic Efficiency of MYCN by FISH Performed on Different Neuroblastoma Sample Materials
M. Singh, P. Bhatia, R. Srinivasan, A. Trehan, D. Bansal, N. Kakkar, R. Jain; IN
- 13:00 - 13:00 249P - The metastases spectrum of neuroendocrine neoplasms in gastrointestinal tract
W. Cai, H. Hu; CN
- 13:00 - 13:00 250P - Biliary tract cancer (BTC) burden in Medical Oncology Department, Yangon General Hospital (YGH): A retrospective review
S.S. Win, P. Theint, H. Maw, Z. Thynn, S. Myint; MM
- 13:00 - 13:00 251P - Investigation of IVS14 &
D. Egamberdiev, Z. Mirakbarova, D. Dalimova, S. Turdikulova, M. Djuraev, D. Pulatov; UZ
- 13:00 - 13:00 252P - Patterns of care and adherence to evidence based guidelines in patients with hepatocellular cancer
S. Sundaram, P. Patil, S. Mehta; IN
- 13:00 - 13:00 253P - Review of esophageal cancer in Medical Oncology Department, YGH
Z. Thynn, S. Win, H. Maw, P. Theint, S. Myint, W. Lwin; MM
- 13:00 - 13:00 254P - Portal vein thrombosis risk factors and clinical findings in Indonesian hepatocellular carcinoma patients
D. Widjaja, M. Leonardo, A.D. Vatvani, K. Waren, A. Kurniawan; ID
- 13:00 - 13:00 255P - Complex treatment of patients with mechanical jaundice of tumor etiology
S. Lukmonov, UZ
- 13:00 - 13:00 256P - Liver responses after previously performed radiofrequency thermoablation interventions for malignant neoplasms
S. Lukmonov, UZ

- 13:00 - 13:00 257P - Comparison of four staging systems to predict overall survival rate in Indonesian hepatocellular carcinoma patients
K. Waren, A.D. Vatvani, D. Widjaja, M. Leonardo, A. Kurniawan; ID
- 13:00 - 13:00 258P - Comparison of results of cytological and histological research of thyroid gland nodes
S. Issaeva, Z. Khalimova, S. Ismailov, A. Yuldashev, F. Yuldasheva; UZ
- 13:00 - 13:00 259P - Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel vs platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers
A. Tamtai, C. Jiarpinitnun, P. Hiranyatheb, N. Unwanatham, E. Sirachainun, C. Supsamutchai, P. Pattaranutaporn, N. Ngamphaiboon; TH
- 13:00 - 13:00 260TiP - Phase 3, randomized, double-blind, placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20)+nab-paclitaxel/gemcitabine in patients with previously untreated, hyaluronan-high, stage IV pancreatic ductal adenocarcinoma (PDA)
D.-Y. Oh¹, Y.-J. Bang¹, E. van Cutsem², A. Hendifar³, M. Reni⁴, L. Zheng⁵, M. Ducreux⁶, W. Harris⁷, P. Corrie⁸, T. Seery³, D. Chondros⁷, A. Bullock⁷, C.-P. Li⁹; ¹KR, ²BE, ³US, ⁴IT, ⁵MD/US, ⁶FR, ⁷AL/US, ⁸GB, ⁹TW
- 13:00 - 13:00 264P - The expression of prostate-specific membrane antigen in circulating tumor cells (CTC) of castration-resistant prostate cancer: The association with poor treatment response
N. Nagaya, M. Kanayama, M. Nagata, S. Horie; JP
- 13:00 - 13:00 265P - Multi-parametric magnetic resonance imaging-based nomogram for predicting prostate cancer and high-grade prostate cancer in men undergoing repeat prostate biopsy
C. Huang, CN
- 13:00 - 13:00 266P - Correlation of a whole blood RNA assay detecting AR-v7 expression with PSA response in patients with metastatic castration-resistant prostate cancer (mCRPC)
E. Kwan¹, S. To¹, H. Fettke¹, M. Docanto², L. Martelotto², N. Ng², A. Mant¹, P. Parente¹, C. Pezaro¹, T. Todenhofer³, A. Azad⁴; ¹VIC/AU, ²AU, ³DE, ⁴British Columbia/AU
- 13:00 - 13:00 267P - Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models
J. Ni, P. Cozzi, J. Beretov, J. Bucci, P. Graham, Y. Li; AU
- 13:00 - 13:00 268P - Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients
Y.S. Kim, KR
- 13:00 - 13:00 269P - Circulating tumor cell in hormone-naive metastatic prostate cancer
N. Nagaya, M. Kanayama, M. Nagata, S. Horie; JP
- 13:00 - 13:00 270P - 68Ga prostate-specific membrane antigen positron emission tomography for evaluation of biochemical recurrence of prostate cancer - our local experience
C. Goh, W. Lam, M.L.K. Chua, J. Tan; SG
- 13:00 - 13:00 271P - 2-weekly docetaxel in newly diagnosed high volume metastatic castration naïve prostate cancer

S. Hussain, G. Gautam, P. Ahluwalia, H. Chaturvedi, A. Punnakal, A. Gupta; IN

- 13:00 - 13:00 273P - Prognostic significance of pre- to postoperative dynamics of prognostic nutritional index in patients with renal cell carcinoma who underwent radical nephrectomy
M. Kang, H.H. Sung, H.G. Jeon, B.C. Jeong, S.I. Seo, S.S. Jeon, H.Y. Choi, H.M. Lee; KR
- 13:00 - 13:00 274P - Efficacy of palliative treatments in renal cancer: A retrospective observational study in a district general hospital in the UK
N. O'Connell¹, H. Iftikhar¹, G. Srinivasan², J. Radhakrishnan¹; ¹GB, ²Essex/GB
- 13:00 - 13:00 275P - Can tumor size, ultrasonographic findings, and serum human chorionic gonadotropin (HCG) levels predict the likelihood of malignant testicular histology?
G. Song, CN
- 13:00 - 13:00 276P - First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of data from a phase III trial
X. Sheng¹, F. Bi¹, X. Ren¹, Y. Cheng¹, J. Wang¹, B. Rosbrook², M. Jiang¹, J. Guo¹; ¹CN, ²CA/US
- 13:00 - 13:00 277P - An overview of pazopanib in metastatic renal cell carcinoma (mRCC) in Ministry of Health (MOH), Malaysia: A multicentre experience
M.S. Sandhu, K. Nurazzahra, S. Sandya, M. Chen; MY
- 13:00 - 13:00 278P - MECA79 positive high endothelial venule density (HEV) correlates with clinical outcomes in upper tract urothelial carcinoma patients treated with radical nephroureterectomy
Y. Hashimoto, T. Yoneyama, H. Yamamoto, S. Hatakeyama, T. Yoneyama, T. Koie, C. Ohyama; JP
- 13:00 - 13:00 279P - Chemotherapy in carcinoma penis: Experience from a tertiary cancer centre in India
S. Mailankody, V. Radhakrishnan, A. Raja, T.S. Ganesan, P. Ganesan, M. Dhanushkodi, T. Joshua, T. Sagar; IN
- 13:00 - 13:00 280P - The evaluation and outcome of a new intravesical BCG protocol for non-muscle invasive bladder cancer in a tertiary care center In India
A. MUKHOPADHYAY, A. Mandal, S. Singh, R. Mavuduru, S. MODAK; IN
- 13:00 - 13:00 281P - Comparative evaluation of safety and efficacy of alternate schedule of sunitinib in non-Asian and Asian patient population for treatment of metastatic renal cell cancer: A meta-analysis
P. Kapse¹, M. Singh¹, M. Alam²; ¹IN, ²ACT/AU
- 13:00 - 13:00 282P - S-1 plus cisplatin combination therapy in patients with urachal carcinoma: A retrospective study
R. Oki, C. Kondoh, Y. Miura, Y. Ozaki, Y. Tanabe, K. Sakaguchi, K. Kurosawa, S. Urakami, T. Okaneya, T. Takano; JP
- 13:00 - 13:00 283P - Association of 25(OH)D3 with outcomes in renal cell carcinoma
A. Bulbul¹, T. Braik¹, A. Mustafa², E.A. Mino¹, S. Chouial¹, H. Aboud³, S. Rashad¹, A. Bautista¹, M. Khorsand¹, T. Dorff⁴; ¹NM/US, ²IN, ³MI/US, ⁴CA/US
- 13:00 - 13:00 284P - Retrospective multicentric analysis of Indian patients with metastatic renal cell carcinoma on first-line sunitinib 2/1 schedule

S. Patil¹, S. Thungappa², K. Kumar², K. Prasad², T. Tilak², H.P. Shashidhara², S.P. Somashekhar²; ¹Karnataka/IN, ²IN

- 13:00 - 13:00 285P - Starting with low dose pazopanib in the treatment of Japanese patients with metastatic renal cell carcinoma
J. Akatsuka, G. Kimura, K. Shibayama, M. Sano, Y. Endo, H. Takeda, T. Hamasaki, Y. Kondo; JP
- 13:00 - 13:00 286P - Nivolumab in renal cell carcinoma patients in India
A. Rauthan¹, P. Patil²; ¹Karnataka/IN, ²IN
- 13:00 - 13:00 293P - Pattern of treatment delay in carcinoma cervix patients and effect on survival
N. Sarkar¹, H.B. Govardhan²; ¹IN, ²Karnataka/IN
- 13:00 - 13:00 294P - Hyperthermic intraperitoneal chemotherapy with angiogenesis inhibitors for control of malignant ascites due to gynaecological and gastrointestinal cancer
L. Wen, Y. Li, X. Shen, J. Zhang, Q. Zhang, Q. Wang, H. Zhang; CN
- 13:00 - 13:00 295P - Utility of p16 over-expression in squamous cell carcinoma cervix with pulmonary metastasis
C. Das¹, H. Walia²; ¹Delhi/IN, ²IN
- 13:00 - 13:00 296P - Quality of life evaluation in patients with ovarian cancer on chemotherapy and its impact on patients' perception of maintenance therapy
T. Le¹, B. Lauzon¹, J. Forget¹, S. McDonald²; ¹CA, ²ON/CA
- 13:00 - 13:00 297P - Prognosis of epithelial ovarian cancer patients (EOC) with abdominal wall metastasis (AWM)
T. Mehmood, M. Muneeb; PK
- 13:00 - 13:00 298P - Use of a cognitive computing system for treatment of cervical cancer
S. Lim, L. Kwang-Beom; KR
- 13:00 - 13:00 299P - Cervical cancer screening in women attending cervical screening camp by Pap smear at a peripheral rural hospital of South India
D. Pawar, C. Sunkavli, A. Suresh; IN
- 13:00 - 13:00 300P - Outcomes of paclitaxel and ifosfamide following surgery for early and advanced stage uterine carcinosarcoma: A single institution experience
K. Sudo¹, Y. Ohtake¹, T. Nishikawa¹, T. Uehara², H. Shimizu¹, M. Ishikawa¹, T. Kato¹, A. Shimomura¹, E. Noguchi¹, K. Yonemori¹, C. Shimizu¹, K. Tamura¹; ¹JP, ²Chiba/JP
- 13:00 - 13:00 301P - Interim Analysis of A Single-Arm Phase 2 Clinical Trial of Regorafenib in Patients with Epithelial Ovarian Cancer
T. Tan, W.S. Ong, S. Chan, J. Chan, W.Y. Chay, E. Lim, S.L. Lim, L.T. Soh, D.S. Tan, J. Chia; SG
- 13:00 - 13:00 302P - Challenge in the management of bulky cervical cancer: A cross-sectional analysis
L. Yuan, X. Du, N. Liu, C. Wang, H. Yu, X. Sheng; CN

- 13:00 - 13:00 303P - Burden of cervical cancer in Kazakhstan
S. Serikov, D. Kaidarova, M. Kairbayev, R. Bolatbekova; KZ
- 13:00 - 13:00 304P - Knowledge, attitude and practice of HPV vaccination in undergraduate medical and nursing students
P. Wibisono, A. Widjaja, A.D. Vatvani, D. Velies; ID
- 13:00 - 13:00 305P - Adjuvant chemotherapy following definitive chemo radiation in patients with locally advanced cervical cancer: A phase II clinical trial
F. Amouzegar Hashemi, IR
- 13:00 - 13:00 306P - Challenges in management of cervical cancer in Mandalay General Hospital, Myanmar
S. Mon, A.A. Myint, T.T. Aye, N.O. Myint; MM
- 13:00 - 13:00 307P - G-CSF induces production of Bv8 in murine bone marrow neutrophils and promotes tumor growth and angiogenesis of U14 murine cervical cancer cell line
X. Wu, B. Yan; CN
- 13:00 - 13:00 308P - p53 expression as a part of cell-free circulating tumor DNA - in cervical carcinoma - as a prognostic marker
H.B. Govardhan¹, R. Chaitra², I. Khaleel², P. Sridhar¹, S. Shubha²; ¹Karnatka/IN, ²IN
- 13:00 - 13:00 309P - Overview on gestational trophoblastic neoplasia (GTN) in Yangon General Hospital, Myanmar
S. Myint, P. Phyu Theint, S.S. Win, Z. Thynn, H. Maw; MM
- 13:00 - 13:00 310P - Some characteristics of brain metastases from gynecological cancers
L. Vladimirova, G. Nerodo, E. Kalabanova, E. Rostorguev; RU
- 13:00 - 13:00 311P - Efficacy and feasibility of paclitaxel and carboplatin-based concurrent chemoradiotherapy for patients with advanced cervical cancer with renal dysfunction
N. Kamiya, Y. Imai, M. Asai-Sato, Y. Ota, Y. Suzuki, N. Ruiz-Yokota, T. Matsunaga, E. Miyagi; JP
- 13:00 - 13:00 312P - PIK3CA gene mutation frequency among cervical cancer patients in Azerbaijan
K. Akbarov, I. Isayev, L. Melikova, E. Guliyev, N. Aliyeva; AZ
- 13:00 - 13:00 313P - Prognostic Significance of Thrombocytosis in locally advanced Carcinoma cervix Patients treated with Chemo radiotherapy
S.D. Shamsundar, K. Aradhana, R. Nanda, B. Thejaswini; IN
- 13:00 - 13:00 314P - Importance of cytokines in women with ovarian cancer
B. Kurbanov, UZ
- 13:00 - 13:00 315P - Incidence of cervical carcinoma in different age groups and compare its pattern between nulliparous and women with multiple birth in tertiary care hospital in Nepal
S. Shrestha, U. Shrestha, A. Samdurkar; NP
- 13:00 - 13:00 316P - Treatment and rehabilitation of hydatidiform mole
T. Tsintsadze, T. Carkviani, L. Metonidze, I. Dvalishvili, S. Carkviani; GE

- 13:00 - 13:00 322P - Prognostic impact of synchronous multiple primary malignant tumors on newly diagnosed hematological malignancies
S. Nishiwaki, S. Okuno, K. Suzuki, S. Kurahashi, I. Sugiura; JP
- 13:00 - 13:00 323P - Association between duration of hydroxyurea administration before matinib mesylate to the achievement of major molecular response (MMR) in chronic phase of chronic myelocytic leukemia: A review on P-glycoprotein
I. Rinaldi¹, A. Reksodiputro², S. Jusman², A. Harahap², R. Setiabudy², S. Wanandi², K. Tambunan², C. Suharti²; ¹DKI JAKARTA/ID, ²ID
- 13:00 - 13:00 324P - Additional cytogenetic abnormalities in chronic myeloid leukemia and outcome - Experience from Pakistan
N. Anwar, S. Khurram, M. Nadeem, T. Shamsi; PK
- 13:00 - 13:00 325P - Effect of clopidogrel on adenosine diphosphate level during nilotinib therapy in chronic myeloid leukemia
S. muktiadmodjo, C. Suharti, S. Santosa; ID
- 13:00 - 13:00 326P - Intercontinental cooperative non-Hodgkin T cell lymphoma prospective registry study
S. Park, W.S. Kim, S.J. Kim; KR
- 13:00 - 13:00 327P - FLT 3 mutation and its prognostic significance in newly diagnosed acute myeloid leukemia in adults
R. Lokadasan, G. Narayanan, N. Sreejith, N. Prakash, S. Hariharan, C. Aswathy; IN
- 13:00 - 13:00 328P - Acute kidney injury in newly diagnosed acute myeloid leukemia patients undergoing remission induction chemotherapy: Experience of a tertiary cancer centre of India
A. Kumar, R. Pramanik, S. Raj, S. Ahmed, L. Kumar; IN
- 13:00 - 13:00 329P - Distribution of chromosomal abnormalities commonly observed in adult acute myeloid leukemia in Pakistan as predictors of prognosis
M.S. Shaikh, Z. Ahmed; PK
- 13:00 - 13:00 330P - Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): Presentation, prevalence and distribution- a single institution experience in Saudi Arabia
A.A. Shaukat, A. Farrag, M. Kandil, B. Muhammad, T. Siddiqui; SA
- 13:00 - 13:00 331P - Role of BLMH, XPO5 and HFE gene polymorphisms in Hodgkin lymphoma susceptibility in the South Indian population
D. Thakkar, IN
- 13:00 - 13:00 332P - Treatment outcome of diffuse large B-cell lymphoma involving the head and neck
Y.-K. Kwak, KR
- 13:00 - 13:00 333P - Multiple neoplasms consist of solid cancer and non-Hodgkin lymphoma
K. Natori, D. Nagase, A. Shibuya, Y. Mitsui, Y. Kuraishi, H. Fujino; JP

- 13:00 - 13:00 334P - The white blood cell differential predict treatment response in diffuse large B cell lymphoma
T. Hastuti, I. Wijaya, A. Oehadian; ID
- 13:00 - 13:00 335P - Primary bone lymphoma: An experience of a regional cancer centre from India
R. Mahajan, B. Yadav, S. Sharma, S. Ghoshal, R. Kapoor, N. Kumar; IN
- 13:00 - 13:00 342P - QOL analysis of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second line or above therapy in recurrent head and neck cancer
R. Chanana, V. Noronha, A. Joshi, V. Patil, S. Dhumal, A. Bhattacharya, A. Chandrasekharan, N. Pande, V. TALREJA, S. Turkar, S. Shrirangwar, K. Prabhash; IN
- 13:00 - 13:00 343P - QTWiST analysis to compare the benefit of Metronomic chemotherapy versus intravenous cisplatin for patients with Head and neck cancer
S. Parthiban, V. Noronha, A. Joshi, V. Patil, S. Dhumal, A. Chandrashekar, N. Pande, K. Prabhash; IN
- 13:00 - 13:00 344P - Acute toxicity profile of concomitant chemoradiotherapy in head and neck cancers: A randomized controlled comparison of weekly versus triweekly cisplatin schedule
S. beryhy, IR
- 13:00 - 13:00 345P - Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients
K. Au, R.K. Ngan, A.W. Ng, D.M. Poon, W. Ng, V.H. Lee, A.W. Lee, A.C. Cheng, H. Tam; HK
- 13:00 - 13:00 346P - Analysis of various prognostic factors on local control and survival in post operative cases of malignant salivary gland tumors
M. Kumar, H. Manchala, S. Kumari, S. R; IN
- 13:00 - 13:00 347P - Sebaceous gland carcinoma of the eyelid: Indian experience of the rare entity
J. Ram, V. Kumar, S. Misra, C. Kori, S. Gupta, N. Akhtar, A. Chaturvedi; IN
- 13:00 - 13:00 348P - Ultrasound, ultrasound guided FNAC and CT for the detection of neck node metastases in clinically N0 patients with carcinoma of upper aero-digestive tract
A. Bajracharya, NP
- 13:00 - 13:00 349P - Response to induction chemotherapy with cisplatin and docetaxel in nasopharyngeal carcinoma and its correlation to overall survival: Tertiary centre experience in the Middle Eastern population
M. Ali, A. Shaukat, A. Farrag, M. Kandil, B. Mohammad, J. Ansari, A. Ali, M. Wahid; SA
- 13:00 - 13:00 350P - Seven field 3-dimensional conformal radiotherapy technique to spare critical structures in head and neck carcinoma
R. Narayanasamy, K. Perumal, S. Kumar, S. Ranjani, S. Thyagarajan; IN
- 13:00 - 13:00 351P - Stage I/II oropharyngeal carcinoma treated with surgery or RT at the Japan National Cancer Center Hospital East
M. Rokugo¹, R. Hayashi¹, T. Shinozaki², T. Tomioka¹, W. Okano¹; ¹JP, ²Chiba/JP
- 13:00 - 13:00 352P - A dosimetric study for improving the therapeutic ratio for patients with nasopharyngeal carcinoma using hybrid IMRT/VMAT technique.
P. kumar, A. Mukherji, T. Elumalai, V. Prabhu; IN

- 13:00 - 13:00 353P - Induction chemotherapy in locally advanced unresectable oral cavity squamous cell cancers: Does it improve treatment outcomes?
T. Chaudhuri, K.C. Lakshmaiah, K.G. Babu, L. Dasappa, L. Jacob, M.C.S. Babu, A.H. Rudresha, K.N. Lokesh, L.K. Rajeev; IN
- 13:00 - 13:00 354P - Study of immunohistochemical expression of VEGF and its association with HPV E6 And E7 oncoproteins in oral and oropharyngeal squamous cell carcinoma
A. Sharma, K. Agarwal, S. Agarwal, S. Kumar, A. Bharti; IN
- 13:00 - 13:00 355P - The impact of national health insurance of Indonesia on delay in diagnosis, treatment and survival of nasopharyngeal carcinoma patients
G. Khuzairi, S. Hutajulu, J. Kurnianda; ID
- 13:00 - 13:00 356P - Betel nut chewing habits and risk of precancerous oral lesions among Paniya tribes of Wayanad, India: A cross sectional study
S. Palliyal, IN
- 13:00 - 13:00 357P - Peripheral neutrophil to lymphocyte ratio as independent prognostic factors in patients with nasopharyngeal carcinoma
A. Achmad, S. Hutajulu, J. Kurnianda; ID
- 13:00 - 13:00 358P - Treatment and outcomes of second primary tumors in patients with head and neck squamous cell carcinoma
T. Siripoon, P. Pattaranutaporn, C. Jiarpinitnun, J. Juengsamarn, S. Bunbanjerdasuk, N. Jinawath, N. Ngamphaiboon; TH
- 13:00 - 13:00 359P - Long-term observation of surgically treated oropharyngeal cancer
T. Shinozaki¹, R. Hayashi², W. Okano², T. Tomioka²; ¹Chiba/JP, ²JP
- 13:00 - 13:00 360P - Predictive factors for relapsed nasopharyngeal carcinoma
C. Sookthon, P. Pattaranutaporn, P. Asawasutsakorn, K. Mahaprom, C. Jiarpinitnun, N. Ngamphaiboon; TH
- 13:00 - 13:00 361P - Results of patients of locally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy or upfront concurrent chemoradiotherapy: A regional cancer centre experience
P.N. Patel, S. Goyal, U. Suryanarayana, A. Anand, H. Panchal, A. Patel, S. Parikh; IN
- 13:00 - 13:00 362P - Evaluation of quality of life (QOL) and time without symptom and treatment toxicity of nimotuzumab vs chemotherapy (weekly cisplatin) concurrently with with radiotherapy in patients with head and neck squamous cell carcinoma
S. Vs Attili, S. Mallik, P.K. Dadireddy, D. Pawar; IN
- 13:00 - 13:00 363P - Prevalence of smoking and awareness about anti-smoking acts among the general public in Gurgaon, Haryana, India
C. Francis, IN
- 13:00 - 13:00 364P - The association between smoking, dietary intakes, C-reactive protein and incidence of nasopharyngeal carcinoma

D. Sulistyoningrum, A. Dewi, P. Putra, J. Fachiroh; ID

- 13:00 - 13:00 365P - The pretreatment albumin has a predictive value for overall survival in nasopharyngeal carcinoma
D. Selvyana, S. Hutajulu, J. Kurnianda; ID
- 13:00 - 13:00 366P - Nimotuzumab in management of recurrent/metastatic head and neck cancer: A pilot study
S. Subramanian¹, N. Sridharan², S. Chaudhari², D. Pawar², V. Balasundaram²; ¹Tamil Nadu/IN, ²IN
- 13:00 - 13:00 367P - Nimotuzumab post marketing surveillance study: A Sri Lanka experience
M. Perera¹, K.A.S.J. Balawardana¹, T. Skandharajah¹, L. Obeysekere¹, A.J. Hilmi¹, N. Yoganathan¹, S. Kandegedera¹, U.G. Sarawanamutthu¹, M. Netthikumar¹, K. Indranatha¹, D. Pawar²; ¹LK, ²IN
- 13:00 - 13:00 368P - Nimotuzumab with Intensity modulated radiation therapy (IMRT) in unresectable and platinum ineligible locally advanced head & neck cancer patients
K. Satish Srinivas, R. Sundaram, C. Divyambika, S. Chaudhari, D. Pawar; IN
- 13:00 - 13:00 369P - Affective states, locus of control and Treatment duration as Predictors of cancer rehabilitation in head and neck cancer patient.
R. SINGH, H. Shukla, M. Tewari, Y. Arya, T. Singh; IN
- 13:00 - 13:00 370P - An assessment of tobacco use and cancer awareness among (tea plantation workers) Irula tribes, Nilgiri hills, Tamilnadu, India
D.L. Francis, IN
- 13:00 - 13:00 371P - Tobacco use, smoking quit rates, and socioeconomic patterning among indigenous tribe of rural Mangalore, India
E. Aluckal, IN
- 13:00 - 13:00 372P_PR - Head and neck cancer occurrences and lifestyle habits in Toungoo, Myanmar
K.K. Nwe¹, S. Aung², S. Thaug², Y. Mon², H. Thazin²; ¹Bago/MM, ²MM
- 13:00 - 13:00 373TiP - KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
C.-J. Yen¹, J.-P. Machiels², L. Licitra³, D. Rischin⁴, J. Waldron⁵, B. Burtneess⁶, V. Gregoire², Y. Tao⁷, J. Yorio⁸, S. Aksoy⁹, S. Ikeda¹⁰, R.-L. Hong¹, J.Y. Ge¹¹, H. Brown¹¹, B. Bidadi¹¹, L. Siu⁵; ¹TW, ²BE, ³IT, ⁴VIC/AU, ⁵ON/CA, ⁶CT/US, ⁷FR, ⁸TX/US, ⁹TR, ¹⁰JP, ¹¹NJ/US
- 13:00 - 13:00 374P - A review of single agent and combination immunotherapy-induced colitis from a tertiary referral centre in Australia
A. Mulvey¹, J. Smith², M. Carlino²; ¹WA/AU, ²AU
- 13:00 - 13:00 375P - Clinical effect and cytokines dynamic change of patient with advanced malignant tumor treated by PD-1 Inhibitors
J. Xiang, G. Zhang, Y. Xia, Y. Hu; CN
- 13:00 - 13:00 376TiP - A study of multiple-antigen specific cellular therapy in vitro combined with PD-1 antibody technology (MASCT-I) in patients with advanced solid tumors

X. Zhang, X. Zhang, D. Weng, J. Xia, R. Xu; CN

- 13:00 - 13:00 377TiP - Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
S. Chan¹, R. Finn², A. Zhu³, J. Knox⁴, A.-L. Cheng⁵, A. Siegel⁶, O. Bautista⁶, M. Kudo⁷; ¹HK, ²CA/US, ³MA/US, ⁴ON/CA, ⁵TW, ⁶NJ/US, ⁷JP
- 13:00 - 13:00 384P - Choice of adjuvant therapy in uveal melanoma: A retrospective analysis in China
L. Mao, L. Si, X. Bai, Z. Chi, C. Cui, X. Sheng, B. Lian, T. Bixia, X. Yan, J. Guo; CN
- 13:00 - 13:00 385P - The search for viable biochemical and clinical prognostic markers for patients with inoperable melanoma being treated with Anti CTLA-4 therapy
J. Chow, D. Alrifai, A. Shields, R. Kandassamy, B. Tan; GB
- 13:00 - 13:00 386P - The treatment of disseminated skin melanoma with high-dose recombinant interleukin-2 in combination with chemotherapy
O. Streltsova, Y. Baranau; BY
- 13:00 - 13:00 387P - Clinicopathological characteristics and prognostic factors of malignant melanoma: A retrospective analysis of a 12-year study
C. Chayangsu, TH
- 13:00 - 13:00 388P - Systemic treatment of metastatic conjunctival melanoma
S. Pinto-Torres¹, T. Tomás², E. Gouveia², M.J. Passos²; ¹Lisboa/PT, ²PT
- 13:00 - 13:00 389TiP - Pembrolizumab in patients with advanced/metastatic acral lentiginous melanoma
H. Loong, C. Yuen, F. Mo, T.-C. Chan, K. Lee, A. Chan, A. Wong, K. Wong, C.-M. Lam, J. Tong, C. Wong, W. Yeo; HK
- 13:00 - 13:00 390P - Liquid biopsies in clinical oncology: Review of validation results
K. Gupta, A. Chougule, V. Ramprasad, V. Noronha, A. Joshi, V. Patil, V. Veldore, K. Prabhaskar; IN
- 13:00 - 13:00 391P - Stealth breast cancer on ring-type dedicated breast PET
S. Sasada¹, N. Masumoto², N. Goda², K. Kajitani², A. Emi², R. Haruta², T. Kadoya², T. Kataoka², M. Okada²; ¹Hiroshima/JP, ²JP
- 13:00 - 13:00 392P - A systematic and objective method in droplet gating analysis of EGFR T790M mutation on the ultra-sensitive droplet digital PCR (ddPCR) platform
C.H. Loh, G.L.X. Toh, C.W. Lim, W.C. Sim, C.M. Yeo, A. Chopra, L.L. Goh; SG
- 13:00 - 13:00 393P - Development of the immuno-wall device for rapid, low-cost detection of EGFR mutations in tumor samples from patients with lung cancer
N. Yogo, T. Hase, T. Kasama, N. Ozawa, M. Sato, N. Kaji, M. Tokeshi, Y. Baba, Y. Hasegawa; JP
- 13:00 - 13:00 394P - A new tool to visualize and quantificate activated epidermal growth factor receptor homodimerization with proximity ligation assay in lung cancer

K. Ota¹, T. Harada², K. Otsubo², A. Fujii², Y. Tsuchiya², K. Tanaka², I. Okamoto², Y. Nakanishi²; ¹Fukuoka/JP, ²JP

13:00 - 13:00 398P - EGFR mutation in early-stage and advanced-stage lung adenocarcinoma: Based on large data in China

C. Pi¹, C. Xu², Z. Qing²; ¹CN, ²Guangdong/CN

13:00 - 13:00 399P - Prognostic impact of new T1 descriptors in TNM classification of non-small cell lung cancer
T. Takenaka, K. Yamazaki, N. Miura, S. Takeo; JP

13:00 - 13:00 400P - Prognostic value of FDG PET/CT parameters in patients with stage IB non-small cell lung cancer: comparison with known high-risk clinicopathologic factors

H.L. Park, I.R. Yoo, J. Kim; KR

13:00 - 13:00 401P - Inter-observer variability in the delineation of gross tumour volume GTV using PETCT in early stage non small cell lung cancer NSCLC

M. Patil, J. Agarwal, A. Tibdewal, A. Chatterji, N. Purandare, V. Rangrajan; IN

13:00 - 13:00 402P - Quantitative severity of lobar emphysema is not associated with location of lung cancer in patients with surgically resected non-small cell lung cancer

S.J. Lee, S.S. Yoon, S. Ju, J.W. Yoo, Y.Y. Jeong, J.D. Lee; KR

13:00 - 13:00 404P - Ramucirumab in East Asian patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy: A pooled analysis of two randomized double-blind studies

J.-Y. Shih¹, K. Yoh², Y. Hosomi², G.-C. Chang¹, T.-C. Hsia¹, T. Tamura², R. Varea³, T. Nakamura², J. Gallo⁴, R. Cheng¹, S. Enatsu², K. Nakagawa²; ¹TW, ²JP, ³ES, ⁴AL/US

13:00 - 13:00 405P - EGFR mutation is associated with short progression free survival in patients with stage IIIB non-squamous cell lung cancer treated with concurrent chemoradiotherapy

S.E. Park, H. Lee, J.H. Cho, Y.J. Kim, H.K. Kim, S. Lim, S.-H. Lee, J.-M. Sun, J.S. Ahn, K. Park, M.-J. Ahn; KR

13:00 - 13:00 406P - Discover prognostic RNAs through identifying lncRNA-miRNA-mRNA triplets in lung squamous cell carcinoma

N. An, CN

13:00 - 13:00 407P - Real world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm

A. Kapoor¹, S. Zanwar², A. Joshi², V. Noronha², V. Patil², A. Chougule², A. Mahajan², P. Bhargava², K. Prabhash²; ¹Uttar Pradesh/IN, ²IN

13:00 - 13:00 408P - Radiation-induced lung toxicity and tumor progression in patients with non-small-cell lung cancer

N. Wang, Z. Nie, L. Xing, J. Yu; CN

13:00 - 13:00 409P - Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small-cell lung cancer treated with induction chemotherapy

H.Y. Lee, W.H. Choi, J.-O. Kim, I.R. Yoo, J.K. Park, S.W. Sung, Y.S. Kim, J.H. Kang; KR

- 13:00 - 13:00 421P - EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC)
H. Akamatsu¹, A. Delmonte², T. John³, W.-C. Su⁴, J.-S. Lee⁵, G.-C. Chang⁴, X. Huang⁶, S. Jenkins⁶, S. Dearden⁷, Y.-L. Wu⁸; ¹JP, ²Forli-Cesena/IT, ³ACT/AU, ⁴TW, ⁵Gyeonggi-do/KR, ⁶GB, ⁷Cheshire/GB, ⁸Guangdong/CN
- 13:00 - 13:00 422P - A real world treatment study of osimertinib: ASTRIS study Korean subgroup analysis
B.C. Cho, D.-W. Kim, K. Park, J.-S. Lee, S.S. Yoo, J.H. Kang, S.Y. Lee, C.H. Kim, S.H. Jang, Y.-C. Kim, H.-K. Yoon, S.-W. Kim; KR
- 13:00 - 13:00 423P - Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)
M. Tamiya¹, A. Hata², N. Katakami², R. Kaji², T. Yokoyama², K. Toshihiko², T. Inoue², H. Kimura², Y. Yano², D. Tamuta², S. Morita², S. Negoro²; ¹Osaka/JP, ²JP
- 13:00 - 13:00 424P - Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously T790M-negative patients?
A. Hata¹, C. Okuda², R. Kaji², N. Katakami²; ¹Hyogo/JP, ²JP
- 13:00 - 13:00 425P - Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
Y. Cao, X. Qiu, G. Xiao, H. Hao; MO
- 13:00 - 13:00 426P - A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
D. Harada¹, N. Nogami¹, T. Kozuki¹, T. Ninomiya¹, A. Bessho², S. Kuyama¹, N. Fujimoto¹, K. Sugimoto¹, K. Aoe¹, N. Ochi¹, D. Minami¹, N. Fukamatsu¹, K. Kudo¹, K. Kiura¹; ¹JP, ²Okayama Prefecture/JP
- 13:00 - 13:00 427P - The efficacy of a reduced dose (40mg) of osimertinib with T790M-positive advanced non-small-cell lung cancer
S. Sonobe, Y. Taniguchi, N. Saijo, Y. Naoki, A. Tamiya, N. Omachi, K. Okishio, S. Atagi; JP
- 13:00 - 13:00 428P - Different first line EGFR-TKI regimen and the clearance of EGFR sensitive mutation in acquired EGFR-TKI resistant lung adenocarcinoma patients
C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Zhu, R. Chen, Y. Guan, X. Yi, M. Fang, G. Chen, T. Lv, Y. Song; CN
- 13:00 - 13:00 429P - Afatinib in the first line therapy of EGFR mutation positive adenocarcinoma of lung: Single institute experience
R.-H. Ye, Y.-Y. Wu, T.-C. Huang, J.-H. Chen, M.-S. Dai, C.-L. Ho; TW
- 13:00 - 13:00 430P - Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
C.S. Chai, C.K. Liam, P.L. Cheah, D.B.L. Ong, Y.K. Pang, M.E. Poh; MY

- 13:00 - 13:00 431P - Rebiopsy of advanced NSCLC after EGFR-TKIs treatment: A systematic review
T. Imakita, Y. Kataoka, H. Matsumoto, T. Morisawa, A. Sakurai; JP
- 13:00 - 13:00 432P - QTWiST analysis to compare the benefit of maintenance Erlotinib versus pemetrexed patients with EGFR non mutated NSCLC
S. TURKAR, A. Joshi, V. Noronha, V. Patil, M. Sharma, C. Vora, S. More, S. Goud, K. Prabhash; IN
- 13:00 - 13:00 433P - Preclinical study of olmutinib (HM61713) with optimal dosing in ectopic and metastatic mouse model of EGFR-mutant (T790M-positive) non-small cell lung cancer (NSCLC)
H.J. LEE, H. Yu, Y. Ha, J.-Y. Byun, J. Oh, T. Song, S. Hong, E.Y. Kim, S.-Y. Jang, G.Y. Kim, Y.H. Kim, K.H. Suh, S.C. Kwon, S.-J. Kim; KR
- 13:00 - 13:00 434P - Phase I study of safety and pharmacokinetics for CT-707 in ALK-positive advanced non-small cell lung cancer
Y.-K. Shi, X. Hao, P. Xing, B. Hu, Y. Sun; CN
- 13:00 - 13:00 435P - Real-world data on treatment patterns and survival among ALK+ NSCLC patients in Japan. Treatment patterns and survival among ALK+ NSCLC patients in Japan: Single institute experience
T. Seto¹, K. Nosaki², R. Toyozawa², K. Taguchi², M. Edagawa², S. Shimamatsu², G. Toyokawa², F. Hirai², M. Yamaguchi², Y. Takeda², M. Takenoyama², Y. Ichinose²; ¹Fukuoka/J, ²JP
- 13:00 - 13:00 436P - The efficacy of dose reduced crizotinib for advanced ALK-positive non-small cell lung cancer
M. Naito, Y. Naoki, S. Takata, S. Ishii, Y. Taniguchi, N. Saijo, A. Tamiya, N. Omachi, K. Okishio, S. Morita, A. Tanaka, T. Shiroyama, N. Morishita, H. Suzuki, N. Okamoto, T. Hirashima, S. Atagi; JP
- 13:00 - 13:00 437P - The efficacy and onset risk of interstitial lung disease of nivolumab in elderly (75 years old or older) patients with non-small cell lung cancer
A. Tamiya, M. Tamiya, K. Nakahama, Y. Taniguchi, T. Shiroyama, S.-I. Isa, T. Inoue, K. Okishio, K. Nishino, T. Kumagai, H. Suzuki, T. Hirashima, F. Imamura, S. Atagi; JP
- 13:00 - 13:00 438P - Efficacy of subsequent cytotoxic chemotherapy after nivolumab for patients with advanced non-small cell lung cancer
N. Tamura, H. Horinouchi, K. Sekine, Y. Matsumoto, S. Murakami, Y. Goto, S. Kanda, Y. Fujiwara, N. Yamamoto, Y. Ohe; JP
- 13:00 - 13:00 439P - Impact of immune checkpoint inhibitors on subsequent chemotherapy
H. Watanabe, T. Kubo, K. Kudo, D. Minami, T. Murakami, N. Ochi, T. Ninomiya, D. Harada, M. Yasugi, H. Takeda, E. Ichihara, K. Ohashi, K. Hotta, M. Tabata, Y. Maeda, K. Kiura; JP
- 13:00 - 13:00 440P - Efficacy and toxicity of nivolumab in real-world; including nivolumab rechallenge
K. Kibata, T. Yokoi, H. Yoshioka, T. Kurata, S. Nomura; JP
- 13:00 - 13:00 441P - A prospective observational study of immune checkpoint inhibitor nivolumab treatment in patients with non-small cell lung cancer
T. Fukui, Y. Nakahara, S. Otani, M. Katagiri, H. Mitsufuji, M. Kubota, Y. Hiyoshi, M. Ishihara, M. Kasajima, S. Igawa, J. Sasaki; JP
- 13:00 - 13:00 442P - Safety of nivolumab in patients with advanced or metastatic non-small cell lung cancer who have received at least one prior systemic regimens: Expanded access program in Korea (ONO-4538-X04)

S.-W. Kim, B.C. Cho, J.H. Kang, M.-J. Ahn, K.H. Lee, D.-W. Kim, Y.-C. Kim, J.S. Lee, J.-S. Lee, S.Y. Lee, K.U. Park, S.-J. Yong, H.J. An, E.K. Cho, T.W. Jang, B.-S. Kim, J.-H. Kim, S.S. Lee, I.I. Na, S.S. Yoo; KR

- 13:00 - 13:00 443P - Final analysis of phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
A. Tanaka, A. Tamiya, M. Tamiya, S. Morita, T. Shiroyama, N. Saijo, S. Minomo, T. Tsuji, N. Takeuchi, N. Omachi, N. Morishita, H. Suzuki, N. Okamoto, K. Okishio, T. Hirashima, S. Atagi; JP
- 13:00 - 13:00 444P - Propensity score-matching analysis of local consolidative therapy for patients with oligometastatic non-small cell lung cancer without progression after front-line systemic therapy
J.-T. Zhang¹, S.-Y. Liu¹, J.-T. Lin², H.-H. Yan¹, X.N. Yang², Y.-L. Wu², W.-Z. Zhong¹; ¹CN, ²Guangdong/CN
- 13:00 - 13:00 445P - Phase II study of efficacy of bevacizumab plus chemotherapy in management of malignant pleural effusion in non-squamous non-small cell lung cancer patients with malignant pleural effusion (MPE) unsuccessfully controlled by tube drainage or pleurodesis (NEJ-13-2 trial)
R. Noro¹, K. Kobayashi¹, J. Usuki¹, Y. Hosomi¹, M. Nishitsuji¹, H. Okamoto², M. Ando¹, M. Hino¹, K. Hagiwara¹, A. Miyanaga¹, M. Seike¹, K. Kubota¹, A. Gemma¹; ¹JP, ²Kanagawa/JP
- 13:00 - 13:00 446P - Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study
Y. Tsutani¹, Y. Miyata¹, T. Masuda², K. Fujitaka², M. Doi², Y. Awaya², S. Kuyama², S. Kitaguchi², K. Ueda², M. Okada²; ¹Hiroshima/JP, ²JP
- 13:00 - 13:00 447P - Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J)
T. Hase¹, S. Takeuchi¹, M. Ando¹, A. Hata¹, H. Kenmotsu¹, T. Fujiwara¹, S. Shimizu¹, K. Nagase¹, K. Yoshimura¹, N. Katakami¹, T. Takahashi², Y. Hasegawa¹, S. Yano¹; ¹JP, ²Shizuoka/JP
- 13:00 - 13:00 448P - The possibility of personalized chemotherapy for non-small cell lung cancer using interactome analyses of PDX/NOG models
T. Chijiwa¹, D. Komura², M. Haraguchi², A. Noguchi², H. Sato², H. Ito², H. Nakayama², M. Katayama², N. Miyao², H. Suemizu², Y. Nakamura², D. Furukawa², T. Moriya², T. Isagawa², H. Katoh², S. Ishikawa², M. Nakamura², Y. Miyagi²; ¹Saitama/JP, ²JP
- 13:00 - 13:00 449P - Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer
T. Mizuno, T. Arimura, H. Kuroda, N. Sakakura, Y. Yatabe, Y. Sakao; JP
- 13:00 - 13:00 450P - Advanced non-small cell lung cancer in never smokers: An institutional experience
B. Stalin¹, S. Gundeti², A. Kumar², M. Lakshmi², L. Srinivas²; ¹Andhra Pradesh/IN, ²IN
- 13:00 - 13:00 451P - Value of F-18 FDG PET/CT to identify metastatic mediastinal lymph node in NSCLC patients with bilateral benign mediastinal lymph node hyperplasia
L.H. KANG, Y.S. Kim; KR

- 13:00 - 13:00 452P - Pemetrexed versus best supportive care following platinum-based doublet chemotherapy for patients with advanced nonsmall cell nonsquamous lung cancer
P. Kumari, Rajasthan/IN
- 13:00 - 13:00 453P - Calcified brain metastasis after systemic treatment predict long survival in advanced non-small cell lung cancer patients
Y.-H. Kuo, Y.-C. Chang, F.-C. Hu, Z.-Z. Lin, J.C.-H. Yang; TW
- 13:00 - 13:00 454P - Metformin-induced activation of caspase-10 inhibits lung adenocarcinoma progression and metastasis
R. Kumari, S. Das; IN
- 13:00 - 13:00 455P - A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild-type EGFR: The Okayama Lung Cancer Study Group Trial 1202 (OLCSG1202)
A. Bessho¹, N. Ochi², S. Kuyama², T. Umeno², G. Ikeda², D. Harada², N. Nogami², K. Ninomiya², D. Kishino², K. Chikamori², N. Fujimoto², K. Hotta², N. Takigawa², K. Kiura²; ¹Okayama Prefecture/J, ²JP
- 13:00 - 13:00 456P - ALK-rearranged may promote VTE by increasing the expression tissue factor (TF) in lung adenocarcinoma
Y. Sen, Q. Wang; CN
- 13:00 - 13:00 457P - Nab-paclitaxel in combination with carboplatin versus docetaxel in chemotherapy-naïve with advanced non-small-cell lung cancer aged 75 years old or more: Retrospective cohort study
K. Katayama, A. Tamiya, Y. Tanaka, K. Nakahama, Y. Taniguchi, N. Saijo, Y. Naoki, N. Omachi, K. Okishio, T. Kasai, S. Atagi; JP
- 13:00 - 13:00 458P - Concordance analysis of IHC and FISH in the detection of ROS1 gene rearrangement in NSCLC: Results of a meta-analysis
N. Godre¹, V. Gupta¹, M. Alam²; ¹IN, ²ACT/AU
- 13:00 - 13:00 459P - Advanced lung cancer inflammation index as a predictor of response rate in first-line chemotherapy for metastatic non-small cell lung carcinoma patients
S. Chompoonuch, P. Pratyarattananon, O. Sukreeyapongse, C. Upachar; TH
- 13:00 - 13:00 460P - Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for previously untreated advanced non-squamous non-small cell lung cancer
T. Uenami, T. Koba, S. Minami, Y. Futami, K. Masuhiro, H. Kimura, S. Futami, M. Yaga, M. Mori, H. Kagawa, S. Komo, T. Otsuka, S. Yamamoto, K. Komuta, T. Kijima; JP
- 13:00 - 13:00 461P - The role of plasma epidermal growth factor receptor mutations test in non-small cell lung cancer
P. Thang, T. Thu, H. Toan, T. Tung, P. Loi, V. My, T.A. Le, L. Suong, L. Vu, N. Hang, N. Son; VN
- 13:00 - 13:00 462P - Prognostic importance of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR) and advanced lung cancer inflammation index (ALI) at diagnosis and post treatment in elderly with stage IV NSCLC
H. Mandaliya¹, M. Jones¹, C. Oldmeadow², I. Nordman²; ¹NSW/AU, ²AU
- 13:00 - 13:00 463P - Outcomes in patients with NSCLC with brain metastases

D. Valiyaveetil¹, M. Malik¹, D. Joseph¹, S. Ahmed², K. Sindhusa²; ¹Andhra Pradesh/IN, ²IN

- 13:00 - 13:00 464P - Prognostic significance of ferritin-to-hemoglobin ratios for survival in patients with advanced non-small cell lung cancer
S.K. Lee, H. Jeon; KR
- 13:00 - 13:00 465P - A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
D. Fujimoto, T. Yokoyama, H. Yoshioka, Y. Demura, K. Hirano, T. Kawai, R. Kagami, T. Ishida, K. Tomii, M. Akai, M. Hirabayashi, T. Nishimura, Y. Nakahara, Y.H. Kim, K. Yoshimura, T. Hirai; JP
- 13:00 - 13:00 466TiP - KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)
C. Zhou¹, C. Caglevic², J. Zhou¹, B. Wang¹, K. Wang¹, J. Ge¹, Y. Zhou¹, B. Piperdi³, Z. Ma¹; ¹CN, ²CL, ³NJ/US
- 13:00 - 13:00 467P - Systematic inflammatory response markers (SIRs) factors associated with pain prevalence and other characteristics in advanced cancer patients
X. Gu, M. Liu, M. Cheng, Z. Zhang, W. Zhao, W. Cheng; CN
- 13:00 - 13:00 468P - Association between opioid use and survival time in patients with unresectable pancreatic cancer: 10 years of clinical experience
T.K. Oh, KR
- 13:00 - 13:00 469P - Validation of the palliative prognostic score (PaP score) in patients with metastatic cancer in RSUP Dr. Sardjito, Yogyakarta, Indonesia
D. Pratiwi, P. Dewanti, K. Widayati, J. Kurnianda; ID
- 13:00 - 13:00 470P - Can we use Chinese revised version of Edmonton Symptom Assessment System to assess symptom burden of Chinese caregivers of advanced cancer patients? PACSSIVE-6
K.W. Woo, H.C.T. Wang, J.L.S. Au, V.W.C. Cho, C.Y. Poon, A.O.L. Kwok; HK
- 13:00 - 13:00 471P - Factors influencing late presentation for treatment, palliative care services among cancer patients attending Hospice Africa Uganda (HAU)
N. Bandese, UG
- 13:00 - 13:00 472P - The reasons and timing of the oral transmucosal fentanyl administration in Japan
S. Kajiuira, T. Kashii, A. Takagi, S. Chikaoka, N. Hayashi, T. Matsushita, S. Fukai, A. Kadota, K. Nakajima, H. Horikawa, Y. Takemura, T. Shima, A. Furuichi, H. Yoshita, T. Ando, T. Miwa, N. Murakami, R. Hayashi; JP
- 13:00 - 13:00 473P - Palliative care as a part of national cancer control plan in Uzbekistan
Y. Ziyaev, M. Tillyashaykhov, S. Abdujapparov, D. Egamberdiev, I. Ziyaeva, Y. Ten; UZ
- 13:00 - 13:00 474P - Effect of palliative care on cognitive function among breast cancer patients in Eastern India
A. Datta¹, P. Guha (chaudhury)², A. Mukhopadhyay²; ¹West Bengal/IN, ²IN

- 13:00 - 13:00 475P - A Trial of developing the Japanese brief version of the caring assessment report evaluation Q-SORT (CARE-Q): To measure the Oncology nursing caring behavior
Y. Orii¹, S. Jeong²; ¹JP, ²NSW/AU
- 13:00 - 13:00 476P - Antidepressants simulate enriched environment enhance platinum chemosensitivity of small cell lung cancer
Y. Wu, H. Tang, Q. Wang; CN
- 13:00 - 13:00 477P - Spiritual well being and depression severity in post-operative breast cancer women
J. Srivastava, H. Shukla, S. Kaushik, M. Tewari; IN
- 13:00 - 13:00 478P - Translation and validation of the Thai version of Family Reported Outcome Measure (Thai FROM-16©) in Thai family members of cancer patients
S. Subongkot, P. Chantarasap, N. Johns, S. Pairojkul, A. Sookprasert; TH
- 13:00 - 13:00 479P - Myths and misconceptions about cancer among patients attending a tertiary care center in a developing country: A cause for concern
D. Valiyaveetil¹, M. Malik¹, D. Joseph¹, S. Ahmed²; ¹Andhra Pradesh/IN, ²IN
- 13:00 - 13:00 480P - Development and validation of yoga therapy module for cervical carcinoma undergoing chemoradiation
N. Nelson¹, H.B. Govardhan², I. Khaleel¹; ¹IN, ²Karnataka/IN
- 13:00 - 13:00 481P - Effects of mindfulness meditation on patients with cancer: A review of literature
K. Samarasekera, LK
- 13:00 - 13:00 482P - Beliefs and perceptions about cancer and its treatment in patients in a developing country
M. Malik¹, D. Valiyaveetil², D. Joseph¹, S. Ahmed²; ¹Andhra Pradesh/IN, ²IN
- 13:00 - 13:00 483P - Assessment of information needs and decision- making preferences in patients with metastatic cancer
D. Joseph¹, B. Narasimhulu², M. Malik¹, S. Ahmed², D. Valiyaveetil¹; ¹Andhra Pradesh/IN, ²IN
- 13:00 - 13:00 489P - Efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma
W. Chew, W. van der Graaf, A. Miah, C. Benson, S. Zaidi, C. Messiou, K. Thway, C. Fisher, R. Jones; GB
- 13:00 - 13:00 490P - NY-ESO expression in osteosarcoma
I. Lugowska¹, T. Klepacka¹, A. Szumera-Cieckiewicz², E. Michalak¹, M. Lenarcik¹, A. Pienkowski¹, P. Teterycz¹, K. Szamotulska¹, P. Rutkowski¹; ¹PL, ²PL/PL
- 13:00 - 13:00 491P - Outcome and factors effecting outcome of osteosarcoma in a low resource country
D. Gunasekera¹, M. Somathilaka², P. Abeysinghe²; ¹EG, ²LK
- 13:00 - 13:00 492P - Pazopanib toxicity in a metastatic sarcoma cohort: Are Indian patients different?

A. Sharma, A. Aggarwal, I. Vanidassane, V. Sharma, A. Sharma, A. Mridha, A. Barwad, S.V.S. Deo, S. Rastogi; IN

- 13:00 - 13:00 493P - Anti-tumor activity of tyrosine kinase inhibitors in alveolar soft part sarcoma
Y. Suehara, Y. Tanabe, K. Akaike, K. Mogushi, T. Hayashi, T. Kurihara, K. Kaneko, T. Saito; JP
- 13:00 - 13:00 494P - Eribulin mesylate in patients with soft-tissue sarcoma other than L-sarcoma
E. Kobayashi, A. Kawai, K. Yonemori, K. Tamura; JP
- 13:00 - 13:00 495P - Treatment of cutaneous Kaposi sarcoma with chemo-radiotherapy vs chemotherapy, in HIV positive patients - A retrospective study
K. VENUGOBAL, IN
- 13:00 - 13:00 496P - Emergency presentations of small cell lung cancer: A retrospective analysis across four hospitals in the UK
K. Ng, D. Yadav, B. Yung, S. Cooper, M. Lawson, G. Dancey; GB
- 13:00 - 13:00 497P - A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
T. Sugiyama¹, H. Imai², T. Tamura¹, H. Minemura¹, K. Kaira¹, K. Kanazawa¹, H. Yokouchi³, T. Kasai¹, T. Kaburagi¹, K. Minato¹; ¹JP, ²Gunma/JP, ³Fukushima/JP
- 13:00 - 13:00 498P - Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
C.S. Chai, C.K. Liam, Y.K. Pang; MY
- 13:00 - 13:00 499P - Pretreatment low nutritional index is linked to worse outcomes in small cell lung cancer
G.-W. Lee, S.-I. Go; KR
- 13:00 - 13:00 500P - Clinical outcome of ifosfamide in combination with carboplatin in small cell lung cancer: Results from third- or further- line chemotherapy
M. Park, J. Lee; KR
- 13:00 - 13:00 505P - A randomised, controlled, double blind study of oral methotrimeprazine versus oral haloperidol in patients with cancer and nausea not related to anticancer therapy
J. Hardy¹, H. Skerman², K. Franzen², K. Foster³, P. Yates³; ¹AU, ²ACT/AU, ³QLD/AU
- 13:00 - 13:00 506P - A framework for education and advocacy for optimal cancer pain management in resource-limited settings
M. Bautista¹, S. Ahmedzai², K. Bouzid³, R. Gibson⁴, Y. Gumara⁵, A. Hassan⁶, S. Hattori⁷, D. Keefe⁴, D. Kravchete⁸, D.H. Lee⁹, K. Tamura⁷, J.J. Wang¹⁰; ¹PH, ²GB, ³DZ, ⁴SA/AU, ⁵ID, ⁶QA, ⁷JP, ⁸BR, ⁹KR, ¹⁰CN
- 13:00 - 13:00 507P - Breath alcohol concentrations in patients undergoing taxane chemotherapy: An observational pilot study (BrACT study)
A. Wann¹, S. Luen², D. Day², L. Spain¹, C. O'Callaghan², B. Yeo², S. White²; ¹AU, ²VIC/AU

- 13:00 - 13:00 508P - A retrospective study on peritoneal fluid analysis profiles to predict bacterascites associated with malignant ascites
H. Moon¹, S.H. Sim²; ¹KR/KR, ²KR
- 13:00 - 13:00 509P - Assessment of chemotherapy induced febrile neutropenia in cancer patients: A prospective observational study in South India
U.V. Mateti, A.M. Sebastian, M.L. Philip, N. Saj, V. Shetty; IN
- 13:00 - 13:00 510P - To determine the feasibility and acceptability of a yoga intervention in cervical carcinoma patients undergoing chemoradiation
H.B. Govardhan¹, N. Nelson², I. Khaleel², P. Sridhar¹, M. Roy²; ¹Karnataka/IN, ²IN
- 13:00 - 13:00 511P - The role of neuropeptide y in cancer-associated anorexia and its correlation with interleukin-1 beta
I. Wahid, ID
- 13:00 - 13:00 512P - Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in solid tumours versus haematological malignancies: Patterns, outcomes and determinants (MONITOR-GCSF study)
M. Apro¹, C. Bokemeyer², M. Boccadoro³, P. Gascón⁴, K. Denhaerynck⁵, A. Krendyukov², I. Abraham⁵, K. Macdonald⁵, H. Ludwig⁶; ¹CH, ²DE, ³IT, ⁴ES, ⁵AZ/US, ⁶AT
- 13:00 - 13:00 513P - Exercise behaviours in oncology patients and barriers to engaging in cancer rehabilitation programs
C. McLaren¹, K. Mackwell², O. Griffiths³, R. Wallace², C. Li², J. Thomson¹; ¹AU, ²VIC/AU, ³NSW/AU
- 13:00 - 13:00 514P - Comparison of pharmacokinetic (PK) profiles of netupitant (NETU) and palonosetron (PALO) in Chinese and Caucasian healthy volunteers (HV)
M. Apro, A. Bernareggi; CH
- 13:00 - 13:00 515P - Randomized phase II study of TJ-54 (Yokukansan) for postoperative delirium in gastrointestinal and lung malignancy patients
J. Morita, T. Aoyama, N. Sugano, T. Sato, S. Amano, T. Nagashima, Y. Ishikawa, M. Taguri, T. Yamanaka, Y. Yamamoto, T. Oshima, N. Yukawa, Y. Rino, M. Masuda; JP
- 13:00 - 13:00 516P - Determinants of quality of life in women with metastatic breast cancer
T. Mehmood, PK
- 13:00 - 13:00 517P - Prospective analysis of the risk factors for cisplatin-induced acute kidney injury
A. Tsunoda¹, H. Oda¹, T. Mizuno², Y. Yamashita¹, S. Tamaru¹, K. Saito¹, M. Ishihara¹, Y. Nishimura¹, K. Nakatani¹, N. Katayama¹; ¹JP, ²Mie Prefecture/JP
- 13:00 - 13:00 518P - Retrospective study of atypical femoral fracture in patients with malignant bone metastasis receiving denosumab therapy: Case series
Y. Ozaki, M. Takahashi, H. Nakajima, R. Ohki, J. Masuda, C. Kondoh, Y. Miura, Y. Tanabe, T. Takano; JP
- 13:00 - 13:00 519P - Cabazitaxel plus prednisolone with primary prophylaxis with pegfilgrastim (PEG) in Japanese patients with metastatic castration-resistant prostate cancer: An open label prospective phase 2 study

H. Uemura, T. Kosaka, M. Sumitomo, K. Harada, M. Sugimoto, N. Hayashi, K. Yoshimura, S. Fukasawa, E. Ecstein-Fraisse, Y. Sunaga, M. Oya; JP

- 13:00 - 13:00 520P - A survey of on platinum ineligible in head and neck cancer patients in India
D. Pawar, R. Ahmed, S. Chaudhari; IN
- 13:00 - 13:00 521P - Is highly concentrated potassium preparation necessary for cisplatin administration?
K. Nakamura, M. Nakamura, T. Onikubo; JP
- 13:00 - 13:00 522P - Proof-of-concept of a risk calculator of chemotherapy induced (febrile) neutropenia (CIN/FN) based on real-world evidence (Monitor-GCSF study)
C. Bokemeyer¹, M. Aapro², H. Ludwig³, P. Gascón⁴, M. Boccardo⁵, K. Denhaerynck⁶, A. Krendyukov¹, K. Macdonald⁶, I. Abraham⁶; ¹DE, ²CH, ³AT, ⁴ES, ⁵IT, ⁶AZ/US
- 13:00 - 13:00 523P - Survey of patients' knowledge relating to their cancer and its concordance with the treating medical teams
A. Chowdhury¹, K. Ahmed¹, W. Faisal²; ¹BD, ²AU
- 13:00 - 13:00 524P - Treatment patterns and outcomes in patients with non-small cell lung cancer (NSCLC) receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropenia: Results from the MONITOR-GCSF study
M. Aapro¹, A. Krendyukov², N. Höbel², P. Gascón³; ¹CH, ²DE, ³ES
- 13:00 - 13:00 525P - Clinical experience with IBM Watson for Oncology (WFO) for multiple types of cancer patients in China
L. Yue, L. Yang; CN
- 13:00 - 13:00 526P - Characteristics and outcome of patient with haematological malignancy admitted to the intensive care unit: A single-centre experience
A. Sunggoro¹, A. Arifin²; ¹ID/ID, ²ID
- 13:00 - 13:00 527P - Prospective, non-interventional, multi-centre trial of rhTPO in the treatment of chemotherapy-induced thrombocytopenia in patients with lymphoma and lung cancer
J. Feng, J. Wu, M. Zhang, X. Xu, L. Liu, J. Qian, J. Zhao, J. Wang, H. Liu, H. Jing, S. Sun, Y. Zhu; CN
- 13:00 - 13:00 528P - Specialized counseling of nurses and/or radiation technicians is underused resource in cancer management
K. Jugar, H.-M. Roosmäe, L.-L. Aruväli, A. Oks, O. Trelin, K. Tähepõld, J. Jaal; EE
- 13:00 - 13:00 529P - Association between illness perception and health related quality of life in Indonesian cancer patients
A.D. Vatvani, C. Gunawan, K. Waren, A. Kurniawan; ID
- 13:00 - 13:00 530P - Association between symptom burdens with delayed medical presentation and treatment in Indonesian cancer patients
A.D. Vatvani, C. Gunawan, K. Waren, I.D. Tobias Adiya, A. Kurniawan; ID

- 13:00 - 13:00 531P - Association between social support levels with delayed presentations and treatments of symptomatic cancers in Indonesia
C. Gunawan, A.D. Vatvani, K. Waren, A. Kurniawan; ID
- 13:00 - 13:00 532P - Acute ototoxicity in adult cancer patients treated with platinum-based chemotherapy
H.-Y. Lee, Y.H. Choi, B.-G. Seo, K.A. Kwon, S.-Y. An, H.Y. Son, H. Chang, Y.S. Kim; KR
- 13:00 - 13:00 533P - Effectiveness of topical steroid therapy for prevention of regorafenib-associated hand-foot skin reaction
H. Ishikawa¹, S. Hamauchi², R. Tanaka², M. Shino², K. Yamazaki²; ¹Shizuoka/J, ²JP
- 13:00 - 13:00 534P - Cancer and our loved ones, how a “we can do it” can change: Diary of a small cancer support group from Eastern India
N. Pal, A. Mukhopadhyay; IN
- 13:00 - 13:00 535P - Safety and effectiveness of oral rivaroxaban for the treatment of venous thromboembolism in cancer patients
Y. Kondo, M. Hirabatake, H. Satake, H. Yasui, T. Hashida; JP
- 13:00 - 13:00 537P - Clinical utility of 18F-FDG PET for chemotherapy response evaluation in patients with malignant pleural mesothelioma
S. Kanemura¹, K. Kuribayashi², E. Fujimoto¹, Y. Negi¹, Y. Koda¹, K. Mikami¹, T. Minami¹, T. Yokoi¹, T. Kijima¹; ¹JP, ²Hyogo/J
- 13:00 - 13:00 538P - Photodynamic therapy approach for central lung cancer
S. Rasul, R. Sadykov; UZ
- 13:00 - 13:00 539P - Survival pattern of primary heart cancer
E. Ramadan, A. Meshref; EG
- 13:00 - 13:00 540P - Prognostic value of neutrophil-to-lymphocyte ratio in patients with esophageal adenocarcinoma
Y. Wang; CN
- 13:00 - 13:00 541P - Role of cancer ratio and carcinogenic embryonic antigen ratio in diagnosis of pleural effusion
A. Alhanafy, G. Abdelaal, I. Elmahlawy, B. Montaser; EG
- 13:00 - 13:00 542P - Response of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer: One-year follow-up study
X. Zhang, Y. Lin; CN
- 13:00 - 13:00 544P - Concordance study between IBM Watson for Oncology (WFO) and clinical practice for breast and lung cancer patients in China
N. Zhou, C.T. Zhang, H.Y. Lv, T.J. Li, J.J. Zhu, M. Jiang, H.L. Hou, D. Liu, A.Q. Li, G. Liu, G.Q. Zhang, X.C. Zhang; CN
- 13:00 - 13:00 545P - Next-generation sequencing of circulating tumor cells isolated from peripheral blood of patients with head and neck, and gastrointestinal cancer
K. Onidani, Y. Seiichi, N. Miura, H. Shoji, K. Kato, T. Shibahara, K. Honda; JP

- 13:00 - 13:00 546P - PAPP-A is a marker of aggressive breast cancer and promotes cancer progression in-vitro
L. Lim¹, P. Prithviraj², M. Walkiewicz¹, A. Behren¹, J. Cebon¹, A. Jayachandran¹; ¹AU, ²NSW/AU
- 13:00 - 13:00 547P - Dried plasma spot assay for sunitinib and its active metabolite by high performance liquid chromatography tandem mass spectrometry
R. Makihara, M. Maeda, K. Itahashi, S. Noda, J. Sato, S. Murakami, Y. Goto, S. Kanda, Y. Fujiwara, H. Horinouchi, T. Tsukamoto, H. Hashimoto, Y. Makino, N. Yamamoto, Y. Ohe, H. Terakado; JP
- 13:00 - 13:00 548P - Frequency of L858R and L861Q EGFR mutation in triple-negative, luminal and HER2 of Indonesian breast cancers patients
D. Budhiarko, T. Putra, A. Harsono, N. Masykura, D. Tjindarbumi, G. Widjajahakim, A. Utomo; ID
- 13:00 - 13:00 549P - Interesting molecular alteration of lung adenocarcinoma in the Thai population
T. Reungwetwattana, N. Trachu, S. Detarkom, P. Incharoen, S. Pramyothin, W. Klaisuban, A. Jinawath, N. Iemwimangsa, S. Aiempradit, A. Charoenyingwattana, W. Pairoj, I. Senson, N. Monnamo, P. Janchompoo, C. Srichunrusami, K. Kampreresart, O. Trachoo, V. Tangsujaritvijit, M. Ngodnbamthaweesuk, W. Chantratita; TH
- 13:00 - 13:00 551P - Genomic profiling for advanced non-small-cell lung cancer (NSCLC) from circulating tumour DNA (ctDNA)
H. Loong¹, V. Raymond², D. Chua¹, P. Teo¹, T. Yung¹, R. Lanman³, S. Skrzypczak³, T.S.K. Mok¹; ¹HK, ²ES, ³CA/US
- 13:00 - 13:00 552P - miR93 regulates epithelial-to-mesenchymal transition process in metastatic colorectal cancer by targeting EphA4
S. Gao, B. Jiang, H. Liu, S. Hou, L. Wu, Z. Yang, J. Shen, L. Zhou, S.-S. Zheng, W. Bai; CN
- 13:00 - 13:00 553P - Cyclin F controls glioma progression by regulation of IDH1-R132H expression
R. Deshmukh, S. Das; IN
- 13:00 - 13:00 554P - Triple negative breast cancer: Indians no better than the West
C. Reddy¹, M. Lakshmi², B. Stalin¹, S. Gundeti², L. Srinivas²; ¹Andhra Pradesh/IN, ²IN
- 13:00 - 13:00 555P - PFKFB2: Different roles of distinct splices
C. Ozcan¹, B. Balaban¹, T. Solakoğlu¹, S. Guzel¹, J. Chesney², A. Yalçın¹; ¹TR, ²KY/US
- 13:00 - 13:00 556P - m-Calpain, a new therapeutic target of triple negative breast cancer
K.-H. JEON, Y. Kwon; KR
- 13:00 - 13:00 557P - Metabolic pathways promoting tumorigenesis in fibroblasts lacking thrombospondin 1
N. Cumbo¹, V. Kalter¹, A. Hedge¹, L. Thomas¹, J. Quintana¹, I. Pinkerton¹, L. Gutierrez²; ¹PA/US, ²US
- 13:00 - 13:00 558P - Clinicopathologic correlation of MACC1 and Sp1 expression in lung adenocarcinoma
W.J. Sung, J.Y. Park, K.-K. Park; KR
- 13:00 - 13:00 559P - CPAP promotes HCC malignancy via the TNF-alpha/NF-kappa B and IL-6/STAT3 pathways

P.-H. Huang, R.-Y. Chen, S.-T. Yang, C.-G. Guo, M.-H. Lee, Y.-J. Lin, C.-J. Yen, H.-W. Tsai, L.-Y. Hung; TW

- 13:00 - 13:00 560P - Micro-RNA and Wnt signaling cascade up regulate CTNNB1 gene in colorectal carcinoma
F. Siddiq, M.N. Faisal, A. Mahmood, H. Muzaffar, J. Hussain, J. Aslam; PK
- 13:00 - 13:00 561P - Micro-RNA down express ABCG2 gene in adjuvant chemotherapy in female breast cancer
S. Saeed, M. Faisal, W. Majeed, J. Hussain, H. Muzaffar, A. Mahmood, H. Javed; PK
- 13:00 - 13:00 562P - Higher expression of Micro-RNA and Wnt signaling cascade in RNASEL candidate gene in prostate cancer
I. Hijazi, M.N. Faisal, A. Mahmood, H. Muzaffar, H. Nazir, J. Hussain; PK
- 13:00 - 13:00 563P - Descriptive analysis of clinicopathological characteristics of breast cancer in Sanglah General Hospital, Bali
A. Putra, S. I Gede Putu, P.A.T. Adiputra; ID
- 13:00 - 13:00 564P - The impact of cancer location and periodontal condition on osteonecrosis of the jaw: A population-based study
Y.-F. Huang, C.-T. Chang, S.-P. Liu, C.-H. Muo; TW
- 13:00 - 13:00 565P - Hematological toxicities following treatment of cancer patients with PARP inhibitors
S. Essameldin¹, E. Salah¹, H. Ahmed², H. Elhalawani², O. Abdel-Rahman¹; ¹EG, ²TX/US
- 13:00 - 13:00 566P - Family exposure to cyclophosphamide during outpatient treatment
M. Yuki¹, A. Miyake¹, H. Nakatsumi¹, K. Hirayama¹, A. Ishioka¹, H. Yamashita¹, Y. Komatsu²; ¹JP, ²Hokkaido/JP
- 13:00 - 13:00 567P - Platinum based chemotherapy induced fatigue among cancer patients
S. MODAK, H. Singh, R. Singh, A. Mukhopadhyay; IN
- 13:00 - 13:00 568P - Cancer and fertility
S. Sulejmanovic, Bosnia and/BA
- 13:00 - 13:00 569P - Cancers among adolescents and young adults in Japan
K. Kamimura, Y. Matsumoto, Q. Zhou, M. Moriyama, Y. Saijo; JP
- 13:00 - 13:00 570P - Breast cancer risk and reproductive status in Naypyitaw region, Myanmar
S. Thaug¹, M. Thiha¹, S. Nyi¹, K.K. Nwe², M. Oo¹; ¹MM, ²Bago/MM
- 13:00 - 13:00 571P - Knowledge and attitudes of productive age women about "SADARI" (breast self-assessment) in early detection of breast cancer in Tihingan village, Klungkung, Bali
A. Satyarsa, L.P. Diah Virayanti, S.A. Arta Suryantari, P.A.T. Adiputra; ID
- 13:00 - 13:00 572P - Clinicopathological evaluation and treatment profiles of second primary cancers reported to Regional Cancer Centre, India.
R. Pothamsetty, B.P. Thaliath, R.R. Ghosh; IN

- 13:00 - 13:00 573P - Associated malignancy in extra-mammary and mammary Paget's Disease: A retrospective analysis of single institute experience
P. Thirasastr, V. Sriuranpong, N. Poovorawan, T. Atikankul, N. Parinyanitikul; TH
- 13:00 - 13:00 574P - Myanmar clinicians' preference of truth telling about cancer diagnosis
S. Mon, T.T. Aye, M. Khine, S.S. Htay, N. Sein, E.P.P. Aung, P.T. Hnin, S.L.L. Thaug; MM
- 13:00 - 13:00 575P - Bone health in cancer survivors
A. Sharma¹, M. Surya², M. Upadhyay², M. Sharma², V. Fotedar², M. Gupta², S. Vats², P. Thakur², M. Sharma², D. Tuli², S. Sharma², R. Seam²; ¹Delhi/IN, ²IN
- 13:00 - 13:00 576P - Insight or confusion: Comparative study of perception and praxis in comprehensive genomic profiling among community oncologists in Singapore and Taiwan
A. Lai, SG
- 13:00 - 13:00 577P - Role of metformin, aspirin and statin in cancer prevention: A population- based study
P. Phetchoo, T. Reungwetwattana, S. Oranratnachai, N. Thongmung, S. Aiempradir, S. Rattanasiri, P. Vathesatogkit, A. Thakkinstian, P. Sritara; TH
- 13:00 - 13:00 578P - Current situation and problems of 'drug lag' for oncology drugs in Japan
E. Noguchi, A. Kuchiba, K. Yonemori, T. Shibata, N. Ushirozawa, K. Tamura, Y. Fujiwara; JP
- 13:00 - 13:00 579P - Urban-rural differences in breast cancer characteristics and outcomes
A. Alhanafy, R. Ibrahim; EG
- 13:00 - 13:00 580P - Analysis of various prognostic factors on local control and survival in post operative cases of malignant salivary gland tumors
M. Kumar, H. Manchala, S. Kumari, S. R; IN
- 13:00 - 13:00 581P - Sister Mary Joseph Nodule: An update on characteristics and outcomes
D. Codipilly¹, C. Jansson-Knodell², S. Nagpal², S. Sweetser²; ¹US, ²MN/US
- 13:00 - 13:00 582P - First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
E. Fujimoto¹, K. Kuribayashi², S. Kanemura¹, Y. Negi¹, Y. Koda¹, K. Mikami¹, T. Minami¹, T. Yokoi¹, T. Nakano¹, T. Kijima¹; ¹JP, ²Hyogo/JP
- 13:00 - 13:00 583P - Serum miRNA Assays for detection and management of gastric and lung cancers
L. Zhou, SG
- 13:00 - 13:00 380P - Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma
Y. Kiyohara¹, T. Takenouchi², H. Uhara², H. Koga², H. Uchi², N. Yamazaki²; ¹Shizuoka/JP, ²JP

14:30 - 16:00	Type: Special Symposium Title: Development of resistance: Kinase inhibitors vs. immune-checkpoint blockade Chair: A. Bardelli, IT; M. Jenkins, AU	Hall 404
14:30 - 14:35	Introduction <u>M. Jenkins</u> , AU	
14:35 - 14:55	Drug resistance and cancer evolution: From kinase inhibitors to immunotherapy <u>A. Bardelli</u> , (TO)/IT	
14:55 - 15:15	Escape from immunotherapy	
15:15 - 15:35	Adoptive T-cell therapy using CAR-T cells <u>M. Jenkins</u> , AU	
15:35 - 15:55	PD-1 blockade and its limitations <u>C. Blank</u> , NL	
15:55 - 16:00	Conclusions and clinical perspectives	
14:30 - 16:00	Type: Educational session Title: Multidisciplinary care of BRCA mutation carriers Chair: M. Zikan, CZ; A. Kwong, HK	Hall 405
14:30 - 14:50	Genetic testing, counselling and ethical pitfalls <u>S.C. Lee</u> , SG	
14:50 - 15:10	Breast cancer surveillance and risk-reducing mastectomy <u>A. Kwong</u> , HK	
15:10 - 15:30	Systemic therapy for BRCA mutant carriers with ovarian cancer <u>J. Ledermann</u> , London/GB	
15:30 - 15:50	Ovarian cancer surveillance and gynaecological surgery <u>M. Zikan</u> , CZ	

14:30 - 15:15	Type: Mini Oral session Title: Haematological malignancies Chair: K. Tsukasaki, JP; P. Johnson, GB	Hall 407
14:30 - 14:35	317O - Bortezomib based versus melphalan based regimen as induction chemotherapy for primary AL amyloidosis with cardiac involvement and factors predicting early mortality <u>V. Srinivasalu</u> ¹ , M. Subramaniam ¹ , A. Shanmugam ¹ , A. Philip ² , A. Susan ¹ , R. Prabhu ¹ , M. Unni ¹ , N. Sidharthan ¹ , W. Jose ³ , S. N V ¹ , P. Keechilat ¹ ; ¹ IN, ² Tamil Nadu/IN, ³ Kerala/IN	
14:35 - 14:40	318O - CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial <u>W.S. Kim</u> ¹ , B. Coiffier ² , C. Buske ³ , M. Ogura ⁴ , L. Kwak ⁵ , W. Jurczak ⁶ , J.M. Sancho ⁷ , E. Zhavrid ⁸ , J.S. Kim ¹ , J.-Á. Hernández-Rivas ⁷ , A. Prokharau ⁸ , M. Vasilica ⁹ , R. Nagarkar ¹⁰ , S.J. Lee ¹ , S.Y. Lee ¹ , Y.J. Bae ¹ ; ¹ KR, ² CEDEX/FR, ³ DE, ⁴ Gifu/JP, ⁵ CA/US, ⁶ PL, ⁷ ES, ⁸ BY, ⁹ RO, ¹⁰ IN	
14:40 - 14:45	319O - Clinical correlation between translocation variant and outcome in Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia patients <u>Z. Ahmed</u> ¹ , T. Moatter ² ; ¹ Sindh/PK, ² PK	
14:45 - 14:50	320O - B-cell non-hodgkin lymphoma and hepatitis C virus: Clinical features and survival <u>A. Alhanafy</u> , N. Elabd, E. Ahmedy; EG	
14:50 - 14:55	321O - Novel biomarker to diagnose ETV6-RUNX1 translocation in B-cell acute lymphoblastic leukemia <u>E. Boby</u> , G. Sharma, A. Jain, M. Mudassir, P. Chattopadhyay, A. Chopra, S. Bakhshi, J. Kumar; IN	
14:55 - 15:15	Discussion <u>P. Johnson</u> , GB	

14:30 - 16:00 Type: Special Symposium Room 309
Title: Adjuvant treatment in soft tissue sarcoma
Chair: P. Rutkowski, PL; A. Hong, AU

14:30 - 14:35 Introduction
P. Rutkowski, PL

14:35 - 14:55 Radiation therapy
A. Hong, AU

14:55 - 15:15 Neo-adjuvant chemotherapy
H. Loong, HK

15:15 - 15:35 Local treatment and surgery after neo-adjuvant therapy
P. Rutkowski, PL

15:35 - 15:55 Pathology response and immune-landscape after chemo-surgery therapy
A.P. Dei Tos, IT

15:55 - 16:00 Conclusions and clinical perspectives
A. Hong, AU

14:30 - 16:00 Type: Special Symposium Room 310
Title: Cellular therapies and T cell engagers
Chair: C. Dhamne, SG; C. Sentman, US

14:30 - 14:35 Introduction
C. Sentman, US

14:35 - 15:00 NK cells in clinical trials
C. Dhamne, SG

15:00 - 15:30 Overview on CAR T cells in the Western world and Latest technologies in CAR T cells
C. Rossig, DE

15:30 - 15:55 Bispecific T cell engagers: ALL and beyond
C. Sentman, US

15:55 - 16:00 Conclusions and clinical perspectives
C. Dhamne, SG

14:30 - 16:00	Type: Special Session Title: Cancer is now a global health priority: How you can help Chair: A. Eniu, RO; R.A. Stahel, CH	Room 324
14:30 - 14:35	Introduction <u>A. Eniu</u> ¹ , <u>R.A. Stahel</u> ² ; ¹ RO, ² CH	
14:35 - 14:50	What needs to be done in your country to implement the 2017 WHO Cancer Resolution <u>A. Eniu</u> , RO	
14:50 - 15:05	Focusing on the essentials: medicine, vaccines, medical devices and oncologists <u>F. Cardoso</u> , PT	
15:05 - 15:20	Why the WHO oncology workforce survey in partnership with ESMO is important in Asia <u>G. Curigliano</u> , IT	
15:20 - 15:35	The ESMO Clinical Cancer Registry Project in Asia <u>R.A. Stahel</u> , CH	
15:35 - 16:00	Q&A and Discussion	
14:30 - 16:00	Type: Educational session Title: Challenges for the implementation of precision medicine Chair: C. Le Tourneau, FR; J. Yoong, SG	Room 325
14:30 - 15:00	Clinical evidence for precision medicine <u>C. Le Tourneau</u> , FR	
15:00 - 15:30	New designs in precision medicine (algorithm testing, PFS ratio, basket and umbrella trials) <u>J. Bogaerts</u> , BE	
15:30 - 16:00	Paying for stratified medicine: Striking a delicate balance J. Yoong, <u>H.L. Wee</u> ; SG	

15:30 - 16:15	Type: Mini Oral session Title: Gastrointestinal tumours 1 Chair: E. Segelov, AU; C. Jackson, NZ	Hall 407
15:30 - 15:35	142O - Phase III study of trifluridine/tipiracil versus placebo in Asian patients with metastatic colorectal cancer (TERRA study): Country subgroup <u>V. Sriuranpong</u> ¹ , T.W. Kim ² , L. Shen ³ , J. Xu ³ , H. Pan ³ , R. Xu ³ , S. Han ² , T. Liu ³ , Y.S. Park ² , C. Shi ³ , Y. Bai ³ , F. Bi ³ , J.B. Ahn ² , S. Qin ³ , Q. Li ³ , C. Wu ³ , F. Zhou ³ , D. Ma ³ , V. Srimuninnimit ¹ , J. Li ³ ; ¹ TH, ² KR, ³ CN	
15:35 - 15:40	143O - Robot-assisted procedure versus open surgery for simultaneous resection of colorectal cancer with liver metastases: Short-term outcomes of a randomized controlled study <u>J. Xu</u> ¹ , Y. Wei ² , W. Chang ² , M. Jian ² , Q. Ye ² , X. Wang ² , L. Ren ² , Y. Zhong ² , X. Qin ² , J. Fan ² ; ¹ Changning/CN, ² CN	
15:40 - 15:45	144O - Prognostic value of an autophagy-related signature for early relapse in stage I-III colon cancer <u>S. Mo</u> , W. Dai, Y. Li, Y. Feng, L. Zhang, Q. Li, G. Cai; CN	
15:45 - 15:50	145O - Validated nCounter platform to stratify colorectal cancer (CRC) into Consensus Molecular Subtypes (CMS) and CRCassigner subtypes in Asian population <u>E. Fontana</u> ¹ , C. Ragulan ² , K. Eason ² , K. Si-Lin ³ , T.W. Siew ³ , G. Nyamundanda ² , Y. Patil ² , P. Poudel ² , I. Chau ¹ , I.B. Tan ³ , A. Sadanandam ² ; ¹ Surrey/GB, ² GB, ³ SG	
15:50 - 16:10	Discussion <u>E. Segelov</u> ¹ , <u>C. Jackson</u> ² ; ¹ NSW/AU, ² NZ	
16:00 - 16:30	Type: Young Oncologist session Title: Meet your mentor Chair: S. Peters, CH; T.S.K. Mok, HK	Exhibition area

16:30 - 18:00	Type: Special Symposium Title: Immunotherapies beyond PD-1 and CTLA-4 Chair: A. Daud, US; J. Cebon, AU	Hall 404
16:30 - 16:35	Introduction <u>J. Cebon</u> , AU	
16:35 - 17:00	T-cell agonistic and antagonistic receptors <u>A. Daud</u> , US	
17:00 - 17:25	Oncolytic viruses or radiation therapy <u>A. Marabelle</u> , FR	
17:25 - 17:50	New vaccines <u>J. Cebon</u> , AU	
17:50 - 18:00	Conclusions and clinical perspectives <u>A. Daud</u> , US	
16:30 - 18:00	Type: Educational session Title: Clinical approach to advanced neuroendocrine tumours Chair: E. Segelov, AU; N. Fazio, IT	Hall 405
16:30 - 17:00	Prognostic stratification in guiding treatment <u>T. Ito</u> , JP	
17:00 - 17:30	Therapeutics strategies: Which, when and how? <u>N. Fazio</u> , IT	
17:30 - 18:00	Global strategies for rare cancers: Opportunity and challenges <u>E. Segelov</u> , NSW/AU	

16:30 - 17:15	Type: Mini Oral session Title: Gynaecological cancers Chair: J. Ledermann, GB; B.-G. Kim, KR	Hall 407
16:30 - 16:35	288O_PR - Determinants of cancer screening awareness and participation among Indonesian women: A nationwide study <u>S.L. Anwar</u> ¹ , G. Tampubolon ² , S. Hutajulu ¹ , J. Watkins ² , W. Wulaningsih ² ; ¹ ID, ² GB	
16:35 - 16:40	289O - Molecular characterization of a panel of ovarian clear cell carcinoma (OCCC) cell lines <u>R. Huang</u> , J. Ye, K.T. Kuay, T.Z. Tan, V. Heong, D.S. Tan; SG	
16:40 - 16:45	290O - Effect of sentinel node mapping strategy in robotic surgical treatment of endometrial cancers <u>T. Le</u> , R. Samany, Z. Eslami; CA	
16:45 - 16:50	291O - Outcomes of vulvar cancer (VC) patients (pts): Impact of clinico-pathological factors and HPV status <u>C. Ortiz</u> , V. Rodriguez Freixinos, J. Hernandez-Losa, L. Fariñas Madrid, A. Gil Moreno, A. Pérez Benavente, J.L. Sancheziglesias, B. Díaz-Feijo, A. Garcia, S. Franco-Camps, S. Cabrera-Diaz, R. Verges, C. Viaplana, G. Villacampa-Javierre, R. Dienstmann, A. Oaknin; ES	
16:50 - 16:55	292O - Will doublet chemotherapy and radiation improve outcome as compared to standard treatment in carcinoma cervix IIIB? Long term results of a prospective randomized phase III trial <u>P. Thakur</u> , R. Seam, M. Gupta; IN	
16:55 - 17:15	Discussion	
16:30 - 18:00	Type: Special Session Title: Update on combined chemo-radiation in locally advanced tumours Chair: S. Senan, NL; F. Mornex, FR	Room 309
16:30 - 17:00	Locally advanced Lung cancer <u>B. Solomon</u> ¹ , <u>S. Senan</u> ² ; ¹ VIC/AU, ² NL	
17:00 - 17:30	Locally advanced Rectal cancer <u>C.S. Pin</u> ¹ , <u>F. Mornex</u> ² ; ¹ SG, ² CEDEX/FR	
17:30 - 18:00	Locally advanced Head and Neck Cancer <u>M.-J. Ahn</u> ¹ , <u>M.L.K. Chua</u> ² ; ¹ KR, ² SG	

16:30 - 18:00	Type: Special Session Title: Rare cancers as a partnership between Asian Pacific and Europe: Achievements of works in progress Chair: D. Thomas, AU; P.G. Casali, IT	Room 310
16:30 - 16:45	The many problems of rare cancers: networking as the only choice amid its many constraints <u>P.G. Casali</u> , IT	
16:45 - 17:00	An effort to look at survival discrepancies also on rare cancers in Asian Pacific and Europe <u>A. Trama</u> , IT	
17:00 - 17:15	The case of nasopharyngeal carcinoma: a project on why it is frequent in Asia and what this implies <u>A. Chan</u> , HK	
17:15 - 17:30	The case of nasopharyngeal carcinoma: a project on why it is rare in Europe and what this implies <u>L. Licitra</u> , IT	
17:30 - 17:45	The pathologic diagnosis of rare cancers: tackling the challenge in Europe <u>A.P. Dei Tos</u> , IT	
17:45 - 18:00	Discussion	

16:30 - 18:00	Type: Multidisciplinary patient cases Title: Long term complications of the Hodgkin lymphoma treatment Chair: L. Specht, DK; M. André, BE; S.-P. Yeh, TW	Room 324
16:30 - 16:45	Cardiovascular disease <u>L. Specht</u> , DK	
16:45 - 16:55	Discussion	
16:55 - 17:10	Preservation of fertility <u>M. André</u> , BE	
17:10 - 17:20	Discussion	
17:20 - 17:35	Second malignancy in the breast <u>S.-P. Yeh</u> , TW	
17:35 - 17:45	Discussion	
17:45 - 18:00	General discussion	

16:30 - 18:00	Type: Special Symposium Title: Rationale for treatment decisions of patients with metastatic NSCLC Chair: R.A. Stahel, CH; R. Soo, SG	Room 325
16:30 - 16:35	Introduction <u>R.A. Stahel</u> , CH	
16:35 - 16:55	Optimal biomarker diagnosis for treatment decision in metastatic NSCLC <u>T.S.K. Mok</u> , HK	
16:55 - 17:15	Approaches to first-line treatment for EGFR mutant and ALK translocated patients <u>T. Mitsudomi</u> , JP	
17:15 - 17:35	Approaches to first-line treatment for other lung cancers <u>S.-W. Kim</u> , KR	
17:35 - 17:55	Second-line treatment of patients with non-oncogenic drivers <u>S. Popat</u> , GB	
17:55 - 18:00	Conclusions and clinical perspectives <u>R. Soo</u> , SG	

17:30 - 18:25	Type: Young Oncologist session Title: Yong oncologist session: case presentations Chair: M. Preusser, AT; G. Pentheroudakis, GR; S. Banerjee, GB	Hall 407
17:30 - 17:35	Introduction <u>M. Preusser</u> , AT	
17:35 - 17:40	YO14 - Durable complete response of metastatic malignant sertoli cell tumor of testis with platinum based chemotherapy <u>V. Kunnavuttivanich</u> , TH	
17:40 - 17:50	Q&A and discussion led by Chairs	
17:50 - 17:55	YO23 - Case Report: The remarkable response to pembrolizumab of a recurrent microsatellite instability high, colon cancer stage IV (liver metastasis) previously treated with cetuximab, FOLFOX and irinotecan <u>K.R. Oracion</u> , PH	
17:55 - 18:05	Q&A and discussion led by Chairs	
18:05 - 18:10	YO24 - Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus <u>T. Maeda</u> , JP	
18:10 - 18:20	Q&A and discussion led by Chairs	
18:20 - 18:25	Conclusions	

19-11-2017

08:30 - 10:45	Type: Proffered Paper session Title: Proffered paper session 3 Chair: F. Cardoso, PT; Y.S. Lu, TW	Hall 405
08:30 - 08:42	57O - A nomogram for predicting the likelihood of axillary lymph node metastasis in breast cancer patients based on ultrasonographic-pathologic features <u>J. Lai</u> , K. Chen, Y. Li, Z. Pan, S. Shen, Y. Yang, R. Gu, F. Liu, Y. Hu, X. Jiang, F. Yu; CN	
08:42 - 08:54	91O_PR - Analysis of the gaps on metastatic breast cancer policies and advocacy efforts to support policy development across the patient journey in Asia <u>K. Hunt</u> ¹ , F. Cardoso ² , M. Thrift-Perry ³ , A. Cabanes ⁴ , T. Cruz ⁴ , K. Faircloth ³ ; ¹ US, ² PT, ³ NY/US, ⁴ TX/US	
08:54 - 09:09	Invited Discussant 57O and 91O	

J. Cortes Castan, ES

- 09:09 - 09:21 92O - Everolimus (EVE) + letrozole (LET) in Asian patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Results of a subgroup analysis from the BOLERO-4 study
T. Toyama¹, J. Jeong², V. Srimuninnimit³, V. Sriuranpong³, W. Noh², K. Tsugawa¹, M. Takahashi¹, H. Iwase¹, C. Arce⁴, A. Ridolfi⁵, C. Lin⁴, M. Royce⁶, F. Cardoso⁷; ¹JP, ²KR, ³TH, ⁴NJ/US, ⁵FR, ⁶US, ⁷PT
- 09:21 - 09:33 93O - Phase 2 study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC): Japanese subgroup results of KEYNOTE 086
M. Hattori¹, K. Tamura², H. Mukai², Y. Miyoshi², N. Masuda², E. Suzuki², H. Ishiguro², S. Ohtani², F. Hara³, T. Shimamoto², K. Yamamoto², Y. Ding⁴, G. Aktan⁵, V. Karantza⁶, H. Iwata²; ¹Aichi/JP, ²JP, ³BS, ⁴AL/US, ⁵PA/US, ⁶NJ/US
- 09:33 - 09:45 94O - Phase Ib study of ribociclib (RIB) + letrozole (LET) in a subset of Asian patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
Y.-S. Yap¹, Y. Ito², O. Bornstein³, Y. Han⁴, T. Samant⁵, X. Liu³, J. Chiu⁶; ¹SG, ²JP, ³AL/US, ⁴US, ⁵TH, ⁶Pokfulam/HK
- 09:45 - 10:00 Invited Discussant 92O, 93O and 94O
Y.S. Lu, TW
- 10:00 - 10:12 95O - Efficacy and safety of palbociclib plus endocrine therapy in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the Asia-Pacific region: Data from PALOMA-2 and -3
S.-A. Im¹, N. Masuda², Y.-H. Im¹, K. Inoue², S.-B. Kim¹, A. Redfern³, J. Lombard⁴, D. Lu⁵, K. Puyana Theall⁶, E.G. Gauthier⁵, H. Mukai², J. Ro¹; ¹KR, ²JP, ³WA/AU, ⁴NSW/AU, ⁵CA/US, ⁶MA/US
- 10:12 - 10:24 96O - MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy
M. Toi¹, C. Huang², Y.-H. Im³, H. Iwata⁴, J.H. Sohn³, H.-C. Wang², N. Masuda¹, Y. Lin⁵, S. Sakaguchi¹, N. Bourayou⁶, A. Llombart⁷, G. Sledge⁸; ¹JP, ²TW, ³KP, ⁴Aichi/JP, ⁵US, ⁶FR, ⁷ES, ⁸IN/US
- 10:24 - 10:39 Invited Discussant 95O and 96O
J.W.-H. Tsang, Pokfulam/HK

09:00 - 10:45	Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines: Adaptation of ESMO guidelines in Asia Chair: J. Tabernero, ES; F. Ciardiello, IT	Hall 404
09:00 - 09:10	Introduction <u>F. Ciardiello</u> , IT	
09:10 - 09:20	Case presentation on metastatic colorectal cancer in an Asian patient <u>H. Taniguchi</u> , Aichi/JP	
09:20 - 09:40	The adaptation process for metastatic CRC <u>T. Yoshino</u> , Chiba/JP	
09:40 - 09:55	Ethnic and regional adaptations in key recommendations: Guidelines in CHina <u>Y.-L. Wu</u> , Guangdong/CN	
09:55 - 10:10	Ethnic and regional adaptations in key recommendations: Guidelines in Japan <u>H. Minami</u> , Hyogo/JP	
10:10 - 10:25	Ethnic and regional adaptations in key recommendations: Guidelines in Singapore and other south Eastern countries <u>R. Kanesvaran</u> , SG	
10:25 - 10:45	The way forward: other ESMO guidelines to adapt. Led by <u>G. Pentheroudakis</u> ¹ , <u>R. Kanesvaran</u> ² , <u>I. Wahid</u> ³ , <u>Y.-L. Wu</u> ⁴ , <u>J.W.-C. Chang</u> ⁵ , <u>H. Minami</u> ⁶ ; ¹ GR, ² SG, ³ ID, ⁴ Guangdong/CN, ⁵ TW, ⁶ Hyogo/JP	

09:00 - 09:45	Type: Mini Oral session Title: Genitourinary tumours Chair: V. Grünwald, DE; V. Kataja, FI	Hall 407
09:00 - 09:05	2610 - Cost-effectiveness analysis of additional abiraterone for hormone-sensitive metastatic prostate cancer treated with androgen deprivation therapy (ADT) <u>C.L. CHIANG</u> , H. Choi, W.H. Mui, T.H. So; HK	
09:05 - 09:10	2620 - Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer <u>G. Ji</u> , G. Song; CN	
09:10 - 09:15	2630 - Comparison of first-line treatment options for metastatic castrate resistant prostate cancer: A retrospective cohort study <u>S. Pillai</u> ¹ , M.C. Semira ¹ , C. Pezaro ² , P. Parente ² , B. Tran ¹ ; ¹ AU, ² VIC/AU	
09:15 - 09:20	2720 - Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: A multicenter study <u>S. Hatakeyama</u> , Y. Kubota, T. Matsumoto, O. Soma, I. Hamano, A. Kusaka, S. Hosogoe, T. Yoneyama, Y. Hashimoto, T. Koie, C. Ohyama; JP	
09:20 - 09:40	Discussion <u>V. Grünwald</u> ¹ , <u>V. Kataja</u> ² ; ¹ DE, ² FI	
09:00 - 10:30	Type: Educational session Title: Detection and management of complex symptoms in advanced cancer Chair: J. Hardy, AU; A. Chan, SG	Room 309
09:00 - 09:30	Nausea and vomiting not caused by chemotherapy: Latest studies on aetiology based treatment <u>J. Hardy</u> , AU	
09:30 - 10:00	Management of immunotherapy-related toxicities <u>A. Chan</u> , SG	
10:00 - 10:30	Optimising therapeutic strategies targeting cancer cachexia anorexia syndrome <u>T. Kohichi</u> , JP	

09:00 - 10:30	Type: Special Symposium Title: Predictive biomarkers Chair: A. Menzies, AU	Room 310
09:00 - 09:05	Introduction	
09:05 - 09:25	Personalised medicine in immunotherapy <u>B. Besse</u> , CEDEX/FR	
09:25 - 09:45	Immune and neoantigen profiling in lung cancer <u>S. Quezada</u> , London/GB	
09:45 - 10:05	The microbiota as a biomarker for immunotherapy <u>T. Gajewski</u> , US	
10:05 - 10:25	Immunoscore: Looking at the big picture <u>J. Haanen</u> , NL	
10:25 - 10:30	Conclusions and clinical perspectives <u>A. Menzies</u> , AU	
09:00 - 10:30	Type: Educational session Title: Novel concepts in trial design and analysis Chair: R. Perez Lopez, GB; T. Yamanaka, JP	Room 324
09:00 - 09:30	Imaging criteria for activity assessment: The same for all interventions? <u>R. Perez Lopez</u> , Surrey/GB	
09:30 - 10:00	Pattern of progression: Does it matter? <u>R. Maria</u> , ES	
10:00 - 10:30	Tumour burden reduction or delay in progression: Are they surrogates for survival <u>T. Yamanaka</u> , JP	

09:00 - 10:30	Type: Special Symposium Title: Symptom management in advanced GI cancer Chair: E. Segelov, AU; I. Chau, GB	Room 325
09:00 - 09:05	Introduction <u>E. Segelov</u> , NSW/AU	
09:05 - 09:25	Management of Dysphagia in GI malignancies <u>H.-Y. Song</u> , KR	
09:25 - 09:45	Terminal bowel obstruction <u>C. Ripamonti</u> , IT	
09:45 - 10:05	Management of peritoneal disease <u>M. Teo</u> , SG	
10:05 - 10:25	Jaundice and biliary obstruction <u>S. Pereira</u> , GB	
10:25 - 10:30	Conclusions and clinical perspectives <u>I. Chau</u> , Surrey/GB	
10:30 - 11:00	Type: Young Oncologist session Title: Meet your mentor Chair: C.S. Pin, SG; C. Zielinski, AT	Exhibition area

11:00 - 12:30	Type: ESMO Colloquium Title: ESMO Colloquium - The incoming wave of oncology Biosimilars, in Asia Chair: J. Taberner, ES; S. Suh, KR	Hall 404
11:00 - 11:10	Clinician's perspective: Building confidence to prescribe biosimilars <u>J. Taberner</u> , ES	
11:10 - 11:20	Biosimilars: Regulator's best practices in Asia <u>S. Suh</u> , KR	
11:20 - 11:30	Oncology pharmacist's perspective in an emerging biosimilars market <u>H. Dhillon</u> , MY	
11:30 - 11:40	The industry's perspective: the development of biosimilars in the Asia-Pacific region <u>M. Schiestl</u> , AT	
11:40 - 11:50	Emerging tier of intended copies of biologics in Asia <u>H. Weber</u> , SG	
11:50 - 12:00	The financial impact of biosimilars on the sustainability of healthcare systems, in Asia <u>D. Singh</u> , SG	
12:00 - 12:30	Panel discussion/Q&A	

11:00 - 12:30	Type: Special Symposium Title: Emerging immunotherapy opportunities in HNC Chair: J.-P. Machiels, BE; B. Ma, HK	Hall 405
11:00 - 11:05	Introduction <u>J.-P. Machiels</u> , BE	
11:05 - 11:25	The role of immunotherapy in NPC <u>A. Chan</u> , HK	
11:25 - 11:45	Potential combination including immunotherapy with other modalities <u>J.-P. Machiels</u> , BE	
11:45 - 12:05	Toxicity and quality of life <u>L. Licitra</u> , IT	
12:05 - 12:25	The approach of immunotherapy beyond immune-checkpoint <u>B. Ma</u> , HK	
12:25 - 12:30	Conclusions and clinical perspectives <u>B. Ma</u> , HK	

11:00 - 11:50	Type: Mini Oral session Title: Supportive and palliative care Chair: A. Chan, SG; R. Chan, AU	Hall 407
11:00 - 11:05	501O - Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetrone (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients J. Vanden Burgt ¹ , L. Zhang ² , S. Lu ³ , A. Dechaphunkul ⁴ , S. Chessari ⁵ , C. Lanzarotti ⁵ , K. Jordan ⁶ , M. Apro ⁵ , <u>Y. Yang</u> ³ ; ¹ US, ² Guangdong/CN, ³ CN, ⁴ TH, ⁵ CH, ⁶ DE	
11:05 - 11:10	502O - Comparative efficacy and safety of pharmacologic interventions for cachexia: A systematic review and network meta-analysis S. Subongkot, <u>M. Sae-Teaw</u> , N. Chaiyakunapruk; TH	
11:10 - 11:15	503O - Evaluation of the impact of a topical lotion, CG428, on permanent chemotherapy induced hair and scalp disorders in cancer survivors: a randomized controlled pilot trial (VOLUME) <u>J. Cho</u> ¹ , D. Kang ¹ , J.-H. Park ¹ , I.-R. Kim ¹ , E. Guallar ² , D.-Y. Lee ¹ , J.S. Ahn ¹ ; ¹ KR, ² AL/US	
11:15 - 11:20	504O - Effects of steroid ointment application on chemotherapy-induced phlebitis: A randomized, double-blind, placebo-controlled clinical trial <u>Y. Hamabe</u> , A. Hanai, H. Ishiguro, T. Kuroda, M. Hirota, M. Nomura, H. Ishikawa, M. Muto; JP	
11:20 - 11:25	LBA7 - Patient reported outcomes during long term treatment with PD-1 inhibitors focusing on chronic toxicity and quality of life <u>J. Man</u> ¹ , R. Mercieca-Bebber ¹ , R. Habib ¹ , M. Carlino ² , A. Nagrial ² , B. Gao ² , H. Gurney ² , M. Wong ¹ , R. Hui ² ; ¹ NSW/AU, ² AU	
11:25 - 11:45	Discussion <u>R. Chan</u> ¹ , <u>A. Chan</u> ² ; ¹ AU, ² SG	

11:00 - 12:30	Type: Multidisciplinary patient cases Title: Exploiting non-medical treatment options for mRCC Chair: A.C.F. Ng, HK; P. Parikh, IN; M. Schmidinger, AT	Room 309
11:00 - 11:15	Role of surgery in mRCC-cytoreductive nephrectomy and metastectomies <u>M. Nagata</u> , JP	
11:15 - 11:20	Discussion	
11:20 - 11:35	Other local treatment interventions in mRCC <u>A.C.F. Ng</u> , HK	
11:35 - 11:40	Discussant	
11:40 - 11:55	The view of the medical oncologist <u>M. Schmidinger</u> , AT	
11:55 - 12:00	Discussion	
12:00 - 12:15	Is there a role for stereotactic radiosurgery in extracerebral RCC-metastases? <u>P. Parikh</u> , Dadar (W)/IN	
12:15 - 12:20	Discussion	
12:20 - 12:30	General discussion	
11:00 - 12:30	Type: Educational session Title: What is new in 2017? Chair: R. Quek, SG; D. Thomas, AU	Room 310
11:00 - 11:30	Bone sarcoma <u>A. Puri</u> , IN	
11:30 - 12:00	Soft tissue sarcoma <u>R. Quek</u> , SG	
12:00 - 12:30	Germline predisposition <u>D. Thomas</u> , NSW/AU	

11:00 - 12:30	Type: Educational session Title: State of the art in melanoma therapy Chair: C. Robert, FR; A. Otsuka, JP	Room 324
11:00 - 11:30	Anti PD1 therapy and immunomonitoring in melanoma <u>A. Otsuka</u> , JP	
11:30 - 12:00	Targeted therapy and immunotherapy <u>O. Michielin</u> , CH	
12:00 - 12:30	Therapeutic decision trees for difficult situations <u>C. Robert</u> , FR	
11:00 - 12:30	Type: Multidisciplinary patient cases Title: Challenges in the management of breast cancer Chair: S. Koppikar, IN; J.W.-H. Tsang, HK; H. Sze, HK	Room 325
11:00 - 11:15	Treating breast cancer in pregnant women <u>S. Koppikar</u> , IN	
11:15 - 11:25	Discussion	
11:25 - 11:40	Brain metastatic disease <u>H. Sze</u> , HK	
11:40 - 11:50	Discussion	
11:50 - 12:05	Management of patients with stage IV but limited oligometastatic breast cancer <u>J.W.-H. Tsang</u> , Pokfulam/HK	
12:05 - 12:15	Discussion	
12:15 - 12:30	General discussion	

12:00 - 12:30	Type: Mini Oral session Title: Gastrointestinal tumours 2 Chair: T. Okusaka, JP; I. Chau, GB	Hall 407
12:00 - 12:05	1940 - Hybrid-capture based comprehensive genomic profiling of hepatocellular carcinoma identifies patients who may benefit from targeted therapies and immune checkpoint blockade <u>J. Suh</u> ¹ , E. Severson ¹ , J. Hechtman ¹ , G. Frampton ² , D. Fabrizio ¹ , J. Sun ² , S. Ali ² , P. Gu ³ , S. Klempner ⁴ , V. Miller ² , P. Stephens ¹ , J. Ross ² ; ¹ US, ² MA/US, ³ NY/US, ⁴ CA/US	
12:05 - 12:10	1950 - Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study <u>C.S. Pin</u> ¹ , T. Yau ² , C. Hsu ³ , Y.-K. Kang ⁴ , M.-M. Hou ³ , W. Yeo ⁵ , K. Numata ⁶ , A. Chopra ¹ , A. Baakil ⁷ , C. Dela Cruz ⁷ , H. Zhao ⁷ , M. Kudo ⁶ ; ¹ SG, ² Pokfulam/HK, ³ TW, ⁴ Songpa-gu/KR, ⁵ CN, ⁶ JP, ⁷ NJ/US	
12:10 - 12:15	1960 - Effect of sofosbuvir and ribavirin on therapeutic efficacy of sorafenib in the treatment of hepatocellular carcinoma <u>A. Rana</u> , PK	
12:15 - 12:35	Discussion <u>I. Chau</u> ¹ , <u>T. Okusaka</u> ² ; ¹ Surrey/GB, ² JP	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 404
12:45 - 13:05	Presentation	
12:45 - 14:15	Type: Industry Satellite Symposium Title: Industry Satellite Symposium	Hall 405
12:45 - 13:05	Presentation	
12:45 - 13:30	Type: Young Oncologist Vesalius Talk Title: Impact of artificial intelligence on oncology Chair: F. Ciardiello, IT; M. Preusser, AT; C. Zielinski, AT	Exhibition area

14:15 - 15:00	Type: Special Session Title: Technical aspects of radiation planning based on case discussion Chair: S. Senan, NL; F. Mornex, FR; M.L.K. Chua, SG	Room 309
14:15 - 14:30	Lung cancer <u>S. Senan</u> , NL	
14:30 - 14:45	Head and Neck cancer <u>M.L.K. Chua</u> , SG	
14:45 - 15:00	Brain Tumours <u>R. Jalali</u> , IN	
14:30 - 16:00	Type: Educational session Title: Recent advances in the management of the head and neck cancer Chair: A. Psyrri, GR; M. Tahara, JP	Hall 404
14:30 - 15:00	Immunotherapy <u>D. Tan</u> , SG	
15:00 - 15:30	HPV and new staging system <u>A. Psyrri</u> , GR	
15:30 - 16:00	Management of thyroid cancer <u>M. Tahara</u> , Chiba/JP	

14:30 - 16:00	Type: Proffered Paper session Title: Proffered paper session 4 Chair: P. Tan, SG; I. Chau, GB	Hall 405
14:30 - 14:42	10 - Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types <u>S. Ikeda</u> ¹ , L. Gay ² , D. Pavlick ³ , J. Chung ⁴ , S. Ramkissoon ⁴ , S. Daniel ³ , J. Elvin ⁴ , E. Severson ³ , T. Bivona ⁵ , K. Reckamp ³ , S. Klemperer ⁵ , S.-H.I. Ou ⁵ , A. Schrock ⁴ , V. Miller ⁴ , P. Stephens ³ , J. Ross ⁴ , S. Ganesan ⁶ , C. Lovly ⁷ , A. Mansfield ⁸ , S. Ali ⁴ ; ¹ JP, ² CA, ³ US, ⁴ MA/US, ⁵ CA/US, ⁶ NJ/US, ⁷ TN/US, ⁸ MN/US	
14:42 - 14:54	Invited Discussant 10 <u>P. Tan</u> , SG	
14:54 - 15:06	LBA3_PR - Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT) <u>T.W. Kim</u> ¹ , Y.S. Park ¹ , K. Muro ² , R. Xu ³ , S. Han ¹ , K. Yamazaki ⁴ , W. Wang ³ , J.B. Ahn ¹ , H. Uetake ⁴ , Y. Deng ³ , S. Cho ¹ , H. Matsumoto ⁴ , Y. Ba ³ , K.-W. Lee ¹ , T. Nishina ⁴ , T. Zhang ³ , S. Iwasa ⁴ , S. Morita ⁴ , J. Sakamoto ⁴ ; ¹ KR, ² Aichi/JP, ³ CN, ⁴ JP	
15:06 - 15:18	Invited Discussant One LBA TBC <u>I. Chau</u> , Surrey/GB	
15:18 - 15:30	1930 - Prognostic gene expression signature in chemotherapy treated patients from the MAGIC trial <u>E. Smyth</u> ¹ , G. Nyamundanda ¹ , D. Cunningham ¹ , I.B. Tan ² , E. Fontana ³ , C. Ragulan ¹ , A. Okines ¹ , S. Lin ² , A. Wotherspoon ¹ , M. Nankivell ¹ , C. Peckitt ¹ , N. Valeri ¹ , R. Langley ¹ , P. Tan ² , A. Sadanandam ¹ ; ¹ GB, ² SG, ³ Surrey/GB	
15:30 - 15:42	Invited Discussant 1930 <u>F. Lordick</u> , DE	

14:30 - 15:25	Type: Mini Oral session Title: Thoracic malignancies 2 Chair: R.A. Stahel, CH; R. Soo, SG	Hall 407
14:30 - 14:35	4170 - Non-hematological toxicity and timing of B12/Folate supplementation in NSCLC patients on pemetrexed based chemotherapy: Secondary analysis of the PEMVITASTART randomized trial <u>M. Baldi</u> , K. Prasad, D. Behera, J. Kaur, N. Singh; IN	
14:35 - 14:40	LBA6_PR - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset <u>B.C. Cho</u> ¹ , B. Chewaskulyong ² , K.H. Lee ¹ , A. Dechaphunkul ² , V. Sriuranpong ² , F. Imamura ³ , Y. Ohe ³ , N. Nogami ³ , T. Kurata ³ , I. Okamoto ³ , C. Zhou ⁴ , Y. Cheng ⁴ , E.K. Cho ¹ , V.P. Jye ⁵ , J.-S. Lee ⁶ , H. Mann ⁷ , M. Saggese ⁸ , T. Reungwetwattana ² ; ¹ KR, ² TH, ³ JP, ⁴ CN, ⁵ MY, ⁶ Gyeonggi-do/KR, ⁷ GB, ⁸ London/GB	
14:40 - 14:45	4180 - A multicenter study of noninvasive genotyping and dynamic monitoring of ROS1+NSCLC receiving treatment with crizotinib by next generation sequencing C. Xu, <u>W. Wang</u> , W. Zhuang, Z. Song, G. Lin, Y. Zhu, X. Chen, R. Chen, Y. Guan, X. Yi, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song; CN	
14:45 - 14:50	4190 - Safety of alectinib in non-small cell lung cancer patients with RET fusion gene (ALL-RET): Results from the dose-finding portion of a phase 1/2 study <u>K. Nosaki</u> ¹ , S. Takeuchi ¹ , S. Takahara ¹ , T. Kawakami ¹ , K. Yoh ¹ , Y. Kono ¹ , A. Horiike ¹ , T. Seto ² , K. Goto ³ , K. Yoshimura ¹ , Y. Imai ¹ , T. Murayama ¹ , S. Yano ¹ ; ¹ JP, ² Fukuoka/JP, ³ Chiba/JP	
14:50 - 14:55	4200 - EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs) <u>R. Soo</u> ¹ , T.S.K. Mok ² , Y.-K. Shi ³ , L. Zhang ⁴ , S. Lu ³ , J.C.-H. Yang ⁵ , K. Nakagawa ⁶ , N. Yamamoto ⁶ , H. Nokihara ⁶ , S. Sugawara ⁷ , M. Nishio ⁶ , T. Takahashi ⁸ , K. Goto ⁹ , J. Chang ³ , M. Maemondo ⁶ , Y. Ichinose ¹⁰ , Y. Cheng ³ , W. Lim ¹ , S. Morita ⁶ , T. Tamura ⁶ ; ¹ SG, ² HK, ³ CN, ⁴ Guangdong/CN, ⁵ TW, ⁶ JP, ⁷ Miyagi/JP, ⁸ Shizuoka/JP, ⁹ Chiba/JP, ¹⁰ Fukuoka/JP	
14:55 - 15:00	3960 - The heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma <u>Y. Liu</u> , S. Ren, P. Yingying, C. Wu, Z. Dong, F. Wu, Q. Tian, Y. Pan, C. Zhou; CN	
15:00 - 15:05	3970 - Antitumoral effect of low molecular weight heparin in localized lung cancer. A randomized phase III controlled trial <u>B. Besse</u> ¹ , P. Girard ² , H. Doubre ² , A. Charles-Nelson ² , S. Aquilanti ² , A. Izadifar ² , R. Azarian ² , I. Monnet ² , C. Lamour ¹ , R. Descourt ² , G. Oliviero ² , L. Taillade ² , C. Chouaid ² , F. Giraud ² , P.-E. Falcoz ² , M.-P. Revel ² , V. Westeel ¹ , M. Alifano ² , G. Chatellier ² , G. Meyer ² ; ¹ CEDEX/FR, ² FR	
15:05 - 15:25	Discussion <u>R.A. Stahel</u> ¹ , <u>R. Soo</u> ² ; ¹ CH, ² SG	

14:30 - 16:00 Type: Special Symposium Room 310
Title: Optimization of melanoma treatment
Chair: C. Blank, NL; G. Long, AU

14:30 - 14:35 Introduction
G. Long, NSW/AU

14:35 - 14:55 Mechanisms of resistance and biomarkers in immunotherapy
C. Blank, NL

14:55 - 15:10 Neo-adjuvant drug therapy: What, when, in who, and what for?
G. Long, NSW/AU

15:10 - 15:25 Biological basis of combining radiotherapy with systemic treatments
K. Harrington, GB

15:25 - 15:40 Genomics and microenvironment of mucosal and acral melanoma. Is it different from cutaneous melanoma?
R. Scolyer, AU

15:40 - 16:00 Preclinical insights and management of mucosal melanoma
J. Guo, Shandong/CN

16:00 - 16:05 Conclusions and clinical perspectives
C. Blank, NL

14:30 - 16:00 Type: Educational session Room 324
Title: New era of targeting therapies for lymphoid malignancies
Chair: S.T. Lim, SG; P. Johnson, GB

14:30 - 15:00 Immune checkpoint inhibitors
R. Raghupathy, HK

15:00 - 15:30 Novel antibody treatments
K. Tsukasaki, Chiba/JP

15:30 - 16:00 Signalling pathways and targeted agents
P. Johnson, GB

14:30 - 16:00 Type: Multidisciplinary patient cases Room 325
Title: Challenges in pain and depression management
Chair: Y. Uchitomi, JP; A. Yee, SG

14:30 - 14:50 Challenges in complex pain management
A. Yee, SG

14:50 - 15:00 Discussion

15:00 - 15:20 Depression in early stage disease
Y. Uchitomi, JP

15:20 - 15:30 Discussion

15:30 - 16:00 General discussion

15:15 - 16:00 Type: Special Session Room 309
Title: Technical aspects of radiation planning based on case discussion
Chair: S. Senan, NL; F. Mornex, FR; M.L.K. Chua, SG

15:15 - 15:30 Rectum cancer
F. Mornex, CEDEX/FR

15:30 - 15:45 GU (prostate, bladder)
M.L.K. Chua, SG

15:45 - 16:00 Sarcoma
A. Hong, AU